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Abstract 
PI3K mediated signalling is crucial for various lymphocyte functions. 
Pharmacological targeting of PI3K is therefore an attractive target for 
therapeutic intervention in a range of inflammatory disorders as well as 
cancer. PI3K mediated signalling is regulated by the actions of lipid 
phosphatases, whilst pharmacological targeting of these lipid phosphatases 
offers an alternative means with which to modulate PI3K mediated signalling.  
 
This thesis aimed to utilise novel pharmacological compounds to probe the 
role of PI3K and the lipid phosphatases SHIP-1 and SHIP-2 in primary human 
T lymphocytes. The acute inhibition of PI3Kδ activity was shown to inhibit the 
secretion of IL-17A by human T lymphocytes. In contrast, the prolonged 
inhibition of PI3Kδ activity or the down-regulation of PI3Kδ expression in 
primary human T lymphocytes resulted in increased secretion of IL-17A. An 
allosteric activator of SHIP-1 was shown to inhibit chemokine mediated 
signalling and in vitro T cell motility. Activation of SHIP-1 also inhibited TCR 
mediated Akt phosphorylation, proliferation and cytokine secretion. SHIP-1 
activation  reduced the affinity state of LFA-1 and abrogated the ability of 
primary human T lymphocytes to adhere to fibronectin and ICAM1. 
Pharmacological inhibition of SHIP-1 activity also reduced chemokine 
mediated signalling and motility. In addition, SHIP-1 inhibition reduced TCR 
mediated signalling and adhesion. The reported SHIP-2 inhibitor 
BiPh(2,3’,4,5’,6)P5 was shown to inhibit the activity of SHIP-1 with equal 
potency as the inhibition of SHIP-2 activity. Pharmacological inhibition of 
SHIP-2 activity alone showed little effect on primary human T lymphocyte 
function, indicating that SHIP-1 is the primary SHIP protein involved in T 
lymphocyte function.  
 
In addition, this thesis showed that the expression and activity of the lipid 
phosphatase INPP4b is not lost in leukemic cell lines. INPP4b was however 
found to be down-regulated in Th17 polarised cells, indicating a possible role 
for INPP4b in Th17 differentiation.  
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IP3  Inositol triphosphate 
ITAM  Immunoreceptor tyrosine-based activation motif 
ITIM  immunoreceptor tyrosine-based inhibitory motif 
LAT  Linker of activated T cells 
LFA-1  Lymphocyte function-asscoated antigen 1 
MHC  Major histocompatibility complex 
mTOR  Mammalian target of rapamycin 
MTT  3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
NFAT  Nuclear factor of activated T cells 
NFκB  Nuclear factor κB 
PAMPs  Pathogen associated molecular patterns 
PBMC  Peripheral blood mononuclear cell 
PDK1  Phosphoinositide-dependent protein kinase-1 
PD-1  Programmed death-1 
PH  Pleckstrin homology 
PHLPP  PH domain leucine-rich repeat protein phosphatase 
PI3K  Phosphoinositide 3-kinase 
PKC  Protein kinase C 
PLC  Phospholipase C 
PMA  Phorbol 12-myristate 13-acetate 
PTEN  Phosphatase and tensin homologue 
RA  Rheumatoid arthritis 
Ras  Rat sarcoma 
Rheb  Ras homolog enriched in brain 
ROS  Reactive oxygen species  
SEB  Staphylococcal enterotoxin B 
SHC  Short hairpin control 
SHIP-1  SH2 domain containing inositol-5-phosphatase-1 
SLE  Systemic lupus erythromatosis 
SLO  Secondary lymphoid organ 
SLP-76  SH2 domain containing leukocyte protein 76 kDa 
s-SHIP  Stem cell SHIP 
TAPP-1  Tandem PH domain-containing protein-1 
   xvi 
TCR  T cell receptor 
TGF  Tumour growth factor 
TLR  Toll like receptor 
TNF  Tumour necrosis factor 
Treg  Regulatory T cell 
TSC1  Tuberous sclerosis complex-2 
VLA-4  Very late antigen-4 
ZAP-70  Zeta chain associated protein kinase 70kDa 
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1.1. The immune system 
The immune system comprises a variety of cells and tissues that recognize and 
destroy pathogens such as bacteria, worms, fungi and viruses, thereby acting to 
prevent infection and disease (Figure 1.1). In addition, the immune system allows 
the identification and destruction of damaged or cancerous host cells. A crucial 
requirement of the immune system is therefore the ability to distinguish self from 
non-self. This prevents over activation and dysregulation of the immune system 
which can lead to damaging autoimmune diseases and chronic inflammation. 
Activation of immune cells is therefore a tightly controlled process.  
 
1.1.1. Innate immunity 
The first line of defence against pathogens is provided by barrier function of the 
skin and the epithelial cell lining of the gut and airways. Tissue resident mast 
cells and macrophages express Toll like receptors (TLRs) that recognize 
pathogen associated molecular patterns (PAMPs) (1) causing the rapid release 
of inflammatory mediators which recruit and activate other immune cells, such as 
neutrophils and lymphocytes (2). Basophils and eosinophils release inflammatory 
mediators and are crucial for the destruction of parasites and bacteria (3). 
Natural killer cells kill infected or cancerous cells which have down-regulated 
expression of major histocompatibility complex I (MHCI) (4). Phagocytic cells of 
the innate immune system, such as macrophages, neutrophils and dendritic cells 
engulf and degrade identified pathogens. Dendritic cells engulf pathogens in non-
lymphoid tissues and subsequently migrate to lymphoid tissues where they 
present antigens in combination with major histocompatibility complex II (MHCII) 
to T cells (5, 6). Binding of antigen+MHCII on a dendritic cell to its cognate T cell 
receptor (TCR) expressed by a T cell initiates T cell activation, (7) and drives the 

























Figure 1.1 Cells of the innate and adaptive immune system. 1. Damage to 
the epithelial layer allows entry of pathogens such as bacteria. 2. Cells of the 
innate immune system such as tissue resident macrophages and mast cells 
recognize pathogen associated molecular patterns (PAMPs) expressed by 
invading pathogens and rapidly initiate an inflammatory response via the release 
of cytokines, chemokines and histamine. 3. Circulating neutrophils extravasate 
from blood vessels and phagocytose invading pathogens. 4. Tissue resident 
dendritic cells phagocytose invading pathogens and subsequently migrate to 
secondary lymphoid organs (SLO) where B and T lymphocytes with cognate 
antigen receptors for the antigen become activated and undergo clonal 
expansion. 5. Activated B cells differentiate into plasma B cells and secrete 
antibodies which in turn bind specific pathogens and aid phagocytosis via a 
mechanism known as opsonisation. Activated T cells migrate to peripheral sites 
of inflammation and secrete cytokines that orchestrate the inflammatory immune 
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1.1.2. Adaptive immunity 
The specificity of the adaptive immune system is driven by B cells and T cells. B 
cells are produced in the bone marrow and migrate to the spleen and secondary 
lymphoid organs where they are likely to encounter antigen specific for their B 
cell receptor (BCR). Ligation of the BCR stimulates B cell proliferation, 
maturation into plasma cells or memory B cells, class switching of cell surface 
antibodies and the secretion of antibodies. Secreted antibodies bind target 
pathogens or infected cells marking them for phagocytosis, in addition antibodies 
can bind and block the function of toxins or viruses (8). T cells are divided into 
two subsets, CD4+ helper T cells and CD8+ cytotoxic T cells. CD8+ T cells 
recognise antigen presented in complex with MHCI and are involved in the killing 
of infected or cancerous host cells (9). In contrast CD4+ T (helper) cells 
recognize MHCII in complex with antigen expressed on the surface of antigen 
presenting cells such as dendritic cells and macrophages. Upon antigen 
encounter, CD4 cells proliferate and differentiate into effector cells which 
orchestrate an inflammatory response against pathogens or cancerous cells. 
 
 
1.2. T lymphocytes 
 
1.2.1. Naïve CD4 T lymphocyte trafficking  
Naïve CD4 T lymphocytes continually re-circulate from the blood through the 
endothelium into secondary lymph node organs such as the mesenteric lymph 
node and spleen and gut-associated lymphoid tissue. Lymph nodes are highly 
specialised tissues which recruit naïve CD4 T cells from the blood, attract antigen 
presenting cells from peripheral tissues and provide an environment for antigen 
presenting cell and lymphocyte interaction and activation. When resident in the 
lymph nodes, T cells screen for cognate antigens for their T cell receptor (TCR) 
presented by antigen presenting cells (10, 11). If no antigen is encountered, 
naïve CD4 T lymphocytes migrate back into the blood stream (10). Trafficking 
from blood to lymphoid organs requires naïve CD4 cells to express a specific 
combination of receptors. Naïve CD4 cells express high levels of CXCR4 and 
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CD62L which are crucial for lymphocyte recirculation (11). Upon encounter of 
antigen cognate for their TCR, naïve CD4 cells become activated which involves 
growth in size, proliferation and a change of receptor expression which allows 
their exit from lymphoid tissues and invasion and entry into peripheral sites of 
inflammation (12). Depending on the specific cytokine melee encountered upon 
antigen binding, CD4 cells differentiate into distinct polarised phenotypes best 
able to deal with a particular pathogen.  
 
1.2.2.  CD4 T lymphocyte subgroups 
CD4 T cells must be able to respond to a plethora of pathogens, from parasites 
to bacteria. These pathogens will require a distinct cytokine and inflammatory 
response to protect the host from infection. The cytokine profile encountered by T 
cells upon TCR stimulation drives the expression of transcription factors, which in 
turn mediate the expression of distinct chemokine receptors and cytokines 
(Figure 1.2). CD4 T cells were initially thought to be divided between Th1 and 
Th2 polarised cells (13). IL-12 secretion by antigen presenting cells stimulates 
Th1 cell differentiation. Th1 cells are characterised by expression of the 
transcription factor Tbet, expression of the chemokine receptor CXCR3 and 
production of IFNγ and IL-12, as well as IL-2, TNFα and lymphotoxin. IFNγ acts 
in a positive feedback loop to further increase Th1 polarisation. Th1 secreted 
cytokines stimulate the recruitment and activation of CD8 cytotoxic lymphocytes, 
natural killer cells, macrophages and neutrophils which are crucial for cell-
mediated immunity against intracellular pathogens and tumour cells. Th1 cells 
also promote phagocytic dependent inflammation (14). Th1 cells and Th1 specific 
cytokines such as IFNγ have been implicated in the pathogenesis of organ-
specific autoimmune disorders (15, 16).  
 
Polarisation of Th2 cells occurs in response to IL-4 and is characterized by 
expression of the transcription factor GATA3, secretion of IL-4, IL-13 and IL-5 
cytokines and expression of the chemokine receptors CCR3, CCR4 and CCR8 
(17). Th2 cells protect mucosal surfaces against extracellular pathogens, aid B 
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cells in producing antibodies, promote antibody class switching to IgE and IgG 
and promote eosinophil recruitment. Th2 cells are however also associated with 
allergic asthma, a chronic airway inflammatory disorder characterised by 
increased allergen specific IgE production, eosinophil infiltration into the lungs 
and increased Th2 cytokines (18). 
 
Th17 cells are characterised by the production of IL-17A, expression of the 
transcription factor RORγt and RORα, as well as expression of the chemokine 
receptors CCR4 and CCR6 (19). Th17 differentiation is induced by the cytokines 
IL-1β, IL-6, TGFβ and IL-21, whilst IL-23 stabilises the phenotype of Th17 cells 
(20). IL-17A stimulates an inflammatory response against invading pathogens 
and is crucial for the clearance of fungal infections such as Candida albicans 
(21), extracellular bacterial pathogens such as Streptococcus pneumoniae (22) 
and Klebsiella pneumoniae (23). In addition, Th17 cells and IL-17A play a crucial 
role in combating intracellular pathogens such as Listeria monocytogenes (24) 
and Salmonella enterica serova Enteritidis (25). Because of the potent ability of 
IL-17A to induce inflammation, Th17 cells have been implicated in various 
inflammatory and autoimmune disorders. For example, in systemic lupus 
erythematosus Th17 cells accumulate in target organs, secrete IL-17A and 
promote tissue damage (26). Th17 cells are also implicated in driving 
inflammation in  inflammatory bowel disease (27), renal disease (28) and in 
rheumatoid arthritis (29). Therefore development of pharmacological compounds 
that inhibit the activity of Th17 cells and IL-17A has been of great interest to the 
pharmaceutical industry. Two different anti-IL-17A antibodies that block the 
activity of IL-17A have been found to significantly reduce psoriasis in humans 
(30, 31) and are effective in the treatment of arthritis (32). Blockade of IL-17A 
was however ineffective in the treatment of Crohns disease (33). In addition, 
antibody mediated blockade of IL-23 receptor signalling has been shown to 
inhibit inflammatory cell recruitment and inhibit the severity of experimental 
autoimmune encephalomyelitis (34). 
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More recently, CD4 T cells which produce IL-22 and TNFα but not IFNγ, IL-4 or 
IL-17 have been identified and termed Th22 cells. IL-22 has a crucial role in the 
maintenance of mucosal barrier function (35), whilst Th22 cells have also been 
described to have a role in inflammatory skin diseases (36, 37). In addition, IL-9 
producing Th9 cells have also recently been described (38, 39). Th9 cells 
differentiate in response to IL-4 and TGFβ, and are thought to have a role in the 
regulation of allergic inflammation, autoimmunity and anti-tumour immunity (40).     
 
Regulatory T cells polarise in vitro in response to TGFβ and IL-10 and are 
characterised by expression of the transcription factor Foxp3 (41) and the 
expression of CD25 (a subunit of the IL-2 receptor). Regulatory T cells act to 
reduce leukocyte activation following an inflammatory response and inhibit self-
reactive T lymphocytes, thereby maintaining immunological self-tolerance. The 
suppressive ability of regulatory T cells is mediated through a number of distinct 
mechanisms. These include the secretion of inhibitory cytokines such as IL-10, 
IL-35 and TGFβ and the competitive depravation of IL-2 and other growth factors 
away from effector T cells which can lead to cytokine depravation-induced 
apoptosis of target cells (42, 43). In addition regulatory T cells act through direct 
cell-cell contact (41, 44). Cytotoxic T lymphocyte-associated molecule-4 (CTLA-
4) is up-regulated by regulatory T cells and CTLA-4 has recently been shown to 
capture B7 ligands from the surface of antigen presenting cells. B7 ligands are 
subsequently endocytosed and degraded inside CTLA-4 expressing cells. 
Because CTLA-4 also binds the crucial co-stimulatory molecule expressed by T 
cells, CD28, CTLA-4 mediated degradation of B7 ligands therefore acts to impair 
co-stimulation and activation of effector T cells (45). Regulatory T cell expression 
of the ectoenzyme CD39 impairs dendritic cell maturation by degrading ATP into 
AMP (46). Regulatory T cells are also able to mediate immune suppression via 
granzyme B-mediated apoptosis of target cells (47). In vivo, regulatory T cells 
have been shown to prevent transplant rejection (48, 49). This indicates that 
pharmacological modulation of regulatory T cells may prove valuable 
therapeutically in humans undergoing transplant surgery. Indeed, clinical trials 
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using regulatory T cell therapy for the treatment of organ transplantation have 






















































Figure 1.2. Following activation naïve CD4 T cells differentiate into distinct 
T helper sub-groups depending on the cytokine profile present. IL-12 and 
IFNγ induce the differentiation of Th1 polarised cells, which are characterised by 
the expression of the chemokine receptor CXCR3, the transcription factor Tbet 
and secretion of IFNγ and IL-2. IL-4 induces the differentiation of Th2 polarised 
cells, which are characterised by the expression of the chemokine receptors 
CCR3, CCR4 and CCR8, the transcription factor GATA3 and secretion of IL-4, 
IL-5 and IL-13. IL-6, IL-21, IL-23 and TGFβ promote the differentiation of Th17 
polarised cells, which are characterised by the expression of the chemokine 
receptors CCR6 and CCR4, the transcription factor RORγt and secretion of IL-
17A, IL-17F and IL-21. IL-10 and TGFβ induce the differentiation of regulatory T 
cells, which are characterised by the expression of the chemokine receptors 
CCR5 and CCR4, the transcription factor Foxp3 and the secretion of TGFβ and 
IL-10. TNFα and IL-6 induce the differentiation of Th22 cells, characterized by the 
skin homing receptor CCR10 and secretion of IL-22. Th9 cells are induced by 
TGFβ and IL-4, and secrete high levels of IL-9.  
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1.3. T cell mediated immune response 
 
1.3.1. T cell activation 
The TCR forms a complex at the surface membrane, consisting of the TCR, 
CD3γ, CD3δ, two CD3ε co-receptors, and two intracellular CD3ζ elements. 
Activation of the TCR requires two distinct signals. One is the binding of a 
peptide in complex with MHCII on an antigen-presenting cell to the cognate TCR 
of a T cell. The second is the co-stimulation of CD28 binding to the B7 family 
ligands expressed by antigen presenting cells. The CD4 molecule expressed by 
T helper cells stabilises interactions of the TCR with MHCII. The specificity of a 
TCR for its antigen can be overcome by so called super-antigens, for example 
Staphylococcal enterotoxin B (SEB) activates the TCR of CD4 and CD8 T cells, 
irrespective of TCR specificity, leading to clonal expansion (51). Ligation of CD28 
activates various signalling cascades crucial for proliferation and survival of T 
lymphocytes (52). Loss of CD28 expression results in reduced immune 
responses to pathogens (52). Co-stimulation through inducible co-stimulator 
(ICOS) is also essential for full T cell activation (53).  ICOS is up-regulated post 
activation of T cells, and is structurally and functionally related to CD28 (54). 
Loss of ICOS expression results in a reduced immune response to pathogens, 
although at a reduced severity to the loss of CD28 expression (55). 
 
1.3.2. Immunoreceptor tyrosine-based activation motifs (ITAMs) 
TCR signalling in response to TCR ligation is initiated by the phosphorylation of 
ITAMs, which have a consensus sequence of YXXL/I(X6-8)YXXL/I, on the 
cytoplasmic tails of CD3 and CD28 by LCK and Fyn. ZAP-70 (ζ-associated 
protein of 70kDa) is recruited by binding to phosphorylated ITAM residues of 
CD3, initiating a cascade of phosphorylation events that drive T cell survival, 
activation and proliferation (56) (Figure 1.3). An important target of ZAP-70 is 
linker for the activation of T cells (LAT) and SH2 domain-containing leukocyte 
phosphoprotein of 76kDa (SLP-76). These act in concert to drive TCR dependent 
signalling events, with loss of LAT or SLP-76 resulting in abrogated TCR 
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signalling events (57, 58). LAT activation in turn results in activation of 
Phospholipase C gamma (PLCγ), Phosphoinositide 3-kinase (PI3K), Interleukin-2 
inducible T-cell kinase (Itk) and recruitment of the adaptor growth factor receptor-
bound protein 2 (GRB2) (56). Activation of these signalling cascades (which are 
described in more detail further on) results in activation of the T cell and drives 















































Figure 1.3. Signalling components activated by TCR ligation. Ligation of the 
TCR results in phosphorylation of ITAM residues on CD3 proteins by the actions 
of Fyn and LCK. ZAP-70 subsequently becomes recruited and activated, in turn 
phosphorylating LAT  and SLP-76. This results in the recruitment and activation 
of PLCγ, release of calcium from the endoplasmic reticulum and NFAT activation. 
PLCγ also activates  PKC and NF-κB. GRB2 activates Ras which stimulates ERK 
phosphorylation and activation. In addition, PI3K becomes recruited and 
activated by phosphorylated ITAM residues in the TCR complex. TCR mediated 
initiation of these signalling cascades drives the survival, proliferation, growth 
and differentiation of T cells.   
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1.3.3. Negative regulation of TCR signalling 
To ensure that a T cell only becomes activated by and responds to antigen that is 
specific for its TCR, activation is tightly regulated by inhibitory co-receptors 
(Figure 1.4) (59). In the absence of CD28 co-stimulation T cells become anergic 
(60). CTLA-4 and programmed death-1 (PD-1) are two receptors which act to 
negatively regulate TCR mediated activation and proliferation (56). CTLA-4 and 
PD-1 are maximally expressed 48 hours post stimulation and are crucial for the 
resolution of T cell mediated immunity. For example, CTLA-4 deficient mice 
display splenomegaly, activated peripheral T cells and lymphocyte infiltration into 
non-lymphoid organs, resulting in early lethality (61). Deficiency of PD-1 in mice 
leads to the development of autoimmune, lupus-like disease, with auto-reactive 
circulating IgG leading to cardiomyopathy (62). It is thought that these inhibitory 
receptors utilise the same ligand and/or the same signalling pathways as the co-
stimulatory receptors, in doing so they act to compete with positive stimulatory 
receptors and/or to sequester ligands or key substrates (56). For example, 
CTLA-4 and CD28 antagonize each other in the regulation of cell cycle proteins 
and cytokine expression, whilst utilizing the same ligands B7.1 and B7.2 on 
antigen presenting cells (63).  
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Figure 1.4. TCR-MHC/antigen and co-stimulatory receptor interactions 
between an antigen presenting cell and a T cell. TCR mediated signalling in 
addition to co-stimulation via CD28, OX40 and ICOS promote the activation of 
naïve CD4 T cells, initiating signalling cascades leading to differentiation, 
proliferation and growth. In contrast, PD-1, BTLA and CTLA-4 antagonize T cell 
activation. CD4 stabilises interactions between the TCR and MCHII in complex 
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1.3.4. Lymphocyte migration 
Lymphocyte migration into secondary lymphoid organs or into peripheral non-
lymphoid tissues is crucial for routine immune-surveillance and for an effective 
immune response against invading pathogens. When specific antigen is 
encountered, CD4 T lymphocytes are required to migrate to peripheral sites of 
infection (10). Homing of lymphocytes to peripheral sites of inflammation requires 
the up-regulation of distinct chemokine receptor profiles to allow access to 
specific tissues (11). For example CCR4, CCR8 and CCR10 direct T cells to the 
skin (64).  
 
Efficient lymphocyte migration requires the cell to become polarised, whereby a 
cell can be defined as having a front (the leading edge) and a back (the uropod). 
The uropod contains the microtubule-organizing centre and mitochondria 
become located here to ensure high levels of ATP to allow efficient driving of cell 
migration (65). At the leading edge, within lamellipodia and filopodia, actin 
polymerization pushes the plasma membrane forward (66). Chemokines are 
small proteins (7-10kDa) that control the recruitment of leukocytes to sites of 
infection and inflammation (67). Chemokine receptors are G protein coupled 
receptors (GPCRs) and ligation of chemokine receptors induces signalling 
cascades that mediate lymphocyte polarisation and migration (68). 
 
Extravasation of lymphocytes through the endothelial layer of blood vessels 
allows T cells to migrate into inflamed tissues and is a sequential process 
involving four distinct steps. These include tethering/rolling, activation, arrest and 
transendothelial migration (69) (Figure 1.5). The principal route of lymphocyte 
transendothelial migration occurs through endothelial cell junctions between 
endothelial cells (70), termed the paracellular route. Alternatively, 
transendothelial migration through the cell body of the endothelium has also 
been observed (71), termed the transcellular route. 
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Figure 1.5. Transendothelial migration of lymphocytes. To exit the blood 
stream lymphocytes must migrate through the endothelial capillary barrier. This 
involves a number of distinct steps. 1. Tethering and rolling: Initial contact and 
slowing of the lymphocyte is mediated by the binding of selectins on lymphocytes 
to ligands expressed by the endothelial cells. 2. Chemokines presented by 
endothelial cells induce increased affinity of integrin’s expressed by lymphocytes. 
3. Arrest: This binding causes the cell to become more firmly attached and crawl 
over the surface of the endothelium. 4. Transmigration: Extravasation of the 
lymphocyte can then occur via the trans- or para-transmigration route through the 




Lymphocytes adhere to endothelial cells to allow them to resist the shear forces 
of blood flow and to extravasate. In addition, lymphocytes must adhere to antigen 
presenting cells to form an immunological synapse, which is required for T cell 
activation. The ability of lymphocytes to adhere to extracellular matrix 
components, for example fibronectin, allows T cells to generate traction and 
crawl through intercellular spaces toward peripheral sites of inflammation.  
 
Adhesion is dependent upon interactions between integrin’s expressed by 
lymphocytes and substrates expressed by other cells or substrates present in the 
extracellular matrix. For example LFA-1 (composed of CD11a and CD18) is 
expressed by T lymphocytes and acts as a migratory receptor, binding ICAM1 
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(Intercellular Adhesion Molecule 1), which is expressed by endothelial cells and 
is crucial for T lymphocyte re-circulation (72). In addition ICAM1 binding to LFA-1 
is crucial for the formation of an immunological synapse between T cells and 
antigen presenting cells (73). VLA-4 (composed of CD49d and CD29) is another 
integrin expressed by leukocytes and binds to VCAM-1 (Vascular cell adhesion 
molecule 1) and the extracellular matrix component fibronectin (74). 
 
Activation of integrin’s occurs through two mechanisms: an increase in avidity by 
lateral mobility and receptor clustering on the cell membrane, and an increase in 
affinity through an alteration in the conformation of an integrin receptor (75). 
Lateral mobility of LFA-1 across the plasma membrane can be induced by 
chemokine stimulation and allows increased frequency of interactions between 
high-affinity LFA-1 and its ligand (76). Lateral mobility of LFA-1 is dependent 
upon RhoA (92-119 amino acid region), PI3K and ζ PKC (Protein kinase C) 
mediated signalling (77). In addition RhoA (23-40 amino acid region), but not ζ 
PKC activity was required for increased LFA-1 affinity (77).  
 
LFA-1 can exist in low and high affinity states, whilst disruption of this switching 
between affinities is associated with decreased lymphocyte motility in vitro and in 
vivo (78, 79). The inactive state of LFA-1 has a closed, bent conformation with a 
low affinity for ICAM1, whilst upon activation by TCR or chemokine stimulation, 
LFA-1 extends, increasing its affinity for ICAM1 (80, 81) (Figure 1.6). Activation 
of LFA-1 occurs by extension of the α and β integrin chains. PLC has been 
shown to activate LFA-1 by stimulating calcium release which activates the 
guanine nucleotide exchange factor (GEFs) CALDAG-GEF1 which in turn 
activates RAP1-GTP. RAP1-GTP forms a protein complex with RIAM and Talin, 
which associates with the cytosolic β chain of LFA-1. This causes a 
conformational change, away from the low affinity state of LFA-1, towards a 
higher affinity for its substrate ICAM1 (80).  In addition, deficiency in the RAP1-
activated RhoA GAP ARAP3 resulted in increased affinity and avidity state of 
LFA-1 (82).   
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Figure 1.6. Schematic showing Rap1 mediated LFA-1 activation. Three 
distinct conformational states of LFA-1 exist in lymphocytes, each with different 
binding affinities for their substrate ICAM1. In the low affinity form the α and β 
chains are bent, whereas in the intermediate and high affinity states the α and β 
chains have become extended. The α and β transmembrane chains of the low 
affinity conformation are held together by ‘membrane clasps’, marked with 
dashed lines. The intermediate form has lost one of the clasps, whilst in the high 
affinity form both clasps are lost, resulting in higher affinity for ICAM1 binding. 
Activation of LFA-1 can be mediated by PLC induced calcium production, which 
in turn activates the guanine nucleotide exchange factor (GEFs) CALDAG-GEF1. 
RAP1 becomes GTP bound and forms a protein complex consisting of RAP1, 
RIAM and Talin, which becomes associated with the cytosolic side of LFA-1. 
Talin binds to the β chain of LFA-1 and causes a conformation change away from 
the low affinity state.  RhoA (23-40 amino acid region) is required for increased 
LFA-1 affinity, whilst RhoA (92-119 amino acid region) and ζ PKC are required 
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1.3.6. Immune homeostasis 
Following antigen engagement, T cells proliferate in large numbers to adequately 
deal with the infection. After successful killing of pathogens, T cell numbers must 
be reduced to ensure immune homeostasis and to prevent chronic inflammatory 
damage and disease. A number of antigen experienced T cells will however 
develop into memory T cells which are resistant to apoptotic death (83). T cells 
that are no longer required are induced into apoptosis through two distinct 
mechanisms. T cells receive pro-survival and anti-apoptotic signals from TCR 
ligation and co-stimulation through CD28 and ICOS, as well as from cytokines 
such as IL-2, IL-13 and IL-15 (84). Activated T cell autonomous death (ACAD) 
occurs in the absence of these signals from growth factors and cytokine 
withdrawal (84). 
 
In contrast, Activation induced cell death (AICD) is triggered by death receptors 
such as CD95 (Fas receptor), TNFR or after reactive oxygen species (ROS) 
exposure (84). Mice with mutated CD95 ligand or decreased levels of CD95 
show increased numbers of lymphocytes and autoantibody production (85-87). 
TNF-mediated apoptosis is crucial for the reduction in numbers of peripheral 
activated T cells (88). Fas ligand expression is induced by ROS mediated 
signaling and is essential for AICD (89). In addition, previously activated T cells 
which receive TCR stimulation without co-stimulation are induced into apoptosis 
(90, 91). 
 
Because of the powerful ability of CD4 T lymphocytes to drive inflammatory 
responses, when T cells become dysregulated and overactive, excessive 
inflammation and autoimmune diseases can occur. For example, dysregulated 
CD4 T cells are thought to drive pathology in psoriasis (92), rheumatoid arthritis 
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1.4.  Phosphoinositide-3 kinase (PI3K) signalling 
 
1.4.1. PI3K mediated signalling in lymphocytes 
Class 1 phosphoinositide 3 kinases (PI3K) are heterodimeric proteins consisting 
of a regulatory subunit and a catalytic subunit. Class 1 A PI3Ks consist of one of 
the catalytic subunits p110α, p110β or p110δ (Figure 1.7 A), in association with 
an SH2 domain containing adaptor protein, either p85α, p55α, p50α, p85β or 
p55γ (97). Class 1 A PI3K isoforms are activated by tyrosine kinase receptors 
and Ras and signal downstream of immune-receptors, including B cell receptor 
(BCR), TCR, growth factor receptors, cytokine receptors, and co-stimulatory 
receptors (98, 99). The single Class 1 B PI3K, p110γ (Figure 1.7 A), is 
associated with the regulatory subunit p84/p87 or p101. In contrast to the Class 1 
A PI3K’s, PI3Kγ signals mainly downstream of GPCRs and is activated by most 
chemokine receptors expressed by lymphocytes (100). In addition, PI3Kγ can 
also be activated by Ras (101). There is however, also evidence for activation of 
PI3Kγ downstream of the TCR (102), tyrosine kinase receptors (103) and Toll-
like receptors (103). Expression of PI3Kα and PI3Kβ have a broad tissue 
distribution, whilst the expression of PI3Kδ and PI3Kγ is largely restricted to 
leukocytes. In addition, PI3Kγ is also expressed in the heart and in endothelial 
cells (104, 105). 
 
Recruitment of PI3K to the surface membrane in response to receptor ligation 
removes adaptor subunit mediated inhibition of catalytic activity and brings PI3K 
in proximity with its substrate phosphoinositide (4,5)-bisphosphate (PI(4,5)P2) 
(106). PI3K catalyses the conversion of PI(4,5)P2 into PI(3,4,5)P3 (Figure 1.7 B) 
which is a second messenger molecule resident in the cytosolic side of the 
plasma membrane that recruits and activates pleckstrin homology (PH) domain 
containing proteins (Figure 1.8). A number of proteins are known to be recruited 
and activated by PI(3,4,5)P3, these include Akt, PLCγ and 3-phosphoinositide-
dependent protein kinase 1 (PDK1) (107, 108).  
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Figure 1.7. Schematic representation of PI3K protein structures and 
PI3K/mTOR signalling. A) The Class I A and B PI3K proteins contain a number 
of important structural domains. Both Class I A and I B PI3Ks share a similar 
structure consisting of a Ras binding domain, a C2 domain,  a helical domain and 
a catalytic domain. Class 1 A PI3Ks have a p85 regulatory subunit-binding 
domain, whereas Class 1 B PI3K has a p101/p84/p87 binding domain. B) In 
response to receptor ligation, PI3K becomes recruited to the surface membrane 
and phosphorylates its substrate PI(4,5)P2 on the D-3 position of the inositol ring, 
creating PI(3,4,5)P3. PI(3,4,5)P3 recruits and activates PDK1 which in turn 
phosphorylates threonine 308 on Akt. mTOR2 phosphorylates serine 473 on Akt 
resulting in maximal Akt activation. Akt in turn phosphorylates and inhibits the 
function of TSC1/2, leading to activation of mTOR1. Serine 473 of Akt can be 
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1.4.2. Akt  
When Akt binds to PI(3,4,5)P3, it induces a conformational change which allows 
phosphorylation by PDK1 (also localised to PI(3,4,5)P3 at the membrane) at 
threonine 308 (Figure 1.7 B). This phosphorylation acts to increase the catalytic 
activity of Akt (109). Upon receptor ligation, Akt also becomes phosphorylated at 
serine 473 by mTORC2 (rictor). Phosphorylation of Akt at serine 473 increases 
its catalytic activity five-fold compared to threonine 308 phosphorylation alone 
(110) and increases the substrate specificity of Akt (111). Intriguingly, Akt can 
also be phosphorylated and activated independently of PI3K by Inhibitor of NFκ-
B Kinase subunit ε (IKBKE) (112). In addition, Akt can be directly de-
phosphorylated on the serine 473 residue by the protein phosphatase, PH 
domain leucine-rich repeat protein phosphatase (PHLPP) (113). By 
phosphorylating other proteins, Akt controls a range of lymphocyte functions, 
including growth, proliferation, survival, cytokine secretion and migration (114).  
 
1.4.3. mTOR 
One important target of Akt is TSC2 (Tuberous sclerosis complex-2). TSC2 
becomes inactivated following phosphorylation by Akt, whilst inactivated TSC2 
leads to accumulation of GTP-bound Rheb (Ras homolog enriched in brain) 
which in turn activates mTORC1 (Raptor) (Figure 1.7 B). Activated mTORC1 
activates S6 kinases, increasing protein translation, cell growth and proliferation 
(115). MTORC1 mediated signalling is crucial for T cell development (116), with 
mTORC1 knockout mice showing decreased T cell proliferation as well as 
impaired Th1, Th2 and Th17 differentiation (117).  
 
1.4.4. Forkhead box O (FoxO) 
Akt phosphorylates FoxO transcription factors, thereby inhibiting FoxO mediated 
transcription. FoxOs induce cell cycle arrest by promoting expression of negative 
cell-cycle regulators such as P130 and CDK1 p27KIP1 (118, 119). FoxOs also 
promote the activity of the pro-apoptotic proteins TRAIL and Puma (119, 120). 
Akt phosphorylation causes FoxO to be retained in the cytoplasm and thereby 
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inhibits FoxO mediated transcriptional events. The crucial role of FoxOs in 
controlling cell apoptosis and proliferation means that it is important for 
preventing transformation of cells. Indeed, mutations of FoxO genes have been 
identified in  acute myeloid leukaemia and in acute lymphoblastic leukaemia 
(120).  
 
1.4.5. Glycogen synthase kinase-3 (GSK-3) 
Akt phosphorylates and inhibits GSK-3, thereby promoting cell metabolism and 
relieving GSK-3 mediated negative inhibition of NFAT (Nuclear factor for 
activated T cells) (121). NFAT family of transcription factors drives the 
expression of genes crucial for T cell activation (122). 
 
1.4.6. Rac 
PI(3,4,5)P3 recruits and activates GTPase activating proteins (GAPs) and 
guanine nucleotide exchange factors (GEFs) which regulate the activity of small 
GTPases such as Rac (97, 123). Activation of Rac mediates actin polymerisation 
in response to chemokines, a key determinant of leukocyte polarisation and 
lamellipodia formation (124). Mutation of Rac abrogates the ability of neutrophils 
to migrate in response to chemokines, whilst patients with mutations of Rac 
experience recurrent bacterial infections, defective phagocytosis and poor wound 
healing (125, 126). 
 
1.4.7. PLCγ 
PI(3,4,5)P3 recruits and activates Tec family kinases which in turn phosphorylate 
and activate PLCγ. Btk expressed by B cells, and  Itk expressed by T cells, 
contain a PH domain which allows their interaction with PI(3,4,5)P3 at the surface 
membrane and subsequent induction of catalytic activity (127, 128). Activation of 
PLCγ drives activation of three transcription factor families which regulate 
proliferation, cytokine secretion and differentiation (129, 130). PLCγ hydrolyses 
PI(4,5)P2 to generate the products DAG (Diacylglycerol) and Inositol(1,4,5)-
triphosphate (IP3). IP3 binds IP3 receptors on the endoplasmic reticulum to 
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induce Ca2+ release and cause activation of NFAT transcription factors (131). 
DAG activates RasGRP which in turn activates Ras. Ras stimulates ERK 
activation which promotes AP-1 transcriptional factor activation. In addition DAG 
activates PKC, which stimulates a signalling cascade involving CARMA1, BCL10 
and MALT1, that acts to increase the activity of NF-κB transcription factors (121, 












































Figure 1.8. Key signalling events downstream of PI(3,4,5)P3 in lymphocytes. 
PI(3,4,5)P3 controls cell motility by driving actin polymerization through a 
RacGEF-Rac mediated pathway and controls myosin assembly through Akt and 
PAKa. Akt inhibits apoptosis by inhibiting the function of pro-apoptotic proteins 
including Bim, Bax and Foxo. Akt also indirectly stimulates the activity of mTOR, 
eIF2B and NFAT leading to cell growth, protein translation and gene 
transcription. PI(3,4,5)P3 recruits and activates Tec kinases such as Btk and Tec, 
which in turn activate PLCγ. Subsequently IP3 is produced which leads to 
calcium release from the endoplasmic reticulum and NFAT transcription factor 
activation. In addition, PLCγ produces DAG, which activates ERK and NF-κB 
mediated gene transcription.  
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1.5. Pharmacological targeting of PI3K 
 
The development of compounds with which to modulate the activity of PI3K has 
been intensely studied by both academia and the pharmaceutical industry (134). 
The first compounds found to inhibit PI3K activity; Wortmannin and LY294002 
were reported in the 1990’s. These compounds have been utilised as 
experimental tools (135), however they both exhibit off-target effects and do not 
discriminate between PI3K isoforms (136). The crystal structure of LY294002 
bound to PI3K has however facilitated the design of more potent and isoform 
specific PI3K inhibitors which utilise regions of the ATP binding pocket of PI3K 
(137-139). The development of isoform specific inhibitors has achieved reduced 
toxicity, whilst PI3K inhibitors with which to treat cancers has made substantial 
progress, with a number of PI3K, Akt and mTOR inhibitors in clinical trials (Table 
1.1) (140-143). However, the progress in developing PI3K inhibitors with which to 
treat inflammatory disorders has been less successful (108).   
 
The restricted expression of PI3Kδ and PI3Kγ, and their involvement in 
inflammatory disorders has meant that intense effort has been made to develop 
specific inhibitors of these isoforms. Specific inhibitors of PI3Kγ have been 
identified, with Merck Serono SA developing a series of PI3Kγ targeting 
compounds. AS-605240 was the most potent of the series and showed high cell 
membrane permeability whilst oral treatment was found to suppress the 
progression of joint inflammatory damage in mouse models of rheumatoid 
arthritis (144). However the development of these compounds to treat human 
inflammatory disorders has not materialised, most likely due to the selectivity 
over other PI3K isoforms not being sufficient enough to avoid toxicity issues. 
However, this may change with the recent discovery of CZC24832 by Cellzome 
(145). CZC24832 demonstrated superior PI3Kγ selectivity compared to previous 
compounds, suppressed inflammation in a collagen-induced arthritis mouse 
model and reduced Th17 differentiation and IL-17A production (145). This new 
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compound may therefore provide a basis for human PI3Kγ inhibitor trials to go 
ahead in the future. 
 
The development of PI3Kδ targeting inhibitors has progressed further. The 
IC87114 compound demonstrated that potent, PI3Kδ selective inhibitors could be 
developed (146). Based on the structure of IC87114, CAL-101 (now termed GS-
1101) was developed and is a more potent PI3Kδ inhibitor with 40-300 fold 
selectivity over other PI3K isoforms. CAL-101 is currently in clinical trials for B 
cell lymphoma and has been shown to cause rapid lymph node shrinkage and 
lymphocytosis. CAL-101 was found to decrease cancer cell survival by reducing 
the interaction of CLL cells with its protective microenvironment, and inhibited 
BCR mediated Akt phosphorylation (147, 148). These studies have 
demonstrated an essential role of PI3Kδ in B cell lymphoma survival and CAL-
101 is currently in phase 3 clinical trials for the treatment of leukaemia’s. In 
addition, CAL-101 has also entered phase 1 clinical trials for the treatment of 
allergic rhinitis, indicating that a PI3Kδ inhibitor may prove therapeutically useful 
in humans for the treatment of inflammatory disorders. 
 
PI3Kγ and PI3Kδ are both critical for immune mediated responses, therefore the 
simultaneous inhibition of PI3Kγ and PI3Kδ with a single compound may be 
beneficial in treating inflammatory disorders. Indeed, a dual PI3Kδ/PI3Kγ inhibitor 
has been developed and was shown to inhibit inflammatory cell activation and 
recruitment in a mouse model of asthma (149), as well as to provide cardio 
protection by inhibiting inflammatory responses to mediators of myocardial 
infarction (150). However, this compound did not progress beyond phase 2 
clinical trials. Another dual PI3Kγ/PI3Kδ inhibitor developed by a separate 
company, is currently in clinical trials for the treatment of inflammatory disorders 
(151), implying that dual inhibition of PI3Kγ and PI3Kδ may still be able to 
provide therapeutic benefit.  
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There has been recent evidence for a role of PI3Kβ in the immune system. For 
example, PI3Kβ was shown to have a crucial role in neutrophil activation by 
immune complexes (152) and also in the co-operation with PI3Kδ to regulate 
neutrophil reactive oxygen species generation (153). Therefore the targeted 
inhibition of both PI3Kδ and PI3Kβ may be beneficial in the treatment of certain 
inflammatory disorders. Intriguingly, dual PI3Kδ and PI3Kβ inhibitors have been 
reported (139), indicating that this may be possible with a single compound. 
However the use of PI3Kβ inhibitors to treat inflammatory disorders should be 
approached with caution due to the known roles of PI3Kβ in the regulation of 
bleeding responses (154).  
 








PI3K BKM120 Phase I/II Novartis Solid 
tumour/leukaemia 
PI3K ZSTK474 Phase I/II Zenyaku Kogyo Neoplasms 
PI3K GS-1101 
(CAL-101) 
Phase III Gilead Lymphoma/ allergic 
rhinitis 
Akt Perifosine Phase III Keryx Colorectal 
cancer/multiple 
myeloma 
Akt MK2206 Phase I/II Merck Solid tumour 
PI3K/ 
mTOR 
BEZ235 Phase I/II Novartis Solid tumour 
PI3K/ 
mTOR 
BGT226 Phase I Novartis Solid tumour 











GSK2126458 Phase I GSK Solid tumour 
PI3K/ 
mTOR 







PKI-587 Phase I Pfizer Neoplasms 
mTOR OSI-027 Phase I OSI Pharma Solid 
tumour/lymphoma 
mTOR AZD8055 Phase I/II AstraZeneca Solid 
tumour/lymphoma 
mTOR Ridaforolimus Phase III Ariad/Merck Metastatic soft-
tissue and bone 
sarcomas 
mTOR Everolimus Approved Novartis Renal cell 
carcinoma/neuroend
ocrine tumour 
mTOR Temsirolimus Approved Wyeth Renal cell 
carcinoma 
 
Table 1.1. PI3K/mTOR inhibitors currently in clinical trials for cancer. 
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1.6. PI3K isoforms in lymphocyte function 
The development of pharmacological inhibitors of PI3K, in combination with 
genetic strategies have identified a plethora of crucial roles for PI3K in controlling 
immune cell function. Indeed, mice which express mutated or which are deficient 
in either the PI3Kδ or the PI3Kγ isoform are viable and apparently healthy, until 
challenged by pathogens whereby it is evident that the immune system is 
compromised (Table 1.2) (155). PI3K is activated by a variety of immune 
receptors expressed by leukocytes, both from the innate response and from the 
adaptive response (T and B lymphocytes). This indicates that PI3Kδ and PI3Kγ 
have crucial roles in mediating leukocyte function. In addition, PI3Kα and PI3Kβ 
are also expressed in leukocytes and do contribute to some p85-assocated PI3K 
activity downstream of certain receptors in immune cells (121). However, 
pharmacological inhibition of PI3Kα has recently been shown to preserve 
lymphocyte function, with little disruption to TCR or BCR mediated proliferation 
(156). 
 
1.6.1. Antigen receptor signalling 
The PI3Kδ isoform appears to be the predominate PI3K isoform involved in 
lymphocyte antigen receptor signalling (121). This is evidenced by abrogated 
antigen receptor signalling in B and T lymphocytes when PI3Kδ expression is lost 
or mutated (155, 157, 158). This compares to the effect of genetic or 
pharmacological PI3Kδ inactivation in mast cells whereby antigen receptor 
mediated signalling is abrogated (159). In addition, the pharmacological inhibition 
of PI3Kδ abrogates antigen receptor mediated signalling in B and T lymphocytes 
(160, 161). Mice deficient for PI3Kδ exhibit reduced serum immunoglobulins, 
reduced B cell proliferation and primary and secondary responses to antigen 
challenge are severely impaired (158). Other PI3K isoforms have also been 
identified to play a role in antigen receptor signalling. For example, PI3Kγ has 
also been identified to signal downstream of the TCR (102). Whilst in 
macrophages and neutrophils, PI3Kβ has been shown to be required for FcγR 
mediated phagocytosis and ROS production (152, 162). 
Chapter 1: Introduction 
28 
1.6.2. Proliferation 
The PI3Kδ isoform is crucial for the proliferation of leukocytes, with 
macrophages, T cells and B cells from PI3Kδ deficient mice exhibiting reduced 
proliferation in response to antigen receptor stimulation compared to wild-type 
cells (155, 160, 163, 164). PI3K signalling promotes lymphocyte proliferation by 
promoting transcription of genes involved in cell cycle progression such as cyclin 
D2 and Cyclin D3 (121, 165), increasing protein synthesis and by inhibiting Foxo 
transcription factor mediated inhibition of cell cycle progression (166).  
 
1.6.3. Cytokine secretion 
PI3K mediated signalling drives cytokine secretion by modulating transcription 
factors  that control cytokine transcription, promoting cytokine protein translation 
via mTOR and S6 kinase and via transport of proteins from the Golgi apparatus 
(121, 167-170). PI3Kδ signalling is crucial for cytokine secretion by T cells (155, 
160) and NK cells (171), whilst in B cells PI3K is crucial for class switching and 
antibody secretion (172). In neutrophils, sequential activation of PI3Kγ and PI3Kδ 
is required for N-formyl-methionyl-leucyl-phenylalanine (fMLP) stimulated ROS 
production (173).  
 
1.6.4. Cell motility 
The majority of homeostatic and inflammatory chemokine’s and mediators that 
influence lymphocyte motility bind to GPCR chemokine receptors, whilst PI3Kγ 
couples to GPCR receptors and is key in regulating lymphocyte migration (174-
176). Deficiency in PI3Kγ inhibits the migratory responses of lymphocytes, 
neutrophils, macrophages and eosinophil’s (177-182). PI3Kγ is required for 
lymphocyte polarisation to occur in response to chemokine, with PI(3,4,5)P3 
accumulation at the leading edge leading to increased integrin-based adhesion 
and polymerized F-actin (183). PI3Kγ also regulates Rac activation and 
reorganisation of the actin cytoskeleton which is key for driving the traction force 
required for cell motility (184, 185). This is similar to the effects in neutrophils, 
whereby pharmacological inhibition of PI3Kδ activity reduced directional 
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migration in response to a fMLP gradient, however unlike PI3Kγ, 
pharmacological PI3Kδ inhibition had no effect on F-actin synthesis or neutrophil 
adhesion (146). In addition, neutrophil transendothelial migration in vivo required 
PI3Kγ for early (less than 90 minutes) migration whilst prolonged responses to 
other chemo-attractants required PI3Kδ signalling and was PI3Kγ independent 
(186).   
 
Cell Type Phenotype of 
PI3Kδ KO/KD 
Phenotype of PI3Kγ 
KO 
Phenotype 
of p85 KO 


















(190).   







regulatory T cell 
function (191). 
Decreased TCR 
signalling and increased 
apoptosis (182). 
Impaired in vivo homing 
to sites of inflammation, 







Table 1.2. Effect of PI3Kδ KO/KD, PI3Kγ KO or p85 KO on B and T 
lymphocyte function.  
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1.7.  PI3K signalling dysfunction in disease 
 
Genetic and pharmacological approaches have identified important roles of PI3K 
mediated signalling in inflammatory and autoimmune disorders, as well in 
cancers. Key immune cell mediated diseases known to involve PI3K signalling 
are discussed below.  
 
1.7.1. Leukaemia 
Given the crucial role outlined above for PI3K mediated signalling in cell 
proliferation and survival, it is perhaps not surprising that PI3K is involved in 
various cancers (140) and that the negative regulator of PI3K mediated 
signalling, PTEN, is a well known tumour suppressor gene (193). Deletions of 
PTEN, and/or mutations leading to over-active PI3K mediated signalling is a 
common occurrence in a variety of human cancers (194). Patient samples of 
Chronic lymphocytic leukaemia (CLL) have shown increased PI3Kδ expression 
and increased Akt activity which was reduced by PI3Kδ inhibition using CAL-101. 
CAL-101 also decreased viability of CLL cells, follicular lymphoma cells, Hodgkin 
lymphoma cells and multiple myeloma cells, although apoptosis of normal T cells 
and NK cells did not increase (147, 148, 195-198). CAL-101 treatment has been 
shown to cause rapid lymphocytosis and lymph node shrinkage (140, 147, 148). 
PI3Kδ activity also increases leukemic cell proliferation and is important for the 
retention of leukemic cells within microenvironment conditions where they 
receive pro-survival signals from non-cancerous stromal cells. PI3Kδ activity is 
therefore key in aiding cancer cell resistance to chemotherapy (147, 148). CAL-
101 has been shown to inhibit CLL cell chemotaxis in response to CXCL12 and 
CXCL13 in a Boyden chamber type assay and underneath a layer of stromal 
cells (148), which is consistent with previous reports of PI3Kδ being crucial for B 
cell chemotaxis (181). CAL-101 inhibited the secretion of cytokines in stromal co-
cultures with CLL cells and inhibited survival signals received by CLL cells from 
BCR and chemokine receptor ligation. In addition CAL-101 treatment sensitized 
CLL cells to standard CLL treatments such as Bendamustine (148). These 
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results indicate that CAL-101 has a dual mechanism of action, whereby CLL cells 
are released from protective micro-environments and are therefore more 
susceptible to standard chemotherapy. In addition CAL-101 directly decreases 
CLL cell survival by inhibiting Akt mediated survival signals.  
 
1.7.2. Systemic Lupus Erythematosus (SLE) 
SLE is a chronic autoimmune disease that affects the skin, joints, kidneys and 
brain. In the early stages of the disease, auto-reactive CD4 T cell numbers are 
increased (199, 200). Subsequently, dysregulated B cell activation leads to 
autoantibody production which in turn form complexes that become retained in 
the kidneys and activate the complement cascade causing inflammation. 
Subsequent recruitment of T cells and macrophages to the site of infection 
increases inflammatory damage and can eventually cause renal failure (199, 
200).  
Inhibition of PI3Kγ activity with the small molecule inhibitor AS-605240 
decreased autoantibody secretion and increased survival in an SLE model in 
mice (201). A mutation of PI3K which increases its activity in mice caused a 
lymphoproliferative disorder and an autoimmune renal disease due to increased 
survival and activation of T lymphocytes (202). In accordance with this, PI3Kδ 
and Akt were both constitutively active in the T cells of humans with SLE and 
increased activation of Akt was associated with more active disease phases. In 
addition, T cells from SLE patients showed resistance to activation-induced cell 
death, which was reversed following  pharmacological inhibition of PI3Kδ (203).  
1.7.3. Rheumatoid Arthritis (RA) 
RA is a chronic inflammatory disorder that is mediated by macrophages, B cells, 
T cells and neutrophils, resulting in inflammation in the joints and destruction of 
cartilage (204). As previously mentioned, PI3Kγ signalling is crucial for leukocyte 
migration (177, 179), therefore the inhibition of PI3Kγ activity was explored as a 
means with which to reduce RA pathology. PI3Kγ deficient mice showed reduced 
neutrophil migration and were protected from collagen induced arthritis (144). In 
Chapter 1: Introduction 
32 
addition, the pharmacological inhibition of PI3Kγ catalytic activity with AS605240 
inhibited collagen induced arthritis in mice (144). More recently, another selective 
PI3Kγ inhibitor, CZC24832, has been shown to inhibit Th17 cell development and 
to reduce bone and cartilage destruction in a mouse model of arthritis (145). 
Pharmacological inhibition of PI3Kδ has also proved effective in inhibiting arthritis 
in mice and reducing joint degradation, whilst dual inhibition of PI3Kγ and PI3Kδ 
was more effective than inhibition of either isoform alone (205). Pharmacological 
inhibition of PI3K has also been shown to inhibit osteoclastogenesis and reduce 
effects of collagen induced arthritis in mice (206). Intriguingly, PI3Kγ deficiency 
reduced matrix metalloproteinase expression by fibroblasts and resulted in 
reduced cartilage damage in mice (207). In humans, synovial fibroblasts 
extracted from patients with RA were found to have up-regulated PI3Kγ 
expression (207).  
 
1.7.4 Airway disorders 
Allergic asthma is a chronic inflammatory disorder characterized by airway hyper-
responsiveness that involves largely Th2 driven inflammation (95, 208). PI3K has 
been implicated in asthma due to its crucial role in mediating mast cell 
degranulation (209), antigen receptor signalling (155) and leukocyte homing to 
the lungs (210). Genetic inactivation or pharmacological inhibition of PI3Kδ 
activity inhibited mucus production, Th2 cytokine secretion, IL-17A secretion and 
inhibited eosinophil recruitment in mouse ovalbumin models of asthma (211-
214). In an ovalbumin induced asthma model in mice, pharmacological inhibition 
of PI3Kδ has been shown to reduce IL-17A and IL-13 levels and to inhibit 
eosinophil, lymphocyte and neutrophil recruitment (108, 215). PI3Kδ inhibition 
also inhibited mucus secretion, eosinophil trafficking and airway hyper-
responsiveness in a model of allergic airway inflammation (216). Intriguingly, a 
PI3Kδ inhibitor developed by GlaxoSmithKline has been shown to be effective in 
a steroid-insensitive model of asthma, whereby PI3Kδ inhibition reduced IL-13 
levels and eosinophilia in bronchoalveolar lavage fluid (108). CAL-101 is also 
currently in clinical trials for the treatment of allergic rhinitis (195). In addition, 
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PI3Kγ has been shown to play a role in airway inflammation. PI3Kγ deficient 
mice showed decreased leukocyte recruitment into the lungs and reduced airway 
hyper-responsiveness in an ovalbumin induced mouse model of asthma (178, 
217). Eosinophil release from the bone marrow during an inflammatory response 
is also decreased by the inhibition of PI3Kγ activity (218). A cause for concern in 
the use of a PI3K inhibitor to treat airway disorders is the identification that PI3Kδ 
inhibition can negatively regulate antibody class switching. Increased levels of 
IgE, which drives hyper-responsiveness, were seen when PI3Kδ was inactivated 
or pharmacologically inhibited (188). In contrast, the loss of PI3Kγ activity did not 




1.8.     Targeting of Class II and Class III PI3K isoforms 
 
Difficulties in the development of inhibitors of PI3Kγ with sufficient selectivity for 
use in humans has led to the search for alternative targets with which to disrupt 
PI3K mediated signalling in leukocytes. It has become increasingly apparent that 
class II and class III PI3Ks also have important roles in immune cells and may 
offer opportunities for pharmacological intervention. 
  
Class II PI3Ks are structurally distinct members of the PI3K family that produce 
the enzymatic product phosphatidylinositol 3-phosphate (PI(3)P), following 
activation by GPCRs or receptor tyrosine kinases (219, 220). The class II PI3K 
isoforms PI3KC2α and PI3KC2β have a wide tissue distribution and are 
expressed in leukocytes. There are currently no selective pharmacological 
inhibitors of class II PI3K. LY294002 and wortmannin do inhibit class II PI3K 
however, this is with lower potency than the inhibition of class I PI3Ks. In 
addition, the PI3Kα/mTOR inhibitor PI-103 exhibits comparable activity against 
PI3KC2β (139). Genetic strategies have however identified that class II PI3KC2β 
is activated following TCR ligation on CD4 T lymphocytes and that PI3KC2β is 
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crucial for calcium flux and T cell activation (221, 222). In addition, class II 
PI3KC2β has been shown to regulate cell adhesion and migration in non-immune 
cells (219, 223), whilst class II PI3Ks have also been shown to be activated by 
CCR2 chemokine’s in monocyte cell lines (224). 
 
The single class III PI3K Vps34 shares high homology with the catalytic subunits 
of class 1 PI3Ks, and produces PI(3)P as its enzymatic product. Vps34 is known 
to have a crucial role in the promotion of autophagy (225, 226) and in nutrient 
mediated activation of the mTOR/S6 kinase signalling pathway (227). Due to the 
important role of autophagy in cancer cell survival Vps34 is therefore an 
attractive pharmacological target for the treatment of cancers (228). In immune 
cells PI(3)P has been shown to accumulate at phagosomal membranes, 
contributing to phagosomal maturation and pathogen destruction (229, 230). 
Silencing of Vps34 expression has shown that Vps34 is responsible for PI(3)P 
production in phagosomes in response to Staphylococcus aureus and 
Escherichia coli (231). Therefore pharmacological inhibition of Vps34 may be of 
therapeutic use in the treatment of inflammatory disorders associated with 
dysregulated phagocytosis. In addition, Vps34 has been shown to promote T 
lymphocyte survival by regulating the signaling and recycling of the IL-7 receptor 
(232) and via Vps34 mediated autophagy which is crucial for maintaining naïve T 
cell homeostasis (233). Currently there are a lack of specific class III PI3K 
pharmacological inhibitors. 3-methyladenine (3MA) is commonly used as a 
Vps34/autophagy inhibitor, however 3MA is known to also inhibit class I and 
class II PI3Ks (234). The crystal structure of Vps34 bound with 3MA has been 
solved and may provide a basis for the development of inhibitors with improved 
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1.9. Lipid phosphatase regulators of PI3K signalling 
 
The crucial role of PI3K mediated signalling in immune responses, inflammatory 
disorders and cancer discussed above means that PI3K mediated PI(3,4,5)P3 
accumulation must be tightly regulated to avoid pathologies, but must still allow 
an effective immune response to invading pathogens. Regulation of PI(3,4,5)P3 
accumulation at the surface membrane is achieved by the actions of various 
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Figure 1.9. Diagram indicating the effects of lipid phosphatases on PI3K 
mediated signalling events. PI3K mediated accumulation of PI(3,4,5)P3 at the 
cell membrane is tightly regulated by the actions of lipid phosphatases. PTEN 
removes the D-3 phosphate group, directly antagonizing PI3K mediated 
signalling. SHIP-1 does not abrogate PI3K signalling, instead SHIP-1 ‘switches’ 
downstream signalling away from PI(3,4,5)P3 signalling events and towards 
PI(3,4)P2 dependent events. Accumulation of PI(3,4)P2 in turn is regulated by 
INPP4b, which removes the D-4 phosphate group, abrogating PI(3,4)P2 
mediated signalling events. PI(3)P binds to PX and FYVE domain containing 
proteins, although the signalling effects of INPP4b produced PI(3)P are unknown. 
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Figure 1.10. Schematic representation of the structures of the lipid 
phosphatase regulators of PI3K mediated signalling. SHIP-1 possesses a 
centrally located catalytic domain, an SH2 domain at the N terminus, and a 
recently identified pleckstrin homology domain which binds PI(3,4,5)P3. In 
addition SHIP-1 has a C2 domain which binds PI(3,4)P2 and allosterically 
increases the catalytic activity of SHIP-1. SHIP-1 also has a proline rich domain 
and NPXY motifs at the C terminus. In comparison to SHIP-1, s-SHIP has a 
truncated N terminus and lacks the SH2 domain, whilst SHIP-2 has a ubiquitin 
interacting motif and a SAM domain. INPP4b contains a C2 domain, NHR 
domain amino acids and a phosphatase domain located at the C terminus. PTEN 
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1.9.1. PTEN  
Phosphatase and tensin homologue (PTEN) de-phosphorylates PI(3,4,5)P3 at 
the D-3 position on the inositol ring, creating the product PI(4,5)P2. PTEN 
therefore acts to negatively regulate PI(3,4,5)P3 accumulation and hence directly 
antagonise PI3K mediated signalling (237). PTEN is expressed ubiquitously and 
is a well known tumour suppressor gene in various cancers (238, 239). Loss of 
PTEN results in Akt activation and excessive cell survival and proliferation (240, 
241). In addition PTEN is involved in the regulation of cell polarity and migration 
(237). Genetic strategies have demonstrated the crucial role of PTEN in 
regulating the immune system. PTEN heterozygous mice develop an 
autoimmune lymphoproliferative disease (242). In addition, T cell specific 
knockout of PTEN resulted in increased T cell Akt activation, increased cytokine 
secretion, over-proliferation and decreased apoptosis (243). T cell specific 
knockout of PTEN also resulted in splenomegaly and enlarged thymus (243). 
More recently, PTEN deletion specifically in CD4 T helper cells was shown to 
increase T cell proliferation and cytokine production and have delayed resolution 
of inflammation, although lymphomas and autoimmunity were not seen (244). 
The leukemic Jurkat cell line lacks both PTEN and SHIP-1 (245), and has 
constitutively activated Akt, as well as increased proliferation and increased cell 
size compared to non-cancerous primary T lymphocytes. PTEN has been shown 
to regulate basal levels of PI(3,4,5)P3, but does not oppose TCR mediated 
PI(3,4,5)P3 accumulation (246, 247). PTEN also sets the requirement for TCR 
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1.9.2. SHIP-1 
SHIP-1 is recruited to the surface membrane upon receptor ligation (Table 1.3) 
and removes the phosphate group from the D-5 position of PI(3,4,5)P3, to form 
the product PI(3,4)P2 (248). In doing so, SHIP-1 acts to negatively regulate PI3K 
mediated accumulation of PI(3,4,5)P3, and hence alters the recruitment and 
activation of PH domain containing proteins (236). SHIP-1 is 145kDa in size and 
is encoded by the INPP5D gene located on chromosome 2 (2q37.1).  
 
SHIP-1 was first identified as a protein that was recruited to the FcγRIIB receptor 
in mast cells and B cells (249). SHIP-1 was initially thought to act primarily as a 
negative regulator of PI3K mediated signalling, much as PTEN. However, SHIP-
1’s product, PI(3,4)P2 is still able to recruit certain PH-domain containing proteins 
and therefore does retain signalling ability. For example, dual adaptor of 
phosphotyrosine and 3-phosphoinositide-1 (DAPP-1) can bind both PI(3,4,5)P3 
and PI(3,4)P2 (250). Grp-1 binds only PI(3,4,5)P3, whilst the tandem PH domain-
containing protein-1 (TAPP-1) binds exclusively to PI(3,4)P2 (251). Akt can also 
bind both PI(3,4,5)P3 and PI(3,4)P2 (252). Therefore, SHIP-1 should be seen 
more as a ‘switch’, able to divert PI3K signalling away from PI(3,4,5)P3 mediated 
effector pathways, and towards PI(3,4)P2 mediated signalling pathways (Figure 
1.9). For example, SHIP-1 generation of PI(3,4)P2 recruits the GTPase Irgm1 and 
is a crucial step in macrophage phagocytosis of bacteria (253). 
 
SHIP-1 expresses a number of structural domains (Figure 1.10) which are crucial 
for the recruitment of SHIP-1 to the surface membrane following receptor ligation 
through protein-protein and protein-lipid interactions (Table 1.4). SHIP-1 is able 
to bind phosphorylated tyrosine residues via its SH2 domain located at the N-
terminus. This allows SHIP-1 to interact with a variety of proteins, including Shc, 
DOK-1, as well as immunoreceptor tyrosine-based inhibitory motifs (ITIMs) and 
some immunoreceptor tyrosine-based activation motifs (ITAMs). A pleckstrin 
homology domain-like region has been identified in SHIP-1 which binds to 
PI(3,4,5)P3 and was found to be required for phagocytosis by macrophages 
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(254). The C2 domain of SHIP-1 binds the SHIP-1 product PI(3,4)P2, which acts 
to allosterically increase the catalytic activity of SHIP-1, acting in a positive 
feedback mechanism (255). SHIP-1 also contains a proline rich region at the C-
terminal which allows interactions with SH3 domain containing proteins such as 
Grb2 and phospholipase-C. In addition SHIP-1 contains NPXY motifs at the C-
terminal, with phosphorylated tyrosine residues important for interactions with 
SH2 domain containing proteins such as DOK1, Shc (195) and DOK-4 (256). 
Interestingly, the SH2 domain of SHIP-1 has been shown to bind phospho-
tyrosine residues within the C-terminus of SHIP-1 itself, acting to regulate 
interactions with other proteins (257). In addition, SHIP-1 protein that lacks the C-
terminus has been shown to be more catalytically active than SHIP-1 where the 
C-terminus is present (258). This indicates that this mechanism is involved in the 
control of the catalytic activity of SHIP-1.  
 
The non-catalytic domains of SHIP-1 also allow SHIP-1 to act as a scaffolding 
protein, and to have functions independent of catalytic activity. For example, 
SHIP-1 has been shown to physically block the recruitment of PI3K to phospho-
tyrosines via the SH2 domain of SHIP-1 (259). SHIP-1 physically interacts with, 
and inhibits the function of Tec kinases (260). SHIP-1 also forms a complex with 
Grb2 and Dok-1 which negatively regulates Akt and PLCγ signalling (261). SHIP-
1 scaffolding functions have also been shown to positively regulate TLR-induced 
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Cell type Receptor 
B cell BCR (264) 
B cells and Mast cells FcγRIIb (249) 
B cell CD22 (265) 
Ba/F3 pro-B lymphoid cell line Granulocyte colony-stimulating factor 
receptor (266) 
T cell CD28 (267) 
T cell TCR/CD3 (261) 
T cell CXCR4 (245) 
Mast cell FcεR1 (268) 
Macrophage FcγRIIa (269) 
Macrophage TLR2 (262) 
Macrophage TLR3 (270) 
Macrophage TLR4 (262) 
NK cell 2B4 (271) 
Neutrophils and Mast cells IL-3 receptor (272) 
NK cell CD16 (273) 
NK cell KLRG1 (274) 
 


















SHIP-1 and SHIP-2 
interacting proteins 
CD2AP (275) Actin, non muscle (276) Btk (260, 277) 
Ezrin, Radaxin and 
Meosin (276) 
APS (278) CIN-85 (279, 280) 
FUBP2 (276) ARAP-3 (281) DOK1 (280, 282, 283) 
Grb2 (276) c-Cbl (284) Filamin (285, 286) 
KLRG1 (274) Glucose-regulated 
protein precursor (276) 
Shc (276) 
LyGDI (276) Heat shock protein 90-
beta (276) 
Tec (287) 
PKC-δ (288) HSP90β (276)  
PLC-γ (289) Intersectin 1 (290)  
DOK4 (256) Protein disulphide-
isomerase A3 precursor 
(276) 
 
 PR130 (291)  
 PTP1B (292)  
 P130Cas (293)  
 JIP1 (277)  
 Tubulin beta-2A chain 
(276) 
 
 Vinexin (294)   
 
Table  1.4. Proteins that have been identified to physically interact with 
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1.9.3. SHIP-1 mediated regulation of immune function 
SHIP-1 is recruited to a plethora of receptors expressed by immune cells (Table 
1.3) (195), where SHIP-1 acts to regulate receptor mediated intracellular 
signalling via the mechanisms discussed above. Genetic strategies have 
previously been used to elucidate the role of SHIP-1 in immune cells and have 
shown that SHIP-1 regulates various processes such as immune cell activation, 
proliferation, cytokine secretion, mast cell degranulation, dendritic cell function, 
macrophage activation and BCR signalling (Table 1.5) (195, 236). SHIP-1 also 
has a crucial role in regulating leukocyte migration, polarization and adhesion 
(295, 296).  
 
A role for SHIP-1 in maintaining a balance between pro-inflammatory and anti-
inflammatory immune cells has also emerged (297, 298). In the absence of 
SHIP-1, the development of Th17 cells was severely impaired in mice, with 
regulatory T cell differentiation more profound (298). SHIP-1 deletion in T cells 
also results in impaired Th2 differentiation, whilst Tbet expression and Th1 
differentiation is increased (299, 300). However, it appears that differences may 
arise depending upon the type of genetic strategy used. For example, in contrast 
to T cell specific SHIP-1 deletion, germ line SHIP-1 deletion resulted in increased 
Th2 differentiation due to increased IL-4 secretion from basophils (297). In 
addition, SHIP-1 regulates the balance of pro-inflammatory (M1 macrophages) 
and anti-inflammatory (M2 macrophages) myeloid cells. Deletion of  SHIP-1 was 
found to result in increased macrophage polarisation towards the M2 phenotype 
(301, 302). SHIP-1 null mice also show increased numbers of myeloid-derived 
suppressor cells than wild-type mice (303).  
 
In B cells, antigen induced cross-linking of the B-cell receptor (BCR) induces 
PI3K activation which in turn activates Akt and Btk, two key enzymes involved in 
the activation of B cells (114). Upon co-aggregation of the BCR with the inhibitory 
receptor FcγRIIB, SHIP is recruited through interaction of its SH2 domain with 
phosphorylated ITIM motifs of FcγRIIB (304). At the surface membrane SHIP-1 
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inhibits PI(3,4,5)P3 accumulation and reduces recruitment of the PH domain 
containing proteins Akt and Btk (305). SHIP-1 has also recently been shown to 
play a key role in the prevention of B cell mediated autoimmunity. Anergic B cells 
showed mono-phosphorylation of ITAM motifs which in turn lead to recruitment of 
SHIP-1 and the inhibition of B cell activation. Deletion of SHIP-1 in B cells lead to 
loss of anergy and autoimmunity (306). SHIP-1 deficient B cells have also been 
shown to have lower thresholds for antigen mediated activation, enhanced B cell 
maturation in the periphery and spontaneous production of isotype-switched 
antibodies (307).  
 
In mast cells SHIP-1 negatively regulates de-granulation following IgE+antigen 
stimulation, with SHIP deletion in mast cells resulting in de-granulation following 
IgE stimulation alone (308). Subsequently, the deletion of SHIP-1 in human mast 




Cell type Phenotype of SHIP-1 knockout 
Basophils Increased IL-4 secretion (297) 
B cell Loss of anergy, secretion of auto-antibodies (306) 
Btk membrane association increased. Hyper-responsive 
to crosslinking of BCR (305, 310) 
Dendritic cell Impaired maturation. Enhanced survival and 
proliferation (311) 
Reduced nitric oxide production (312) 
Mast cell Enhanced maturation and degranulation (263, 308) 
Increased TLR expression and TLR-mediated cytokine 
secretion (263) 
Myeloid cell Increased myeloid suppressor cell numbers (303) 
Increased ratio of PI(3,4,5)P3 to PI(3,4)P2 on 
phagosomal membrane. Decreased early oxidase 
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activity in phagosomes (313) 
Enhanced M2 macrophage skewing (due to increased 
IL-4 secretion from basophils) (301) 
Natural killer cell Decreased IFNγ secretion and cytolytic function. 
Increased numbers and deficient receptor repertoire 
(314) 
Loss of peripheral NK cells (315) 
T cell Decreased Th2 polarisation, increased Th1 polarisation 
and CD8 cytotoxic activity (300) 
Decreased Th17 polarisation, enhanced regulatory T 
cell development (298) 
 




1.9.4. SHIP-1 in haematological malignancies 
As mentioned earlier, the role of PTEN in cancer is well established (238, 241). 
However the role of SHIP-1 in haematopoietic cell cancers has been more 
controversial.  
 
Mutations of SHIP-1 have been identified in acute lymphoblastic leukaemia (316) 
and in acute myeloid leukaemia (317, 318). SHIP-1 has also been identified as a 
target of the oncogene fli-1, with a role in the development of erythroleukaemia 
(319). SHIP-1 expression is targeted by the micro-RNA miR-155, with reduced 
SHIP-1 expression and increased miR-155 identified in acute lymphoblastic 
leukaemia in mice (320) and increased miR-155 in large B cell lymphoma (321). 
micro-RNAs (miRNA) are non-protein coding RNAs of between 19-23 
nucleotides long which act to regulate gene expression post-transcription. 
miRNAs bind to complementary sequences in the 3’ UTR region of messenger 
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RNA and subsequently cause the down-regulation of target protein expression 
(322).  
 
An indirect, alternative mechanism by which the loss of SHIP-1 expression may 
lead to the development of cancers is through the crucial role discussed earlier of 
SHIP-1 in regulatory myeloid and T cell differentiation (298, 303). SHIP-1 loss of 
function or expression may therefore lead to increased suppression of immune-
mediated anti-tumour responses. For example, reduced SHIP-1 expression in 
splenocytes of murine pancreatic cancer cells was associated with increased 
numbers of myeloid suppressor cells (323). 
 
However, in certain cancers, SHIP-1 has been shown not to act as a tumour 
suppressor gene. For example, in myeloma cells, unlike PTEN, SHIP-1 did not 
act as a tumour suppressor gene (324) whilst the pharmacological inhibition of 
SHIP-1 (discussed in greater depth in the subsequent section) induced the 
apoptosis of multiple myeloma cells (325). This indicates that SHIP-1 is required 
for the survival of certain blood-based cancers. Intriguingly, SHIP-1 has been 
shown to protect against Fas-mediated apoptosis in T cells (326). This may be 
due to the enzymatic product of SHIP-1, PI(3,4)P2, activating Akt and hence the 
promotion of cell survival (240).  
 
1.9.5. s-SHIP 
The expression of s-SHIP was originally thought to be restricted to stem cells 
where it regulates stem cell growth and survival (327, 328). However a recent 
study provided evidence for the participation of s-SHIP in adult haematopoietic 
cells. s-SHIP was found to synergize with SHIP-1 and regulate macrophage 
activation (329). In structural terms, s-SHIP lacks the N-terminus and therefore 
the SH2 domain that SHIP-1 expresses. This means that s-SHIP is not able to 
bind phospho-tyrosine residues directly, altering the binding partners of s-SHIP. 
For example SHIP-1 but not s-SHIP is able to bind shc, whilst both isoforms can 
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SHIP-2 is encoded by a separate gene from SHIP-1 but retains about 65% 
homology. SHIP-2 is 142kDa in size and like SHIP-1 also hydrolyses PI(3,4,5)P3, 
however SHIP-2 has also been reported to hydrolyse PI(4,5)P2 in vitro. SHIP-2 
contains a Sterile-alpha-motif (SAM) domain that is involved in SAM-SAM 
domain interactions, for example with ARAP3 (281). SHIP-2 also possesses a 
ubiquitin interacting motif at the C-terminal. Again differing from SHIP-1, the 
expression of SHIP-2 is more ubiquitous, with SHIP-2 expression detected in 
various tissues including skeletal muscle, brain tissue and heart, although SHIP-
2 is still expressed by leukocytes (331, 332). The major role of SHIP-2 appears to 
be the negative regulation of insulin signalling in non-immune cells (333). SHIP-2 
has therefore become an attractive target for the treatment of Type 2 diabetes. In 
accordance with the different roles of SHIP-1 and SHIP-2, they differ in their 
ability to bind and interact with other proteins due to differences in the structural 
domains of these two proteins (195, 276, 334) (Table 1.4).  SHIP-2 has also 
been described to have a role in the regulation of cell polarization and motility in 
glioma cells (335), podocytes (336) and keratinocytes (337). In addition, SHIP-2 
has been detected at focal adhesions and in the lamellipodia of cells, further 
indicating a role for SHIP-2 in cell adhesion and migration (338). 
 
1.9.7. INPP4b 
INPP4b hydrolyses the enzymatic product of SHIP-1 and SHIP-2, PI(3,4)P2, 
removing the phosphate on the D-4 position of the inositol ring to from PI(3)P 
(339). INPP4b therefore acts to negatively regulate SHIP-1 and SHIP-2 mediated 
signalling and reduce Akt activation. INPP4b contains a N-terminal C2 domain 
which binds PI(3,4,5)P3, a central NHR2 domain (Nervy Homology 2 domain) 
that is involved in protein-protein interactions and oligomerization, whilst the 
catalytic domain responsible for PI(3,4)P2 hydrolysis is located at the C-terminal 
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(339). INPP4b is highly expressed in the brain, heart, skeletal muscle and 
epithelial cells of the prostate and breast (340, 341) and  has been described to 
act as a tumour suppressor gene in various cancers. Loss of INPP4b expression 
is associated with hormone receptor negative breast cancer and decreased 
patient survival (342, 343). In prostate cancer, INPP4b and PTEN were down-
regulated in primary prostate tissues compared to normal tissue, and depletion of 
INPP4b was shown to increase Akt activation and proliferation (344). INPP4b 
has also been implicated as a tumour suppressor gene in ovarian teratomas 
(345) and laryngeal cancer (346). Recently, evidence for the loss of INPP4b 
expression has been shown in leukaemia patients with downs syndrome (347). In 
addition, INPP4b has been shown to modulate osteoclast differentiation and 
regulate bone mass in mice and humans (348).   
 
 
1.10. Pharmacological targeting of lipid phosphatases 
 
1.10.1.  Limitations of directly targeting PI3K for the treatment of 
inflammatory disorders 
As previously mentioned, the inhibition of PI3K looks extremely promising for the 
treatment of certain cancers (140, 147) in particular the targeting of PI3Kδ 
against lymphoid malignancies. However, the development of PI3K inhibitors with 
which to treat inflammatory disorders has to date been disappointing. This may 
be because the treatment of inflammatory disorders requires a ‘lighter touch’ than 
the treatment of cancers and the window of inhibitor selectivity for PI3Kγ over 
other PI3K isoforms (some of which have ubiquitous expression) has not been 
sufficient. This is perhaps due to the close structural conservation of the ATP 
binding pocket between different Class 1 PI3Ks. Efforts to develop PI3K 
inhibitors for the treatment of inflammatory disorders are still ongoing at multiple 
pharmaceutical companies (108), however the lack of progress in the 
development of PI3K inhibitors has led to the search for alternative or 
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complementary means with which to modulate PI3K mediated signalling in the 
immune system.  
 
1.10.2.    Pharmacological targeting of SHIP-1 
An alternative approach to the direct inhibition of PI3K is to pharmacologically 
modulate  the activity of the lipid phosphatase regulators of PI3K mediated 
signalling. The restricted expression of SHIP-1 to the haematopoietic system 
makes it an attractive drug target because this should limit the effects of SHIP-1 
targeting drugs to cells of the immune system. Given the variety of roles that 
SHIP-1 and PI3K have in immune cells, inflammatory disease settings and in 
haematopoietic cancers, the pharmacological targeting of SHIP-1 may be 
therapeutically useful for a range of immune cell mediated disorders.  
 
1.10.3.   Allosteric activators of SHIP-1 
The natural product, pelorol, is an extract from the marine invertebrate 
Dactylospongia elegans and was first identified as an activator of SHIP-1 in 2005 
(349). Subsequently, more potent synthetic analogues were produced by 
Aquinox Pharmaceuticals. AQX-016A and AQX-MN100 (Figure 1.11) were 
shown to inhibit the activation of mast cells and macrophages in vitro, and 
demonstrated anti-inflammatory effects in vivo in mouse models of acute 
cutaneous anaphylaxis and endotoxemia (255). This study also showed that the 
SHIP-1 enzymatic product, PI(3,4,)P2, allosterically increased the catalytic activity 
of SHIP-1. Pelorol and analogues were shown to mimic binding of PI(3,4)P2 to 
the C2 domain of SHIP-1, and to increase the catalytic activity of SHIP-1. As 
would be predicted, pharmacological activation of SHIP-1 reduced levels of 
PI(3,4,5)P3 and increased levels of the SHIP-1 product, PI(3,4)P2.  
 
Pharmacological activation of SHIP-1 has also been shown to increase the 
apoptosis of multiple myeloma cells in vitro, whilst in combination with 
bortezomib (an established multiple myeloma treatment) demonstrated more 
potent killing than either treatment alone (350). Pharmacological activators of 
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SHIP-1 are currently in clinical trials for the treatment of airway inflammatory 
disorders. AQX-1125 has recently completed phase 2 clinical trials for the 
treatment of mild to moderate asthma, with LPS challenge in healthy human 
volunteers resulting in a 66% decrease in neutrophil numbers in sputum by AQX-
1125 treatment (351).  
 
1.10.4.    SHIP-1 inhibitors 
The identification of a selective SHIP-1 inhibitor, termed 3 α-aminocholestane 
(3AC) (Figure 1.11), was first reported in 2010 (325). High throughput screening 
of a library of compounds was used to identify 3AC which inhibited the catalytic 
activity of SHIP-1 but not SHIP-2 or PTEN. The site of drug-protein interaction 
remains unclear. The inhibition of SHIP-1 in mice with 3AC was found to increase 
the numbers of myeloid-associated suppressor cells, reduce the priming of 
myeloid associated cell responses and to be protective against graft-versus-host 
disease (325). These results demonstrate that SHIP-1 may be a promising novel 
target to therapeutically aid transplant acceptance in patients who have 
undergone transplant surgery. Pharmacological SHIP-1 inhibition also increased 
the levels of neutrophils, platelets, granulocytes and erythrocytes in mice. This 
indicates that SHIP-1 inhibition may also have potential in the restoration of blood 
cell numbers in patients suffering from myelodysplastic syndrome or 
myelosuppressive infection.    
 
Pharmacological inhibition of SHIP-1 has also been shown to induce the 
apoptosis of human acute myeloid leukaemia cells in vitro (325). A subsequent 
study showed that pharmacological SHIP-1 inhibition reduced multiple myeloma 
cell growth in a mouse tumour xenograft model (352). This would appear to 
contradict evidence that pharmacological activation of SHIP-1 induced the 
apoptosis of leukemic cells (350). However, as mentioned earlier the SHIP-1 
product, PI(3,4)P2 as well as the SHIP-1 substrate, PI(3,4,5)P3 can both activate 
Akt (240). In addition, William Kerr has proposed a “Two PIP Hypothesis”, 
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whereby a cancer cell requires certain levels of both PI(3,4,5)P3 and PI(3,4)P2 for 
optimal Akt activation and survival (353).  
 
1.10.5.    Pharmacological targeting of SHIP-2  
SHIP-2 has an important role in regulating insulin mediated signalling pathways, 
whilst the described role of SHIP-2 in obesity, type-2 diabetes, cancer and 
atherosclerosis (333, 354) has provided a rationale for the development of 
selective SHIP-2 inhibitors. Small molecule compounds that selectively inhibit the 
catalytic activity of SHIP-2 have recently been identified (355). In vitro, SHIP-2 
inhibition was found to increase the phosphorylation of Akt and increase glucose 
uptake by L6 myotube cells, whilst in vivo the inhibition of SHIP-2 in diabetic mice 
reduced plasma glucose levels (355).  
 
Another group has recently described an inhibitor of SHIP-2 catalytic activity, 
termed BiPhenyl 2,3’,4,5’,6-pentakisphosphate (356). BiPhenyl 2,3’,4,5’,6-
pentakisphosphate mimics the substrate of SHIP-2 but does not get hydrolysed 
and therefore acts as an inhibitor. The compound in its current structure is not 
cell permeable however and therefore does not possess drug-like properties. 
This compound has however been used to identify a flexible loop of SHIP-2, but 
not SHIP-1, that folds over the substrate to enclose it (357), which may be 
utilised in the design of more specific SHIP-2 targeting compounds.  
 
As discussed previously, SHIP-1 inhibitors have been reported to kill leukemic 
cells (325). However, leukemic cells that become resistant to SHIP-1 inhibition 
have been found to up-regulate expression of SHIP-2 in compensation (352). 
Therefore the dual inhibition of SHIP-1 and SHIP-2 may prove beneficial in 
certain cancers. Interestingly, panSHIP-1/2 inhibitors have recently been 
identified and have been shown to promote apoptosis and induce cell cycle 
arrest in multiple myeloma cells (352). In addition to having therapeutic potential 
for the treatment of diabetes and cancers, the development of selective SHIP-2 
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inhibitors provide a useful tool with which to probe the little known role of SHIP-2 




LY294002 (pan PI3K) CAL-101 (PI3Kδ)  AS-605240 (PI3Kγ)  IC-87114 (PI3Kδ)  
Pelorol  AQX-MN100  AQX-016A  3α-aminocholestane  
AS1949490  BiPhenyl(2,3,4,5,6)P5  



















To summarise, PI3K mediated signalling is crucial for the immune system to 
respond and destroy invading pathogens as well as cancerous cells. Over-active 
PI3K mediated signalling however can lead to the development of inflammatory 
and autoimmune pathologies as well as cancer. Progress in the development of 
pharmacological inhibitors of PI3K with which to treat inflammatory disorders has 
been disappointing. The development of small molecule compounds that potently 
and selectively modulate the activity of SHIP-1 has provided a novel, alternative 
mechanism to specifically alter PI3K mediated signalling in leukocytes. Most 
studies that have previously investigated the role of SHIP-1 in the immune 
system have used genetic strategies, either in mice or in human cells. The 
availability of novel inhibitors and activators of SHIP-1 activity therefore opens up 
a new approach to investigate the role of SHIP-1 in the immune system, and may 
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1.12. Aims of research 
 
The aim of this thesis was to probe the role of lipid phosphatase regulators of 
PI3K mediated signalling in primary human T lymphocytes using small molecule 
SHIP-1 and SHIP-2 targeting compounds. In particular, key objectives were: 
 
 
• To investigate the effect of PI3K inhibition on human Th17 function 
• To determine the effect of pharmacological SHIP-1 inhibition or activation 
on chemokine/GPCR mediated signalling and motility in T lymphocytes 
• To investigate the effect of pharmacological SHIP-1 modulation on the 
adhesion of T lymphocytes   
• To investigate the effect of pharmacological SHIP-1 modulation on 
TCR/tyrosine kinase coupled receptor mediated signalling and 
proliferation  
• To determine the effect of SHIP-1 inhibition or activation on the survival 
and viability of T lymphocytes 
• To examine the role of SHIP-1 in cytokine expression and secretion 
• To determine the effect of novel SHIP-2 inhibitors on T lymphocyte 
function  
• To characterise the expression and function of INPP4b in primary human 
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2.1. Cell Culture 
 
2.1.1. Leukemic T cell lines 
The leukemic T cell lines Jurkat, MOLT-4, CEM and HUT-78 were cultured in 
RPMI 1640 medium supplemented with 10% fetal calf serum (FCS), 10µg/ml 
streptomycin and 10µg/ml penicillin (Complete RPMI medium). Cells were 
cultured at 0.5-1x106 cells/ml every 2-3 days, at 37°C in 95% air and 5% CO2. 
 
2.1.2. Isolation of peripheral-blood mononuclear cells (PBMC) 
Procedures using human blood were carried out under The University of Bath 
safety and ethical guidelines for the use of human tissue. Peripheral blood 
donated by healthy human volunteers was heparinised (10 Units/ml) in syringes 
and mixed at a 1:1 ratio with RPMI 1640 medium. 35ml of blood/RPMI was 
layered on top of 15ml Lymphoprep (Greiner Bio One) in 50ml Falcon tubes. 
These were centrifuged for 30 minutes at 1500RPM with the brake off on 
deceleration. The PBMC layer was then extracted from the tube using a Pasteur 
pipette and washed three times in RPMI 1640 medium.  
 
2.1.3. Staphylococcal enterotoxin B (SEB) -activated T lymphocytes 
PBMCs were isolated as described above then suspended in complete RPMI 
medium at the same volume as blood taken. SEB (1µg/ml) was added to cells for 
72 hours. Cells were washed three times in RPMI and re-suspended in complete 
RPMI medium plus IL-2 (36 Units/ml). The volume of media was doubled every 
three days and cells were used between days 8-12 post isolation.  
 
2.1.4. Isolation of Naïve CD4+ T lymphocytes 
To isolate untouched naïve CD4+ cells from the PBMC, the Naïve CD4+ T cell 
Isolation Kit II (Miltenyi Biotech) was used. This technique uses a magnetic 
labelling system to allow the depletion of non-T helper cells as well as memory T 
cells.  
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After isolation of the PBMC as described above, cells were re-suspended in 40µl 
buffer (PBS, pH7.2, 0.5% bovine serum albumin and 2mM EDTA) per 10×106 
cells and 10µl Naïve CD4+ T cell Biotin-Antibody Cocktail II added per 10×106 
cells. Cells were mixed and incubated at 4°C for 10 minutes. 10ml buffer was 
then added and the cells centrifuged for 10 minutes at 1500RPM. The cell pellet 
was re-suspended in 80µl buffer per 10×106 cells, 20µl Anti-Biotin MicroBeads 
added per 10×106 cells and incubated at 4°C for 15 minutes, after which 10ml 
buffer was added and the cells centrifuged for 10 minutes at 1500RPM. The cell 
pellet was then re-suspended in 500µl buffer and applied to a column (pre-rinsed 
with 3ml buffer) in a MACS Separator magnet. 9ml buffer was washed through 
the column and the eluted fraction which contained the untouched naïve CD4 
cells was centrifuged at 1500RPM for 10 minutes. Cells were then washed twice 
in RPMI and used as required.  
 
2.1.5. Production of anti-CD3/anti-CD28 antibody coated micro-beads 
Anti-CD3 antibody (UCHT1) 75µg was mixed with anti-CD28 antibody (9.3) 75µg 
in 0.1M Borate buffer (pH 9.5), added to 4×108 magnetic Dynabeads (Invitrogen, 
UK) and rotated overnight at 37oC.  Beads were then removed from Borate buffer 
using a magnet and re-suspended in Bead wash buffer (PBS, Human AB serum, 
Sodium azide, EDTA, pH 8). Beads were washed at 4oC in Bead wash buffer 
three times for 10 minutes, once for 30 minutes and once overnight. 4×108 anti-
CD3/anti-CD28 antibody coated beads were re-suspended in 10ml Bead wash 
buffer and stored at 4oC. Beads were washed three times in RPMI medium 
before addition to cells.  
 
2.1.6. Generation of activated CD4+ T lymphocytes (Th0) 
Naïve CD4 T lymphocytes were cultured in RPMI 1640 medium supplemented 
with 10% fetal calf serum (FCS), 10µg/ml streptomycin and 10µg/ml penicillin 
and activated using anti-CD3 and anti-CD28 antibody coated beads at a 1:1 
ratio. Cells were cultured at 0.5-1x106 cells/ml in the presence of IL-2 (36 
Units/ml) for up to 12 days post isolation. 
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2.1.7. Polarisation of Th17 cells 
To induce a Th17 polarised phenotype, naive CD4 T lymphocytes were cultured 
in complete RPMI medium in the presence of IL-6 (50ng/ml), IL-1β (10ng/ml), IL-
23 (50ng/ml), IL-21 (25ng/ml), TGFβ (5ng/ml), anti-IFNγ (1µg/ml) and anti-IL-4 
(0.2µg/ml). Cells were cultured at 0.5-1x106 cells/ml and cultured every 2-3 days 
and analysed on day 9. 
 
2.1.8. Polarisation of Th1 cells 
To induce a Th1 polarised phenotype, naive CD4 T lymphocytes were cultured in 
complete RPMI medium in the presence of IL-12 (2ng/ml), anti-IL-4 (200ng/ml) 
and IL-2 (36 Units/ml). Cells were cultured at 0.5-1x106 cells/ml and cultured 
every 2-3 days and used between days 9-12. 
 
2.1.9. Polarisation of Th2 cells 
To induce a Th2 polarised phenotype, naive CD4 T lymphocytes were cultured in 
complete RPMI medium in the presence of anti-IFNγ (200µg/ml), anti-IL-12 
(200µg/ml), IL-4 (20ng/ml) and IL-2 (36 Units/ml). Cells were cultured at 0.5-
1x106 cells/ml and cultured every 2-3 days and used between days 9-12. 
 
2.1.10 .   A20 B cells 
The mouse B cell lymphoma cell line, A20, was cultured in complete RPMI 
culture medium supplemented with 2-Mercaptoethanol (Dilution factor 1:25). 
Cells were cultured at 0.5-1x106 cells/ml every 2-3 days, at 37°C in 95% air and 
5% CO2. 
 
2.1.11. Human embryonic kidney (HEK) 293 
HEK 293 cells were cultured at 37°C in 95% air and 5% CO2 in RPMI 1640 
medium supplemented with 10% fetal calf serum (FCS), 10µg/ml streptomycin 
and 10µg/ml penicillin. HEK 293 cells were cultured every 2-3 days and were not 
allowed to reach confluency of more than 80%. To culture HEK cells, cells were 
first removed from RPMI medium and washed once in phosphate buffered saline 
Chapter 2: Materials and Methods 
58 
(PBS). Cells were then trypsinised for 2 minutes at 37°C until all cells were 
removed from the bottom of the flask. The RPMI medium was then added back 
to the detached cells, centrifuged and re-suspended in fresh complete RPMI 
medium at the required density.  
 
 
2.2. Protein detection using Western blotting 
 
2.2.1. Western Blotting 
Cells were washed out of IL-2 the night before stimulations. On the day of 
stimulation, cells were washed twice in plain RPMI medium and re-suspended at 
2×106/ml in RPMI medium. Cells were then treated as described in the figure 
legends, centrifuged and lysed in 50µl lysis buffer (50 mM Tris-HCl [pH 7.5], 150 
mM NaCl, 1% Nonidet P-40, 5 mM EDTA, 1 mM sodium vanadate, 1mM sodium 
molybdate, 10 mM sodium fluoride, 40 µg/ml PMSF, 0.7 µg/ml pepstatin A, 10 
µg/ml aprotinin, 10 µg/ml leupeptin, 10 µg/ml soybean trypsin inhibitor). Samples 
were rotated for 30 minutes at 4°C and centrifuged for 10 minutes at 12,000RPM. 
20µl supernatant was collected and mixed with 5µl 5× sample buffer and boiled 
at 100°C for 5 minutes, briefly centrifuged to remove condensation and 20µl per 
sample loaded into the required wells of a 10% acrylamide gel. Proteins were 
separated using electrophoresis with the gel run at 75V for 15 minutes then run 
at 150V for 60 minutes to resolve the proteins. Gels were transferred to a 
nitrocellulose membrane at 40mA per membrane for 60 minutes and the 
membrane blocked for 1 hour in 5% milk/TBS-Tween. Membranes were 
incubated with the required primary antibody (Table 2.1) which was diuted in 
TBS-tween, 5% BSA and 0.01% Sodium Azide, overnight at 4oC. The membrane 
was then washed three times in TBS-Tween, and incubated with anti-rabbit IgG 
or anti-goat IgG HRP conjugated secondary antibody diluted in TBS-Tween/ 1% 
milk for 60 minutes at room temperature. Membranes were washed three times 
in TBS-Tween and antibody bound protein bands visualized using ECL 
(Amersham Bioscience) and x-ray film (Fuji).      
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Name Manufacturer Catalogue number 
Phospho-Akt (ser473) Cell Signalling 
Technology 
4060 
Phospho-PLCγ (Tyr783) Cell Signalling 
Technology 
2821 








SHIP-2 Cell Signalling 
Technology 
C76A7 





GRB2 Cell Signalling 
Technology 
3972 
INPP4b Cell Signalling 
Technology 
4039 








ERK1 Santa Cruz 
Biotechnology 
C-16 
Phospho-Tyrosine Santa Cruz 
Biotechnology 
SC-508 
Type II 4-phosphatase Santa Cruz 
Biotechnology 
SC-12318 
RORα Santa Cruz 
Biotechnology 
SC-133973 






Anti-Mouse IgG (Whole 
molecule) 
Sigma M7023 
HRP conjugated anti- Dako P0448 














5×106 cells were treated as stated in the figure legends and lysed in 1ml lysis 
buffer (50 mM Tris-HCl [pH 7.5], 150 mM NaCl, 1% Nonidet P-40, 5 mM EDTA, 1 
mM sodium vanadate, 1mM sodium molybdate, 10 mM sodium fluoride, 40 µg/ml 
PMSF, 0.7 µg/ml pepstatin A, 10 µg/ml aprotinin, 10 µg/ml leupeptin, 10 µg/ml 
soybean trypsin inhibitor) for 30 minutes at 4°C. Samples were centrifuged for 10 
minutes at 12,000 RPM at 4°C, transferred to fresh eppindorf tubes and 
incubated overnight at 4°C with 10µl of the required primary antibody. A/G 
agarose beads (Peprotech) were washed twice in lysis buffer then 5µl agarose 
beads was added to each 1ml lysis buffer sample and incubated for two hours at 
4°C. Samples were centrifuged and washed three times in 1ml lysis buffer, after 
the final wash samples were centrifuged to collect beads and the supernatant 
aspirated away. Agarose beads/protein were then re-suspended in 2× sample 
buffer and heated at 100°C for 5 minutes, centrifuged for 1 minute at 10,000 
RPM and the supernatant which contained immuno-precipitated protein was 
loaded on to a 10% polyacrylamide gel for detection of proteins using western 
blotting as described in section 2.2.1.  
 
2.2.3. Subcellular fractionation 
10×106 cells per point were washed three times in plain RPMI medium and 
stimulated as stated in the figure legend. Cells were then suspended in 1ml 
hypotonic lysis buffer (10mM HEPES (pH 7.2), 5mM EDTA, 1 mM sodium 
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vanadate, 1mM sodium molybdate, 10 mM sodium fluoride, 40 µg/ml PMSF, 0.7 
µg/ml pepstatin A, 10 µg/ml aprotinin, 10 µg/ml leupeptin, 10 µg/ml soybean 
trypsin inhibitor) and placed on ice for 10 minutes. Sonication using three 2 
second pulses with 20 second intervals was used to burst cells. Samples were 
then centrifuged for 10 seconds at 13,000RPM to remove the cell nucleus and 
any remaining whole cells. Remaining supernatants were centrifuged at 100,000 
g at 4°C for 20 minutes (Beckman ultra centrifuge, rotor 701T1). This separated 
the cytosolic proteins (supernatant) from the membrane bound proteins (pellet). 
The pellet was rinsed once in hypotonic lysis buffer then re-suspended in 100µl 
nonidet containing lysis buffer. The supernatant was mixed 1:1 with ice-cold 
acetone and left on ice for 10 minutes. Samples were then centrifuged for 10 
minutes at 4°C at 13,000 RPM. Pelleted protein was re-suspended in 100µl 
nonidet containing lysis buffer. 20µl supernatant was collected and mixed with 
5µl 5× sample buffer and boiled at 100°C for 5 minutes. Proteins were separated 
using electrophoresis with a 10% SDS-PAGE gel and transferred to a 
nitrocellulose membrane. The membrane was then blocked for 1 hour in 5% milk 
and incubated overnight at 4°C in the required antibody. Bands were visualized 
using ECL (Amersham Bioscience, #RPN2106).   
 
 
2.3. Flow Cytometry 
 
2.3.1. Intracellular cytokines 
1×106 cells per point were stimulated with ionomycin (1µg/ml) (invitrogen) and 
PMA (50ng/ml) for 4 hours in the presence of the protein transport inhibitor 
Golgiplug (containing Brefaldin A) to retain cytokines within the cell. Cells were 
centrifuged and re-suspended in 250µl BD Bioscience Fixation/Permeabalization 
solution for 20 minutes at 4°C. Cells were washed one in PERM solution (BD 
Bioscience) and incubated for 20 minutes in PERM solution at 4°C. Cells were 
then re-suspended in 100µl PERM solution containing 1µl primary antibody 
conjugated to FITC or PE (Table 2.2) and incubated for 30 minutes at 4°C. Cells 
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were washed twice for 5 minutes in PERM solution and re-suspended in 400µl 
PBS containing 1% fetal calf serum. Samples were then analysed using flow 
cytometry. 
 
2.3.2. Intracellular protein detection 
Cells were stimulated as stated in the figure legend then fixed in BD Fixation and 
Permeabilization solution (BD Biosciences) for 30 minutes at 4°C. Cells were 
washed twice in BD PERM solution and incubated with anti-phospho Akt (serine 
473) (Cell Signalling Technology #4060) for 30 minutes at 4°C. Cells were 
washed twice in BD PERM solution (BD Biosciences) and incubated with anti-
rabbit IgG PE conjugated secondary antibody for 30 minutes at 4°C. Cells were 
washed twice in BD PERM solution, re-suspended in 400µl PBS/1% FCS and 
analysed using FACSCanto flow cytometer (BD Bioscience) and DIVA software. 
 
 
Name Manufacturer Catalogue number 
IL-4  BD Pharmingen 557728 
IFNγ  BD Pharmingen 557718 
IL-17A R&D Systems IC171P 
CXCR3 R&D Systems FAB160P 
Phospho-Akt (ser473) Cell Signalling 
Technology 
4060 
CCR4 BD Biosciences 551120 
CCR6 eBioscience R6HI 
CXCR4 eBioscience 12GS 
CD11a Immunotools 2120114 
CD49d Immunotools 21488494 
7AAD eBioscience 00-6993-50 
KIM127 Gift from Dr Nancy hogg - 
 
Table 2.2. Flow cytometry antibodies 
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2.3.3. Cell surface receptor expression 
1×106 cells were treated as stated in the figure legends, washed once in ice-cold 
PBS and re-suspended in 50µl PBS. 5µl FITC or PE labelled primary antibody 
was added and incubated at 4°C for 20 minutes. Cells were then washed twice in 
ice cold PBS, re-suspended in 400µl PBS and analysed using flow cytometry. 




2.4. Migration assays 
 
2.4.1. Neuroprobe Chemotaxis Assay 
Cells were washed three times in RPMI medium, re-suspended in phenol red 
free RPMI 1640 with 0.1% BSA  (Chemotaxis media) at 3.2×106 cells/ml and 
treated as described in figure legends. Lower chambers of the 96-well plate 
(Neuro Probe, Inc) (Figure 2.1 A and B) were loaded with 29µl RPMI (basal 
conditions) or CXCL11 (10nM, Peprotech) for previously activated cells or 
CXCL12 (10nM, Peprotech) for naïve CD4 cells. This was overlaid with a 5-µm 
pore-size filter. 25µl cell suspension was added over each required well and the 
plate incubated at 37°C, 5% CO2 for 3 hours. Following this, remaining cells left 
on top of the membrane were wiped away and the plate centrifuged for 10 
minutes at 1400RPM. All solution contained in the lower wells was transferred to 
FACs tubes containing 300µl PBS. Viable cells recovered from the bottom 
chamber of each well were then counted using flow cytometry. 
 
2.4.2. Ibidi µ-slide chemotaxis assay 
IBIDI µ-slides (IBIDI, 80301, Thistle Scientific) (Figure 2.1 C) were coated with 
fibronectin (45µg/ml, R&D Systems) in PBS for 1 hour at room temperature, then 
the slide washed three times with chemotaxis media. The slide was filled with 
80µl chemotaxis media and 18µl 100nM CXCL11 was added to the top chamber 
and drawn through the slide by withdrawing 18µl form the lower chamber, to 
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create a chemokine gradient over the cells located on the bridge. 6µl cells at 
5×106/ml density in chemotaxis media were treated for 15 minutes as stated in 
the figure legends and added to the left side chamber. Caps were then added to 
the four wells and the slide left to equilibrate for 15 minutes at 37°C on the 
microscope stand. Images were taken every 15 seconds for 15 minutes at 37°C 
using a Zeiss LSM 510 META microscope. Individual cells were tracked for the 
15 minute time period using the ImageJ manual tracker and analysed using 









Figure 2.1. Chemotaxis assays used for the assessment of lymphocyte 
motility. A) Photograph of a 96-well plate Neuroprobe chemotaxis plate (Image 
taken from: http://www.neuroprobe.com/products/chemo_tx.html) B) Diagram of 
a single well of a Neuroprobe chemotaxis 96-well plate. Cell suspension is 
pipetted on top of a synthetic membrane, below which is filled with RPMI medium 
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2.5. MTT assay 
 
The yellow tetrazolium salt, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) is converted to a water insoluble blue formazan 
product by mitochondrial succinic dehydrogenases. DMSO is used to solubilize 
formazan, with the resulting intensity proportional to the number of viable cells 
present per well.  
 
Naïve CD4 cells were treated as stated in the figure legends 30 minutes prior to 
the addition of anti-CD3/anti-CD28 antibody coated beads at a 1:1 ratio. Cells 
were then incubated at 37°C and 5% CO2 for 48 hours in complete RPMI 
medium in a 96-well plate. The plate was then centrifuged for 5 minutes and the 
media aspirated off. 100µl per well of RPMI minus phenol red, 10% FCS and 
500µg/ml MTT reagent was added for 2 hours and incubated at 37°C. The plate 
was centrifuged for 5 minutes and the media aspirated off. 100µl per well of 
DMSO was added for 5 minutes at 37°C. Absorbance was then read on a plate 
reader at 540nm.  
 
 
2.6. Carboxyfluorescein diacetate succinimidyl ester (CFSE) 
proliferation assay 
 
CFSE diffuses in to cells and becomes cleaved by intracellular esterase’s to form 
fluorescent conjugates. These conjugates bind amide groups of proteins and are 
retained within living cells and passed on to daughter cells following meiosis, 
whereby fluorescence levels have halved. The intensity of fluorescence in a cell 
population can then be quantified using flow cytometry. Naïve CD4 cells were 
stained with CFSE according to the manufacturers’ instructions (Invitrogen) and 
treated as stated in the figure legends 30 minutes prior to addition of anti-
CD3/anti-CD28 antibody coated beads at a 1:1 ratio and IL-2 (36 units/ml). Cells 
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were incubated at 37°C, 5% CO2 in complete RPMI medium for 4 days, then 
analysed using flow cytometry (Day 0 cells were analysed using flow cytometry 
immediately after staining on day 0).  
 
 
2.7. Cell viability assays 
 
2.7.1 LDH assay 
The LDH assay can be used to quantitate cytotoxicity. Lactate dehydrogenase 
(LDH) is a cytosolic protein that is released through the plasma membrane by 
non-viable cells. LDH release will result in the conversion of the salt INT into the 
red product Formazan, which in turn can be measured by a plate reader. 
 
SEB-activated primary T lymphocytes or Jurkat cells were suspended in phenol 
red free-RPMI medium at 1×106/ml and 90µl aliquoted into required wells of a 96-
well plate, in triplicate. 3AC or novel derivative was added at stated concentration 
for three hours at 37oC, 5% CO2. Triton X-100 was used as a positive control of 
LDH release and was added to required wells for 5 minutes. The 96-well plate 
was centrifuged at 250 g for 10 minutes and 50µl supernatant from each well 
transferred to a clear bottomed 96-well plate. 50µl LDH assay reagent (Promega, 
Southampton, UK) was added to each required well and the plate incubated in 
darkness for 30 minutes. The reaction was stopped by addition of 50µl acetic 
acid (1M) and the absorbance measured at 490nm using a plate reader.  
 
2.7.2 7AAD (7-amino-actinomycin D) staining 
7AAD is a membrane impermeant dye which binds to DNA and is excluded from 
viable cells. Non-viable cells however lose their membrane integrity and can 
therefore be differentiated from viable cells using 7AAD staining. 1×106 cells 
were treated as stated in the figure legends, washed once in ice-cold PBS, re-
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suspended in 300µl PBS and stained with 10µl 7-AAD for 5 minutes on ice. Cell 
viability was then immediately assessed using flow cytometry.  
 
2.7.3 Propidium Iodide (PI) staining 
PI binds to both DNA and RNA and subsequently increases in fluorescence. PI is 
not cell membrane permeable and is excluded from the nucleus of viable cells. PI 
can therefore be used to determine the viability of a cell population. 1×106 cells 
were treated as stated in the figure legend, washed once in ice-cold PBS then re-
suspended at 1×106 cells/ml in PBS (pH 7.4). Propidium Iodide was added at 
2µg/1×106 cells and cells analysed immediately using flow cytometry. 
 
 
2.8. Malachite green phosphatase assay 
 
SHIP-1 or INPP4b protein was immuno-precipitated so that per well of the 96-
well plate, the equivalent of 1×106 cell protein of SHIP-1 or INPP4b and 1µl 
antibody was present. 10×106 cells were lysed in 1ml lysis buffer for 30 minutes 
at 4°C, centrifuged for 10 minutes at 12,000 RPM at 4°C and the supernatants 
transferred to fresh eppindorf tubes and incubated overnight at 4°C with 10µl 
primary antibody. The following morning, A/G agarose beads (Peprotech) were 
washed twice in 1% Nonidet P-40 lysis buffer, 5µl agarose beads added to each 
sample and incubated for two hours at 4°C. Samples were then washed three 
times in 1ml lysis buffer and three times in malachite green reaction buffer (5% 
glycerol, 20mM Tris HCL (pH7.5) and 10mM MgCl2). Beads were then re-
suspended in 20µl reaction buffer per 1×106 cells used. 20µl of beads/solution 
were added to the required wells of a 96-well plate and 2.5µl drug if required was 
added for 5 minutes at room temperature. 2.5µl substrate (Ins(1,3,4,5)P4 from 
Echelon Biosciences (#Q-1345). D-Ins(1,3,4,5)P4, L-Ins(1,3,4,5)P4, Ins(1,3,5)P3, 
Di-C8-PtdIns(3,4,5)P3, DI-C16-PtdIns(3,4,5)P3 and Ins(1,3,4)P3 were produced 
by Andy Riley (Pharmacy and Pharmacology, University of Bath, UK)) was then 
added at required concentration for 30 minutes at 37°C. 100µl malachite green 
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solution (Echelon) was added directly to each required well and incubated for 15 
minutes at room temperature in the dark. The plate was then read at 650nm 
using a plate reader. For assays using SHIP-2 protein, recombinant SHIP-2 
protein was used at 0.16µM concentration (gifted by Gyles Smith, Pharmacy and 
Pharmacology, University of Bath, UK).  
 
 
2.9. Cytokine detection assays 
 
2.9.1.  ELISA 
1×106 day 9 Th17 or Th0 polarized CD4 T lymphocytes were treated as stated in 
the figure legends then stimulated with anti-CD3/anti-CD28 antibody coated 
beads at a 1:1 ratio for 16 hours in complete RPMI medium. The supernatant 
was harvested and levels of IL-17A determined using a Ready-Set-Go IL-17A 
homodimer ELISA (eBioscience, #88-7176-22). The ELISA was performed 
according to manufactures instructions and levels of IL-17A determined at 450nm 
using a plate reader.   
 
2.9.2.  MSD plate reader 
1×106 day 9 Th2 polarized CD4 T lymphocytes were treated as stated in the 
figure legend then stimulated with anti-CD3/anti-CD28 antibody coated beads at 
a 1:1 ratio. After 16 hours the supernatant was collected and stored at -80°C. 
Th1/Th2 10-plex MSD plate was blocked for 1 hour at room temperature in 
Blocker B solution and shaken at 300RPM. The plate was then washed three 
times with PBS/0.05% Tween-20. 25µl sample or standard was added to the 
required wells, the plate was sealed and shaken at 300RPM for 2 hours. 25µl 
detection antibody was then added to each well of the plate and shaken at room 
temperature for 1 hour. The plate was washed three times in PBS/0.05% Tween-
20, 150µl of Read buffer added and the plate analysed using a MSD SECTOR 
6000 imager.  
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2.10. Silver Staining 
5×106 SEB-activated T cells were treated as stated in the figure legend, lysed 
and SHIP-1 immuno-precipitated as described in section 2.2.2. Samples were 
then run on a NuPage 4-12% Bis-Tris gel. Proteins on the gel were visualized 
using the SilverXpress Silver Staining kit from Invitrogen. The gel was first fixed 
in fixing solution (40%mq H20, 50% methanol, 10% acetic acid) for 10 minutes, 
then incubated in sensitizing solution (50% mq H20, 45% methanol, 5ml 
sensitizer) for two 30 minute incubations. The gel was washed twice for 5 
minutes in mq H20, incubated in staining solution (5% Stainer A, 5% Stainer B, 
90%mqH20) for 15 minutes and washed twice with mq H20 for 5 minutes. 
Developing solution (5% developer, 95% mq H20) was then added for the 
required time period until proteins could be visualized (~10 minutes). Stopping 
solution (100% stopper) was added to the gel and washed three times in mq H20 
for 10 minutes each wash.  
 
 
2.11. Confocal microscopy 
1×106 cells were treated a stated in the figure legends then fixed in BD cytofix for 
30 minutes at 4°C. Cells were washed twice in BD PERM solution, suspended in 
100µl PERM buffer (BD Biosciences) and incubated with anti-INPP4b primary 
antibody at a dilution of 1:100 for 1 hour at 4°C. Cells were washed twice in 
PERM buffer and re-suspended in 100µl PERM buffer with Goat anti-rabbit IgG 
FITC conjugated secondary antibody (dilution of 1:100) and DAPI for nuclear 
staining (1µg/ml) for 1 hour at 4°C. Cells were then washed twice in PERM 
solution, suspended in 100µl PERM solution and centrifuged onto coverslips 
using a Shandon Cytospin 3 centrifuge for 10 minutes at 500 rpm. Mowiol was 
placed on top of the cell pellet and a coverslip placed on to the Mowiol and 
allowed to set overnight at room temperature. Cells were visualized using a Zeiss 
LSM 510 Meta confocal microscope.  
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2.12. Lentiviral methods 
The lentiviral system allows the efficient silencing of specific target genes in 
otherwise difficult to transfect cell types and allows long term stable expression of 
the inserted gene (358, 359). The lentivirus incorporates an expression plasmid 
which can encode a short hairpin (sh) RNA or GFP protein into the target cell that 
is subsequently transcribed into DNA and inserted into the host genome. The 
inserted sequence is therefore passed on to daughter cells following cell division. 
This DNA sequence is transcribed into shRNA or protein in the case of GFP. 
shRNA is cleaved by Dicer within the host cell and, in complex with RNA-induced 
silencing complex (RISC) targets complimentary mRNA for destruction, thereby 
silencing protein expression of the target gene (Figure 2.2) (360). 
 
2.12.1.    Generation of lentiviral particles  
HEK 293 cells were cultured into fresh complete RPMI medium the night before 
transfection. The following morning HEK 293 cells were only used if they were 
between 50-70% confluent, evenly distributed on the flask and looked healthy 
with very few dead/floating cells present. Four hours before transfection HEK 293 
cells were cultured into 10ml of fresh complete RPMI medium.  
 
Mirus LT1 transfection reagent and RPMI medium/25mM HEPES were warmed 
to 37°C. Plasmids composed of 9.31µg pREV, 9.31µg pGAG/Pol, 3.62µg pVSV-
G, 7.7µg vector were combined in an eppindorf tube and mq H20 added to give a 
final DNA concentration of 0.5µg/µl. VSVG, pREV and GAG/Pol encode viral 
proteins required to form the lentivirus, the vector is the expression plasmid 
encoding the gene of interest, for example GFP or a short hairpin (sh) RNA 
(Table 2.3). 90µl LT1 was then added directly into 750µl RPMI, vortexed for 1 
second and incubated at room temperature for 5 minutes. After this the DNA 
plasmid mix was slowly added directly to the pre-mixed RPMI/LT1 solution and 
vortexed for 1 second and incubated for 45 minutes at room temperature. This 
was then pipetted up and down twice and applied directly to the RPMI medium in 
the HEK 293 cell flask. Cells were gently rocked and placed in a cell culture 
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incubator at 37oC, 5% CO2 and left undisturbed for 48 hours. Following this, the 
10ml RPMI medium was centrifuged for 5 minutes at 1500RPM to remove any 
residual cells and the virus containing medium aliquoted into cryotubes and 
















T lymphocyte  
 
Figure 2.2. Lentiviral delivery of short hairpin RNA. VSVG, pGAG/POL and 
pREV plasmids encode proteins required for virus production inside HEK 293 
cells. The expression plasmid includes a packaging signal (ψ) and is 
incorporated into the virus particle. The lentivirus infects the T lymphocyte and 
the expression plasmid RNA is reverse transcribed into DNA and inserted into 
the host genome. This DNA sequence is then transcribed into short hair pin RNA, 
cleaved by DICER and in complex with RISC targets complementary mRNA 
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Table 2.3. Lentiviral shRNA plasmids 
 
 
2.12.2. Infection of Jurkat cells 
Jurkat cells were cultured at 1×106/ml in fresh complete RPMI medium the night 
before infection. The following morning, 2ml of lentivirus supernatant was added 
to 3ml of 1×106/ml Jurkat cells in a 6-well plate for 48 hours. Cells were then 
centrifuged for 5 minutes at 1400 RPM and re-suspended in 10ml complete 
RPMI medium for 3 days. Puromycin (0.3µg/ml) was added for 3 days and cells 
analysed after 9 days of culture.  
 
2.12.3. Infection of primary CD4 T lymphocytes 
Naïve CD4 cells were isolated as described in section 2.1.4 and suspended at 
1×106/ml in complete RPMI medium. Cells were activated with anti-CD3/CD28 
antibody coated beads at a 1:1 ratio in the presence of IL-2 (36 Units/ml) for 24 
hours. 3ml of CD4 cells was then combined with 2ml viral supernatant, 
centrifuged for 90 minutes at 1500RPM, and incubated at 37oC, 5% CO2 for 24 
hours. Following this, cells were centrifuged for 5 minutes at 1500RPM and the 
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medium replaced with 5ml complete RPMI medium plus IL-2 (36 Units/ml) for 48 
hours. Puromycin (0.3µg/ml) was then added for 3 days. Following this, cells 
were washed out of puromycin and cultured into complete RPMI medium plus IL-
2 (36 Units/ml) up until day 12 post isolation.  
 
 
2.13.  Adhesion assay’s 
 
2.13.1.    96-well plate adhesion assay  
A flat bottomed 96-well plate was coated with fibronectin (10µg/ml, R&D 
Systems) or ICAM1 (10µg/ml, R&D systems) overnight at 4°C, washed once with 
PBS and incubated with PBS/0.2% BSA for 1 hour at 37°C. The plate was then 
washed once with PBS and once in RPMI 1640 medium without phenol red. 
Previously activated or naïve CD4 cells were washed twice in RPMI medium, re-
suspended at 5×106 in RPMI 1640 without phenol red with 0.1% BSA and treated 
as stated in the figure legends. 100µl per well of cells was added to the required 
wells and incubated with or without UCHT1 (anti-CD3 antibody, 12-0038, 
eBioscience) at 10µg/ml for 30 minutes at 37°C, 5% CO2. 200µl RPMI 1640 
medium without phenol red warmed to 37°C was added to each well and the 
plate sealed and turned upside down at 37°C for 15 minutes. The plate sealer 
was removed whilst the plate was still upside down to remove non-adherent cells 
and 100µl per well EDTA (10mM) added. Remaining cells were transferred to 
FACs tubes containing 300µl PBS and viable cells counted using flow cytometry. 
 
2.13.2.      Lamellipodia extension assay 
IBIDI µ-slides (IBIDI, 80301, Thistle Scientific) were coated with Poly-L-lysine for 
60 minutes at 37oC. mqH20 was washed through the chamber and replaced with 
chemotaxis media. The slide was filled with 80µl chemotaxis media and 18µl 
100nM CXCL11 was added to the top chamber and drawn through the slide by 
withdrawing 18µl from the lower chamber, to create a chemokine gradient over 
the cells located on the bridge. 6µl cells at 5×106/ml density in chemotaxis media 
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were treated for 15 minutes as stated in the figure legends and added to the left 
side chamber. Caps were then added to the four wells and the slide left to 
equilibrate for 15 minutes at 37°C on the microscope stand. Images were then 
taken at 37°C using a Zeiss LSM 510 META microscope. 
 
 
2.14.     Calcium flux measurement 
Fluo-4 is a labelled calcium indicator which fluoresces upon binding to Ca2+. 
Fluo-4,AM was used in this thesis and is attached to an acetoxymethyl (AM) 
ester derivate. AM allows the Fluo-4 molecule to pass through a cell membrane 
but becomes cleaved by non-specific esterases inside the cell, resulting in a 
charged molecule which can only pass back through the cell membrane much 
more slowly. 
 
A20 B cells were suspended in buffer (HBSS, 25mM HEPES, 0.1% BSA, pH 7.4) 
at 4×106/ml and incubated with 2µM flou-4,AM (Invitrogen, #F-14201) at 37°C for 
30 minutes. Cells were centrifuged and re-suspended in buffer at 4×106/ml for 30 
minutes at 37°C with or without AQX-1 as stated in the figure legend. Cells were 
placed in a cuvette which already contained 1ml of buffer, giving a final 
concentration of 2×106 cells/ml. Fluorescence was then measured every 15 
seconds for 180 seconds using a F-4500 fluorescence spectrophotometer 
(Hitachi). After 30 seconds of recording, cells were stimulated with the anti-
mouse IgG (whole molecule) antibody (Sigma, #M7023). After 120 seconds of 
recording ionomycin (6µM) was added to cells to induce 100% calcium release. 
 
2.15.  Statistical analysis 
Statistical analysis was performed using Graphpad Prism 4 software. Data 
represented in graphs is mean ± standard error of the mean (SEM). One Way 
ANOVA followed by the Tukey’s post-test was used to assess statistical 
significance of data.  * p<0.05, **p<0.01, ***p<0.001 
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3.1. Background and objectives of research 
IL-17A is a potent pro-inflammatory cytokine that is crucial for the resolution of 
infection in response to various pathogens (20, 361, 362). However, Th17 cells 
and IL-17A have also been shown to drive inflammatory and autoimmune 
diseases (26, 92, 363). Therefore pharmacological inhibition of IL-17 signalling 
and Th17 cells is an attractive target for the pharmaceutical industry (364), 
indeed antibodies targeting IL-17A are currently in phase 2 clinical trials (365). As 
discussed in the introduction, compounds that inhibit the activity of PI3K are 
being developed for the treatment of inflammatory disorders such as asthma 
(95). It is therefore important to determine the effect of PI3K inhibition on Th17 
cells and IL-17A secretion.   
 
PI3Kδ has previously been shown to be required for Th1 and Th2 differentiation 
in mice (163) and for regulatory T cell suppressor function (366). Before this 
thesis was undertaken a number of publications had indicated that PI3K may 
play a role either in IL-17A mediated signalling or in the development of Th17 
cells and IL-17A secretion. IL-17A secretion by PBMC’s isolated from patients 
with rheumatoid arthritis was inhibited by PI3K inhibition using Wortmannin or 
LY294002 (367), whilst IL-15 induced IL-17A secretion by CD4 T lymphocytes 
was reduced by inhibition of PI3K (368). In a mouse model of airway 
inflammation, pharmacological inhibition of PI3K was shown to reduce IL-17A 
expression and decrease pathogenesis of airway disease (369). In contrast to 
these publications however, is evidence that PI3K-Akt mediated signalling 
actually impairs Th17 development, with elevated Akt signalling associated with 
reduced severity of experimental autoimmune encephalomyelitis and increased 
Foxp3+ regulatory T cell development (370). In addition, negative regulation of 
PI(3,4,5)P3 mediated signalling by SHIP-1 is required for Th17 development, with 
SHIP-1 deficient mice displaying decreased Th17 differentiation compared to 
wild-type mice (298).  
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The aim of these experiments was to explore the role of PI3K in primary human 
Th17 differentiation and IL-17A secretion through the utilisation of pan-PI3K and 
isoform specific PI3K inhibitors (Table 3.1). In addition, a lentiviral delivery 
system to silence the expression of individual PI3K isoforms in primary human T 
lymphocytes was used to compare with results obtained from the 






Compound PI3Kα PI3Kβ PI3Kδ PI3Kγ Reference 
PIK-75 7.8 343 907 - (371) 






AS605240 60 270 300 8 (144) 
ZSTK474 16 44 4.6 49 (373) 
 
Table. 3.1. Individual PI3K isoform IC50 (nM) values of compounds listed 
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3.2. Effect of pharmacological PI3K inhibition on TCR and 
chemokine mediated signalling in primary human T lymphocytes 
 
Genetic strategies have identified PI3Kδ as the key PI3K isoform responsible for 
immune cell antigen receptor mediated signalling (121, 155, 163), although a role 
for PI3Kβ in neutrophils (152) and PI3Kγ in T cells (102) has also been identified. 
In this thesis, small molecule compounds that preferentially inhibit an individual 
PI3K isoform were used to identify the PI3K isoform responsible for primary 
human T lymphocyte chemokine receptor (CXCR3) and TCR mediated 
signalling. PI3K inhibitors that were used in this thesis are listed in Table 3.1 with 
IC50 values for each Class 1 PI3K isoform.  
 
Pharmacological inhibition of PI3Kδ with IC87114 caused a reduction in CXCL11 
mediated Akt phosphorylation, although IC87114 inhibited TCR mediated Akt 
phosphorylation more potently (Figure 3.1 A, C and D). Treatment of cells with 
the PI3Kγ inhibitor AS605240 reduced CXCL11 mediated Akt phosphorylation at 
100nM concentration (Figure 3.1 A and C). At 1µM AS605240 reduced TCR 
mediated Akt phosphorylation, although no inhibition was seen at 100nM 
concentration (Figure 3.1 A and D). Inhibition of PI3Kα with PIK-75 or inhibition of 
PI3Kβ with TGX-221 had no effect on TCR or CXCL11 mediated phosphorylation 
of Akt in primary human T lymphocytes (Figure 3.1 B, C and D). 
 




 Basal           CXCL11 (10nM)      UCHT1 (10µg/ml) 
-    +      -      -     +    +      -     -     -     +    +      -     -       PIK-75     
-     -      +     -     -      -     +     +    -      -     -     +     +      TGX-221  
0  100 100   0    10  100 10  100  0   10  100  10  100     (nM compound) 
Phospho-Akt 
ERK 
 Basal         CXCL11 (10nM)      UCHT1 (10µg/ml) 
-    +      -      -     +    +      -     -     -     +    +      -      -       IC87114     
-     -      +     -     -      -     +     +    -      -     -     +     +      As605240  






Figure 3.1. Effect of PI3K inhibition on chemokine and TCR mediated Akt 
phosphorylation. SEB-activated T cells were treated with A) IC87114 or 
AS605240 or with B) PIK-75 or TGX-221 at stated concentrations for 30 minutes 
then stimulated with CXCL11 (10nM) or UCHT1 (10µg/ml) for 5 minutes. Cells 
were lysed and levels of phospho-Akt (ser473) and total ERK determined using 
Western blotting. Data is representative of A) three and B) two independent 
experiments. C) Shows % of CXCL11 control (after normalised to total ERK) D) 
Shows % of UCHT1 control (after normalised to total ERK).  
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3.3. Effect of PI3K inhibition on IL-17A production and 
secretion by CD4 T lymphocytes 
 
3.3.1. Effect of short term PI3K inhibition on IL-17A secretion 
PI3K has previously been shown to be required for cytokine secretion by T 
lymphocytes (121, 160, 167), this involved control of cytokine transcription and 
control of the secretion of cytokines from the Golgi apparatus. However, the role 
of PI3K in primary human CD4 T lymphocyte secretion of IL-17A had not 
previously been investigated. Naïve CD4 cells were isolated from healthy human 
donors, treated with a Th17 polarising cocktail of cytokines and incubated with 
anti-CD3/CD28 antibody coated beads for 8 days (timeline schematic shown in 
Figure 3.2 A). Day 8 post isolation, Th0 control (IL-2 treated) cells or Th17 
polarised cells were cultured into fresh RPMI medium to remove any IL-17A 
already present, and stimulated with anti-CD3/CD28 antibody coated beads for 
16 hours. Th17 polarised cells showed increased IL-17A secretion compared to 
Th0 cells (Figure 3.2 B,C,D and E) indicating that the polarisation technique was 
successful. Subsequently, the effect of acute PI3K inhibition on IL-17A secretion 
was examined, with PI3K inhibitors added 20 minutes prior to TCR stimulation on 
day 8 post isolation. Inhibition of PI3Kδ using IC87114 was found to significantly 
(p<0.05) reduce TCR mediated IL-17A secretion by Th0 and Th17 polarised cells 
(Figure 3.2 C). In contrast pharmacological inhibition of PI3Kγ with AS605240 
(Figure 3.2 B), inhibition of PI3Kα with PIK-75 (Figure 3.2 D) or inhibition of 













Day     0           1           2           3           4           5           6           7          8  
Isolation of naive CD4+ T cells 
Addition of anti-CD3/CD28 antibody 
coated beads and polarizing cytokines 
Addition of fresh media  
+ polarizing cytokines 
Cultured into fresh media + PI3K inhibitor for 20 
minutes. Cells then re-stimulated with anti-CD3/
CD28 antibody coated beads for 16 hours 
Addition of fresh media  
+ polarizing cytokines 
E) 
 
Figure 3.2. Effect of acute PI3K inhibition on IL-17A secretion. Th0 and Th17 
cells were polarised as described in the Materials and Methods. A) shows 
timeline schematic of treatments. 8-10 days post isolation 1×106 cells/point were 
cultured into fresh RPMI medium, incubated with B) AS605240 (1µM) C) 
IC87114 (10µM) D) PIK-75 (100nM) or E) TGX-221 (100nM) for 20 minutes. 
Cells were then stimulated with anti-CD3/anti-CD28 antibody coated beads for 16 
hours. Supernatant was harvested and levels of IL-17A detected using an ELISA 
as described in the Materials and Methods. Data is mean ± SEM of three 
independent experiments. One Way ANOVA followed by Tukey’s post test used 
to determine statistical significance *p<0.05. 
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3.3.2. Effect of long term PI3K inhibition on IL-17A production  
Pharmacological inhibition of PI3K to treat inflammatory disorders has significant 
potential (374, 375), with inflammation reduced after PI3Kδ inhibition for a 
duration of 5 days in a murine model of asthma (211). It was therefore important 
to investigate the effect of PI3K inhibition on IL-17A production for longer time 
periods than 16 hours as for Figure 3.2, to more closely correspond with likely 
treatment durations in humans undergoing PI3K inhibitor therapy. Because 
inhibition of PI3Kδ was shown to inhibit IL-17A secretion in Figure 3.2 and 
because PI3Kγ and PI3Kδ are leukocyte restricted PI3K isoforms, the effect of 
AS60240, IC87114 and the pan-PI3K inhibitor ZSTK474 were assessed on IL-
17A production by CD4 cells cultured in the presence of a PI3K inhibitor for 8 
days. Naïve CD4 T lymphocytes were isolated and treated with IC87114, 
AS605240 or ZSTK474 for 30 minutes prior to activation with anti-CD3/anti-CD28 
antibody coated beads, cells were then cultured in the presence of PI3K 
inhibitors under either Th17 or Th0 polarized conditions for 8 days (timeline 
schematic shown in Figure 3.3). Cells treated with ZSTK474 (Figure 3.4 B) or 
IC87114 (Figure 3.4 C) showed reduced Akt phosphorylation under basal 
conditions. Inhibition of PI3Kγ with AS605240 showed less of an effect than 
PI3Kδ inhibition, but a slight reduction in basal phosphorylation of Akt was 
evident (Figure 3.4 A). 
Day    0          1          2          3          4          5          6           7          8 
Isolation of naive CD4+ T cells 
Addition of anti-CD3/CD28 
antibody coated beads and IL-2 
Addition of PI3K inhibitor 
Addition of fresh media + polarizing 
cytokines + PI3K inhibitors 
Cultured into fresh media and 
assessed in the absence of 
PI3K inhibitors 
Addition of fresh media + polarizing 
cytokines + PI3K inhibitors  
Figure 3.3. Timeline schematic of long-term PI3K inhibitor treatment. 
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Th0                                  Th17 




Th0                                   Th17 





Figure 3.4. Effect of PI3K inhibitors on Akt phosphorylation following 8 
days of in vitro culture. Naive CD4 cells were treated with A) AS605240, B) 
ZSTK474 or C) IC87114 for 30 minutes then activated with anti-CD3/anti-CD28 
antibody coated beads at a 1:1 ratio and cultured under Th0 or Th17 polarised 
conditions for 8 days as described in Materials and Methods. Day 8 post 
isolation, 1×106 cells were lysed and levels of phospho-Akt (ser473) and ERK 




The chemokine receptor expression profile differs between different CD4 T 
helper sub-groups and is crucial for the homing of lymphocytes into peripheral 
tissues (Figure 1.2) (100). The effect of 8 day PI3K inhibition on CCR6 (Th17 
associated receptor) and CXCR3 (Th1 associated receptor) expression was 
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investigated to give an indication of Th1 and Th17 differentiation. Inhibition of 
PI3Kδ (Figure 3.5 A) or pan-PI3K inhibition (Figure 3.5 C) caused an increase in 
the percentage of cells that express CCR6 under both Th0 and Th17 polarised 
cell culture conditions, although this was not statistically significant. There 
appeared to be large variations in the effect of PI3Kδ on CCR6 expression 
between individual human donors. In contrast, inhibition of PI3Kδ (p<0.05, Figure 
3.5 B) or inhibition of pan-PI3K isoforms (p<0.05, Figure 3.5 D) decreased the 
percentage of cells positive for Th1 associated CXCR3 surface expression. 
Inhibition of PI3Kγ activity had no effect on CCR6 or CXCR3 expression by Th0 
or Th17 polarised cells (Figure 3.5 E and F).  
 
Subsequently the effect of PI3K inhibition for 8 days on IL-17A production was 
investigated. Intracellular staining for IL-17A showed that inhibition of PI3Kγ with 
AS605240 had little effect on IL-17A production (Figure 3.6 A and B). In contrast, 
the inhibition of pan-Class 1 PI3K isoforms or the inhibition of PI3Kδ resulted in a 
50% inhibition of intracellular IL-17A levels, both in Th0 and Th17 polarised cells 
(Figure 3.6 C and D). No difference was seen between pan-PI3K or PI3Kδ 
selective inhibition, which indicates that PI3Kδ is predominantly responsible for 
PI3K mediated IL-17A production.  
 
It was next important to discern the effect of PI3K inhibition on secreted IL-17A in 
T lymphocyte medium supernatants, due to the known role of PI3K in controlling 
cytokine intracellular trafficking and export from the cell (167). After 8 days of 
culture in the presence of PI3K inhibitors, cells were cultured into fresh medium 
without PI3K inhibitors and re-stimulated for 16 hours with anti-CD3/anti-CD28 
antibody coated beads. Surprisingly, IL-17A secreted levels were not in 
accordance with the effects on intracellular IL-17A expression. In contrast, IL-17A 
secretion by Th17 polarised cells after withdrawal from PI3K inhibition was found 
to be significantly increased if cells were cultured previously for 8 days in the 
presence of IC87114 (p<0.05, figure 3.7 A) or ZSTK474 (p<0.01, figure 3.7 B). 
Inhibition of PI3Kγ however, showed no effect on IL-17A secretion (Figure 3.7 C). 






3.5. Effect of long term PI3K inhibition on chemokine receptor expression. 
Naive CD4 cells were treated with A) B) IC87114, C) D) ZSTK474 or E) F) 
AS605240 for 30 minutes then activated with anti-CD3/anti-CD28 antibody 
coated beads at a 1:1 ratio and cultured under Th0 or Th17 polarised conditions 
for 8 days as described in Materials and Methods. 1×106 day 8 post isolation 
cells were then stained for CCR6 or CXCR3 and analysed using flow cytometry 
as described in the Materials and Methods. Data is % cells positive for receptor 
expression from at least three independent experiments. One Way ANOVA 
followed by Tukey’s post test used to determine statistical significance * p<0.05. 
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Figure 3.6. Effect of long term co-incubation with PI3K inhibitors on 
intracellular IL-17A expression. Naive CD4 cells were treated with AS605240 
A) and B) or ZSTK474/IC87114 C) and D) for 30 minutes then activated with anti-
CD3/anti-CD28 antibody coated beads at a 1:1 ratio and cultured under Th0 or 
Th17 polarised conditions for 8 days as described in Materials and Methods. Day 
8 post isolation 1×106 cells/point were stimulated with ionomycin and PMA for 4 
hours in the presence of Golgiplug. Levels of intracellular IL-17A were 
subsequently detected using flow cytometry as described in the Materials and 
Methods. A) and C) show representative flow cytometry plots. Numbers indicate 
% cells positive for IL-17A expression. B) and D) show mean ± SEM of three 
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independent experiments. One Way ANOVA followed by Tukey’s post test used 







3.7. Effect of long term co-incubation with PI3K inhibitors on IL-17A 
secretion. Naive CD4 cells were treated with IC87114 (10µM) A), ZSTK474 
(1µM) B), or AS605240 (1µM) C) for 30 minutes then activated with anti-
CD3/anti-CD28 antibody coated beads at a 1:1 ratio and cultured under Th0 or 
Th17 polarised conditions for 8 days as described in Materials and Methods. Day 
8 post isolation cells were then re-stimulated with anti-CD3/anti-C28 antibody 
coated beads at a 1:1 ratio in fresh RPMI medium for 16 hours. Levels of IL-17A 
in the supernatant were determined using ELISA as described in the Material and 
Methods. Data is mean ± SEM of three independent experiments. One Way 
ANOVA followed by Tukey’s post test used to determine statistical significance * 
p<0.05 ** p<0.01.  
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3.4. The effect of loss of PI3Kδ expression on primary human 
CD4 T lymphocyte function 
 
3.4.1. Effect of silencing PI3Kδ protein expression on Akt phosphorylation 
To further investigate the role of PI3K activity in IL-17A production, a lentiviral 
delivery system was used to silence the expression of PI3Kδ in primary human 
CD4 T lymphocytes. A timeline schematic of infection and times of treatment is 
shown in Figure 3.8 A. The lentivirus delivery system has previously been used 
to silence the expression of SHIP-1 in primary human CD4 T lymphocytes (295). 
Silencing of PI3Kδ expression will be complimentary to results gained from the 
use of pharmacological inhibitors, however silencing of PI3Kδ expression will 
also disrupt any scaffolding roles of the catalytic isoform or associated adaptors. 
This is important because PI3K has been shown to have non-catalytic functions 
which could have a role in IL-17A production by T lymphocytes. For example, 
down-regulation of PI3Kβ expression revealed kinase independent regulation of 
Akt activation (376, 377), whilst PI3Kγ regulates cardiac contractility through 
kinase independent activity (105). In addition, it was important to compare the 
results gained from pharmacological inhibition of PI3Kδ activity with the genetic 
silencing of PI3Kδ expression because this would give an insight into whether the 
effects seen were due to off-target effects of the inhibitors used. 
 
To initially test the lentiviral delivery system, Jurkat cells were infected with a 
lentivirus encoding GFP protein. Using flow cytometry 9 days post-infection, it 
was found that over 99% of cells were positive for GFP (Figure 3.8 B). 
Subsequently, as a positive control for the lentiviral mediated introduction of short 
hairpin RNA into primary human T lymphocytes, the short hairpin RNA that has 
previously been used to silence SHIP-1 protein (295) was used in this thesis. 
Figure 3.8 C shows that the lentiviral delivery system was able to silence the 
expression of SHIP-1 in primary human CD4 T lymphocytes. A short hairpin RNA 
targeting PI3Kδ was then used in conjunction with the lentiviral delivery system 
and was successful in reducing the expression of PI3Kδ in primary human CD4 T 
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lymphocytes (Figure 3.8 D). PI3Kδ silenced CD4 cells showed reduced basal Akt 
phosphorylation (Figure 3.8 D) and reduced Akt phosphorylation in response to 




Untreated  GFP Transfected 
B) 









shc             sh PI3Kδ 
-     -      +      -      -     +      CXCL11 (10nM) 







Day    0          1          2          3          4          5          6           7          8 
Isolation of naive CD4+ T cells. 
Addition of anti-CD3/CD28 
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Figure 3.8. Lentiviral introduction of short hairpin RNA to silence the 
expression of SHIP-1 and PI3Kδ. A) Timeline schematic of lentivirus infection 
protocol. B) Jurkat cells were transfected with a lentivirus encoding a GFP 
construct as described in the Materials and Methods, or left untreated. Day 9 
post-transfection expression of GFP was determined using flow cytometry. C) 
Naïve CD4 primary human T lymphocytes were infected with a lentivirus 
encoding a short hairpin RNA targeting SHIP-1 as described in the Materials and 
Methods. Day 9 post isolation cells were lysed and expression of SHIP-1 and 
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ERK determined using Western blotting. D) Naïve CD4 primary human T 
lymphocytes were infected with a lentivirus encoding a short hairpin RNA 
targeting PI3Kδ or a scrambled short hairpin RNA control (shc) as described in 
the Materials and Methods. Day 9 post isolation cells were lysed and expression 
of phospho-Akt, PI3Kδ and ERK determined using Western blotting. E) Naïve 
CD4 primary human T lymphocytes were infected with a lentivirus encoding a 
short hairpin RNA targeting PI3Kδ or a scrambled short hairpin RNA control (shc) 
as described in the Materials and Methods. Day 9 post isolation cells were 
stimulated with CXCL11 (10nM) or UCHT1 (10µg/ml) for 5 minutes, lysed and 




3.4.2. Effect of down-regulated PI3Kδ expression on IL-17A production 
Because of the crucial role of PI3K in influencing apoptotic pathways and cell 
survival (114, 119, 120), the effect of PI3Kδ silencing on T lymphocyte viability 
was assessed. Using propidium iodide staining, PI3Kδ down-regulation was 
found to have no effect on cell viability compared to scrambled short hairpin RNA 
control treated cells (Figure 3.9 A). Pharmacological inhibition of PI3K was 
shown to modify chemokine receptor expression profiles of T lymphocytes 
(Figure 3.5), therefore the effect of PI3Kδ knock-down on CCR6 and CXCR3 
surface expression was assessed. However, PI3Kδ silenced cells showed no 
change in the expression of CXCR3 or CCR6 compared to control cells (Figure 
3.9 B). Subsequently, the effect of PI3Kδ down-regulation on IL-17A production 
was assessed. It was found that in PI3Kδ silenced cells, intracellular IL-17A 
expression was 50% higher compared to scrambled short hairpin RNA control 
cells (Figure 3.9 C and D). In addition, the supernatants of PI3Kδ silenced T cells 
showed nearly a 100% rise in IL-17A levels compared to short hairpin RNA 
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Figure 3.9. Effect of PI3Kδ silencing on T lymphocyte function. Naïve CD4 
primary human T lymphocytes were infected with a lentivirus encoding a short 
hairpin RNA targeting PI3Kδ as described in the Materials and Methods or a 
scrambled short hairpin control and assessed on days 9-12 post isolation. A) 
Cells were washed once in PBS, stained with Propidium iodide and analysed 
using flow cytometry. Numbers indicate % positive cells. B) Cells were washed in 
PBS and surface expression of CXCR3 and CCR6 determined using flow 
cytometry. Results show representative flow cytometry plots with % cells positive 
for receptor expression indicated. C) and D) 1×106 cells/point were stimulated 
with ionomycin and PMA for 4 hours in the presence of Golgiplug. Levels of 
intracellular IL-17A were subsequently detected using flow cytometry as 
described in the Materials and Methods. Numbers in C) indicate number of % 
positive cells for IL-17A. D) Graph is mean ± StDev of two independent 
experiments E) 1×106 cells/point were stimulated with anti-CD3/anti-CD28 
antibody coated beads for 16 hours. Levels of IL-17A in the supernatant was 
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detected using an ELISA as described in the Materials and Methods. Data is 







3.5. Effect of pharmacological PI3K inhibition on IL-17A 
production by SEB-activated primary human T lymphocytes 
 
Investigation into the effect of PI3K inhibition on IL-17A production in this thesis 
has so far used naïve CD4 cells that have subsequently been activated with anti-
CD3/anti-CD28 antibody coated beads and cultured under Th0 or Th17 polarised 
conditions. It was therefore important to determine whether the effects of PI3K 
inhibition would be replicated using a different method of in vitro primary human 
T lymphocyte activation. For this, Staphylococcal enterotoxin B (SEB) was used 
to activate PBMCs as described in the Materials and Methods. PBMCs were 
incubated with ZSTK474 or IC87114 for 30 minutes prior to the addition of SEB, 
cultured in the presence of IL-2 and PI3K inhibitor for 9 days and then IL-17A 
production was assessed. Pan-PI3K or PI3Kδ inhibition for 9 days increased by 
~50% the percentage of cells that stained positive for intracellular IL-17A (Figure 
3.10 A and B). In addition, re-stimulation of the TCR for 16 hours in fresh RPMI 
medium on day 9, showed that cells which had previously been cultured in the 
presence of  ZSTK474 or IC87114 for 9 days secreted more IL-17A into the 
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Figure 3.10. Effect of PI3K inhibition on IL-17A in SEB-activated primary 
human T lymphocytes. PBMC’s were isolated and treated with ZSTK474 or 
IC87114 for 30 minutes prior to the addition of SEB. SEB-activated primary 
human T cells were generated as described in the Materials and Methods and 
analysed on day 8. A) 1×106 cells/point were stimulated with ionomycin and PMA 
for 4 hours in the presence of Golgiplug. Levels of intracellular IL-17A were 
subsequently detected using flow cytometry as described in the Materials and 
Methods. A) show representative flow cytometry plots. B) shows mean ± SEM of 
three independent experiments. C) 1×106 cells/point were re-stimulated with anti-
CD3/anti-C28 antibody coated beads at a 1:1 ratio in fresh complete RPMI 
medium for 16 hours. Levels of IL-17A in the supernatant were determined using 
ELISA as described in the Material and Methods. Data is mean ± SEM of three 
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independent experiments. One Way ANOVA followed by Tukey’s post test used 





3.6. IL-17A does not induce signalling or migratory responses 
in primary human T lymphocytes 
 
IL-17A has been shown to induce PI3K and NF-κB dependent cytokine secretion 
by airway epithelial cells (378, 379) whilst another study showed that IL-17A 
induced the phosphorylation of ERK and STAT-3 and that IL-17A mediated 
chemokine production was ERK dependent but PI3K independent (380). IL-17A 
also stimulates the recruitment of neutrophils to sites of infection by inducing the 
production of pro-inflammatory mediators such as granulocyte colony-stimulating 
factor (G-CSF), CXCL8 and IL-6 (381). In addition, IL-17A can directly induce 
chemotaxis of monocytes extracted from the blood of mice (382). In lymphocytes, 
IL-17A has been shown to directly promote B cell survival (383), however, in a T 
cell line IL-17A had no effect on proliferation, survival or apoptosis, which may 
have been due to lack of IL-17RC expression (384). It had not previously been 
assessed however, whether IL-17A is able to directly stimulate signalling 
pathway activation or modulate motility in primary human T lymphocytes. 
 
Stimulation of primary human T lymphocytes with IL-17A at 10ng/ml or 100ng/ml 
for 1 or 5 minutes had no effect on the phosphorylation of S6 ribosomal subunit 
or ERK (Figure 3.11 A). In contrast, as a positive control, CXCL11 induced 
phosphorylation of ERK and S6 ribosomal subunit at 1 and 5 minutes post-
stimulation (Figure 3.11 A). Because of the previously described role of IL-17A in 
the induction of monocyte chemotaxis (382), it was subsequently investigated 
whether IL-17A could increase the motility of CD4 T lymphocytes. Using a 
Neuroprobe chemotaxis assay, CXCL11 (positive control) increased the motility 
of CD4 cells in a concentration dependent manner, however, at a range of 
concentrations, IL-17A had no effect on lymphocyte motility (Figure 3.11 B).  
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Figure 3.11.  Effect of IL-17A on primary human T lymphocyte signalling 
and motility. A) SEB-activated primary human T lymphocytes were stimulated 
with CXCL11 (10nM) or IL-17A (100ng/ml or 10ng/ml) for 5 minutes, lysed and 
levels of phospho-S6 ribosomal protein, phospho-ERK and total ERK were 
determined using Western blotting. A representative western blot from two 
independent experiments is shown. B) Migration of SEB-activated cells in 
response to CXCL11 or IL-17A at a range of concentrations was assessed using 
the Neuroprobe chemotaxis assay as described in the Materials and Methods. 
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3.7. Results Chapter 3 Summary 
 
• Use of a range of isoform specific PI3K inhibitors revealed that PI3Kδ is 
primarily required for TCR mediated signalling in T lymphocytes and that 
PI3Kγ is primarily responsible for chemokine mediated signalling 
• PI3Kα and PI3Kβ appeared to have no role in TCR or chemokine 
mediated signalling in T lymphocytes 
• Inhibition of PI3Kδ, but not PI3Kα, PI3Kβ or PI3Kγ significantly reduced 
TCR mediated secretion of IL-17A over a 16 hour time period  
• 8 day PI3Kδ, but not PI3Kγ inhibition, reduced intracellular IL-17A 
expression by CD4 T lymphocytes 
• Incubation of CD4 T cells with ZSTK474 or IC87114 for 8 days increased 
the secretion of IL-17A following TCR re-stimulation on day 8 in fresh 
medium in the absence of PI3K inhibitors 
• Inhibition of PI3Kγ activity for 8 days had no effect on secretion of  IL-17A 
by T cells 
• CCR6 expression was increased by certain donors following the inhibition 
of PI3Kδ for 8 days 
• CXCR3 surface expression was reduced by inhibition of PI3K activity for 8 
days 
• Lentiviral mediated silencing of PI3Kδ expression in primary human CD4 
lymphocytes decreased Akt phosphorylation in response to TCR ligation 
• Down-regulation of PI3Kδ increased intracellular IL-17A expression and 
increased levels of secreted IL-17A 
• Co-culture of SEB-activated T cells with IC87114 or ZSTK474 resulted in 
increased IL-17A secretion and increased intracellular IL-17A expression  
• No effect of IL-17A was seen on the phosphorylation of ERK or S6 
ribosomal subunit in CD4 lymphocytes 
• IL-17A did not influence the motility of CD4 T lymphocytes  
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3.8. Results Chapter 3 Discussion 
 
3.8.1. Acute pharmacological inhibition of PI3Kδ reduced IL-17A secretion 
PI3Kδ is known to be crucial for TCR mediated signalling in mice (121, 155), 
however, before this research was undertaken, no studies had investigated the 
effect of PI3Kδ inhibition on TCR mediated signalling in primary human T 
lymphocytes. In this thesis treatment of primary human CD4 T lymphocytes with 
IC87114, a potent PI3Kδ selective inhibitor (Table 3.1), inhibited TCR mediated 
Akt phosphorylation and inhibited TCR mediated secretion of IL-17A. After this 
research was undertaken, a study also showed that IC87114 inhibited TCR 
mediated Akt phosphorylation and cytokine secretion by primary human T 
lymphocytes (160). The results of this thesis and other studies (160, 211, 212, 
385) indicate that pharmacological inhibition on PI3Kδ activity may inhibit T 
lymphocyte mediated pathologies.  
 
In addition, it was not known if other Class 1 PI3K isoform’s also contributed to 
TCR mediated signalling and cytokine secretion in primary human T 
lymphocytes. Pharmacological inhibition of PI3Kγ with AS605240 potently 
inhibited CXCL11 mediated Akt phosphorylation, in accordance with the 
previously identified role of PI3Kγ in mediating GPCR mediated signalling (177, 
386, 387). AS605240 also inhibited TCR mediated Akt phosphorylation at 1µM. 
However, Table 3.1 shows that AS605240 will inhibit over 50% of the activity of 
PI3Kδ, PI3Kα and PI3Kβ at 1µM concentration. This inhibition of TCR mediated 
signalling with AS605240 may therefore be due to off-target effects on PI3Kδ 
activity. In addition IC87114 reduced CXCL11 mediated Akt phosphorylation, 
although this may have been due to effects on PI3Kγ activity (Table 3.1). 
Pharmacological inhibition of PI3Kα or PI3Kβ in T cells showed no effect on Akt 
phosphorylation in response to either chemokine or TCR stimulation. In addition, 
the inhibition of PI3Kα, PI3Kβ or PI3Kγ activity showed no significant effects on T 
lymphocyte secretion of IL-17A. The results of this thesis therefore indicate that 
PI3Kα inhibition during cancer treatment may not have immunosuppressive 
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effects. In agreement with these results, a study has recently been published 
which shows that PI3Kα inhibition has little effect on B and T lymphocyte function 
(156).  
 
3.8.2.  8 day PI3K inhibition increased IL-17A secretion 
When this research was undertaken no results had previously been published on 
the role of PI3K in T lymphocyte IL-17A secretion. The results of this thesis 
revealed that acute inhibition of PI3Kδ reduced IL-17A secretion, whilst 
intriguingly, the prolonged inhibition of PI3Kδ over a number of days, or the 
knock-down of PI3Kδ expression, increased IL-17A secretion by T lymphocytes 
(summarised in Figure 3.12).  
 
Since this research was undertaken a number of research articles have been 
published showing that PI3K mediated signalling is required for Th17 
differentiation and IL-17A production. PI3Kδ inhibition using IC87114 reduced 
serum levels of IL-17A in mice following intravenous anti-CD3 antibody 
stimulation (160). Another study showed that mice which express catalytically 
inactive PI3Kδ during experimental autoimmune encephalomyelitis (EAE), which 
is a largely Th17 driven disease, had reduced numbers of CD4+ CCR6 positive 
cells, reduced intracellular IL-17A expression and decreased severity of EAE 
(388). In addition this study showed that in vitro Th17 development was impaired 
when co-cultured with LY294002 or IC87114 (388). A recent study has also 
shown that pharmacological inhibition of PI3K, deletion of p85a or T cell specific 
deletion of raptor (an essential component of mTORC1) reduced intracellular IL-
17A expression and IL-17A secretion in mice (389). Pharmacological inhibition of 
PI3Kδ or PI3Kγ blocked IL-17 secretion by PBMCs isolated from psoriatic 
patients whilst mice deficient in functional PI3Kδ or PI3Kγ were protected from 





































Figure 3.12. Prolonged pharmacological inhibition of PI3Kδ or silencing of 
PI3Kδ expression increases IL-17A secretion by primary human T 
lymphocytes. Acute treatment with IC87114 on day 8 post isolation/activation 
caused a decrease in IL-17A secretion by primary human T lymphocytes. In 
contrast, prolonged (8 day) incubation with IC87114 or ZSTK474, or the silencing 
of PI3Kδ expression in primary human T lymphocytes resulted in increased 
levels of IL-17A secretion following re-stimulation of the TCR in fresh medium in 
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However, a number of other publications have shown results that contradict the 
above mentioned studies, whilst being largely in agreement with the results from 
this thesis. Loss of PI3Kγ expression in mice enhanced IL-17A secretion in vitro 
and in vivo in response to TCR stimulation, indicating that PI3K signalling 
negatively regulates IL-17A production (391). Another study showed that in mice, 
elevated Akt signalling severely impaired the percentage of cells positive for 
intracellular  IL-17A expression following in vitro culture of cells under Th17 
polarised conditions, and that disease severity of EAE was also reduced (370). In 
addition the co-culture of monocyte derived dendritic cells with T lymphocytes for 
48 hours in the presence of a pan-PI3K inhibitor (LY294002) led to a 50% 
increase in IL-17A producing cells (392). Pharmacological inhibition of PI3Kδ in 
combination with a TLR agonist in mice was found to increase the frequency of 
IL-17 positive CD4 T cells in vivo (393). Another study indicated that PI(3,4,5)P3 
dependent signalling events inhibited Th17 differentiation, with SHIP-1 deficient T 
cells unable to differentiate into IL-17A producing T cells (298). 
 
One of the studies mentioned above was very similar to this thesis in that they 
co-cultured T cells with PI3K inhibitors in vitro, however, their results showed that 
Th17 differentiation was impaired (388). One possible reason for these 
contrasting results is that the study used T cells isolated from the spleens of 6 
week old mice, whereas in this thesis, naïve CD4 T cells were isolated from the 
peripheral blood of healthy human adults. Differences between human and 
mouse Th17 cells have previously been described, both in terms of the cytokines 
required to induce Th17 development in vitro and in their receptor expression 
profile’s (394). In addition, this study only stated that cells were co-cultured with 
PI3K inhibitors, and did not give the timing of PI3K introduction or whether PI3K 
inhibitors were replenished during the 5 days of culture (388). In this thesis, PI3K 
inhibitors were applied to cells 30 minutes prior to CD3/CD28 ligation, and were 
added to the RPMI medium every time media was added for 8 days of culture. 
This study also cultured cells for 3 days in Th17 polarising cytokines, then cells 
were rested in IL-2 for 48 hours (388), this may have effected the results, 
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because IL-2 is inhibitory for Th17 development (395) and IL-2 was not used for 
Th17 polarised conditions in this thesis.  
 
Various in vivo studies using pharmacological inhibition of PI3K or knock-down of 
PI3K expression have shown reduced auto-immune or inflammatory disorders 
compared to untreated or wild-type controls (212, 388, 396). However, in this 
thesis it was shown that prolonged PI3K inhibition in T cells then subsequent 
withdrawal of PI3K inhibition leads to increased IL-17A secretion upon TCR re-
stimulation. Perhaps this would also be the case in these in vivo models if PI3K 
activity was subsequently restored. It would be interesting to determine whether 
inflammatory disease is more or less severe following removal of PI3K inhibition 
in mice previously treated with a PI3K inhibitor.  
 
Th17 cells and IL-17A have important roles in mediating inflammatory disorders 
(397-400) whilst seemingly contradictory results on the role of PI3K in Th17 cell 
differentiation and IL-17A production have been published both in the literature 
and in the results presented in this thesis. These results indicate that the short 
term and long term effects of PI3K inhibition on Th17 cell differentiation in 
humans needs to be fully established before PI3K inhibitors can be safely used 
therapeutically for the treatment of Th17 mediated pathologies.  
 
 
3.8.3.   IL-17A had no effect on T lymphocyte signalling or motility 
IL-17A is a pro-inflammatory cytokine able to drive leukocyte recruitment to sites 
of infection (401, 402). The receptor for IL-17A is composed of at least two IL-
17RA subunits, and a single IL-17RC subunit (403), and upon receptor ligation, 
recruits the adaptor protein Act1 which in turn mediates downstream signalling 
(404). IL-17A has been shown to directly signal to epithelial cells and smooth 
muscle cells (378, 380). IL-17A stimulates the recruitment of neutrophils to sites 
of infection by inducing the production of pro-inflammatory mediators such as 
granulocyte colony-stimulating factor (G-CSF), CXCL8 and IL-6 (381, 405). In 
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leukocytes, IL-17A can directly induce chemotaxis of monocytes extracted from 
the blood of mice (382) and directly promote B cell survival (383). However, in T 
cells IL-17A had no effect on proliferation, survival or apoptosis, which may have 
been due to lack of IL-17RC expression (384). In accordance with this, no effect 
of IL-17A was seen on signalling or motility of CD4 T lymphocytes in this thesis. 
However, since this research was undertaken, a publication has shown that IL-
17A does directly signal to mouse T lymphocytes (391). This discrepancy could 
perhaps be due to differences between mouse and human T lymphocytes, with 
Th17 cells in particular having known differences between mouse and human 
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4.1.  Background and objectives of research 
The development of isoform specific PI3K inhibitors with which to treat certain 
cancers has shown promise (143), whilst inhibition of the leukocyte restricted 
PI3Kδ and PI3Kγ isoforms have been identified as an attractive means with 
which to modulate leukocyte function in inflammatory disorders. However, the 
use of PI3K inhibitors to treat inflammatory disorders has to date been 
disappointing (406). This has led to the search for alternative targets with which 
to selectively modulate PI3K mediated signalling specifically in leukocytes. SHIP-
1 is of particular interest as a drug target because of its restricted expression in 
leukocytes. Previous knowledge on the role of SHIP-1 in T lymphocytes has 
been gained from studies that have genetically targeted the expression of SHIP-1 
(Table 1.5), this has therefore resulted in the removal of SHIP-1 catalytic activity 
as well as the removal of the various non-catalytic functions of SHIP-1 (195). In 
contrast, pharmacological modulation of SHIP-1 allows only the catalytic site of 
SHIP-1 to be targeted, leaving any non-catalytic functions of SHIP-1 intact. In 
addition, the pharmacological targeting of SHIP-1 allows the role of SHIP-1 in 
human naïve T cells to be assessed, this was not previously achievable using the 
lentiviral system because cells must first become activated by TCR ligation.  
 
Pharmacological activation of SHIP-1 would decrease PI(3,4,5)P3 levels, thereby 
in theory, mimicking the effect of a PI3K inhibitor. SHIP-1 activators based on the 
structure of pelorol were first described in 2005 (349). Subsequently, more potent 
analogues were created and shown to allosterically increase the catalytic activity 
of SHIP-1 and to inhibit immune cell activation (255). In collaboration with 
Aquinox Pharmaceuticals, this thesis has utilised a novel small molecule 
activator of SHIP-1, termed AQX-1. The structure of AQX-1 is not available but it 
is related to the core scaffold of the published compound, AQX-MN100 (255). In 
this thesis AQX-1 was used to pharmacologically activate SHIP-1 in primary 
human T lymphocytes and to probe the role of SHIP-1 in lymphocyte functions.  
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In addition this thesis has utilised pharmacological inhibitors of SHIP-1. Genetic 
mouse models have shown that the knockdown of SHIP-1 expression decreases  
graft-versus-host disease (GVHD) in post-transplant mice compared to wild-type 
controls, whilst SHIP-1 deficient mice are more tolerant for mismatched MHC 
bone marrow grafts, have decreased allogeneic T cell responses and have 
increased numbers of myeloid suppressor cells (303, 330, 407, 408). In addition, 
SHIP-1 has been shown to inhibit PI3K mediated signalling downstream of 
growth factor receptors that are crucial for the production of haematopoietic cells 
in the bone marrow (409). The development of pharmacological inhibitors of 
SHIP-1 may therefore allow the increase of blood cell numbers in patients with 
myelosuppressive infection, or may aid transplant acceptance in patients 
undergoing transplant surgery.  
 
The first inhibitor of SHIP-1, 3-αaminocholestane (3AC /alpha amino) was 
identified in 2010 (325) and was found to increase the numbers of 
immunoregulatory cells and to inhibit allogeneic T cell responses in vivo. In 
addition 3AC increased numbers of erythrocytes, neutrophils and platelets in 
myelosuppressed mice (325), whilst surprisingly, 3AC mediated SHIP-1 inhibition 
induced the apoptosis of leukemic cell lines. A subsequent study showed that the 
inhibition of SHIP-1 with 3AC induced cell cycle arrest and apoptosis in multiple 
myeloma cells and that in vivo, the inhibition of SHIP-1 reduced multiple 
myeloma growth (352). This may be explained by the fact that the SHIP-1 
enzymatic product, PI(3,4)P2 has also been shown to activate Akt (252), and it 
has been proposed that cancer cells require certain levels of both PI(3,4,5)P3 
and PI(3,4)P2 to maintain a malignant state (353). Therefore SHIP-1 inhibition 
would disrupt this balance and promote cancer cell apoptosis. This thesis has 
utilised 3AC to probe the effect of pharmacological SHIP-1 inhibition on primary 
human T lymphocyte function. 
 
SHIP-2 is expressed in various tissues including skeletal muscle, brain tissue 
and heart whilst the major role of SHIP-2 appears to be the negative regulation of 
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insulin signalling in non-immune cells (333, 410). Overexpression of SHIP-2 
caused elevated insulin mediated Akt activation and increased glucose uptake 
(411, 412), whilst decreased SHIP-2 activity improved insulin resistance and the 
symptoms of type 2 diabetes in vivo (413, 414). In addition, a role of SHIP-2 in 
cancer has also been identified (354), with SHIP-2 expression elevated in breast 
cancer tissues and in breast cancer cell lines compared to non-cancerous breast 
tissues. SHIP-2 has also been shown to promote cancer cell proliferation in vitro, 
promote cancer cell survival and support cancer metastasis (352, 415). The 
development of pharmacological inhibitors of SHIP-2 activity has therefore been 
of interest for the potential treatment of type 2 diabetes as well as cancer. In this 
regard, progress has been made in the develop of potent SHIP-2 inhibitors (355, 
356), however there are currently no SHIP-2 inhibitors in clinical trials.  
 
SHIP-2 expression can be detected in leukocytes (331, 332) (Figure 5.1) 
however, little is currently known about the role of SHIP-2 in the immune system. 
Intriguingly, SHIP-2 has been identified to play a role in actin remodelling (416, 
417) and cell migration (335), although it is not known if this is also the case in 
lymphocytes. This thesis aimed to determine if previously described SHIP-2 
inhibitors would also inhibit the catalytic activity of SHIP-1, which would have 
important consequences on the ability of the patients immune system to 
effectively deal with pathogens whilst undergoing treatment that involved the use 
of SHIP-2 inhibitors. In addition, this thesis aimed to use pharmacological SHIP-2 
inhibitors to probe the role of SHIP-2 in primary human T lymphocyte function. 
 
In summary, this chapter aimed to determine the effect of SHIP-1 or SHIP-2 
modulation on primary human T lymphocyte function and to identify the potential 
of pharmacological SHIP-1 modulation as a therapy for the inhibition of 
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4.2. SHIP-1 activating compounds 
4.2.1. Validation of pharmacological SHIP-1 activators   
SHIP-1 has previously been shown to utilise PI(3,4)P2 as a substrate (418). In 
accordance with this, using a malachite green phosphatase assay, immuno-
precipitated SHIP-1 protein was found to be able to hydrolyse the in vitro 
substrates D-Ins(1,3,4,5)P4 (both the commercially available product from 
Echelon and the substrate provided by Dr Andy Riley, The University of Bath) 
and Di-C8-Ptdns(3,4,5)P3 (Figure 4.1). In contrast, SHIP-1 was not able to utilise 
Di-C16-Ptdns(3,5)P2, Ins(1,3,5)P4 or the enantiomer of D-Ins(1,3,4,5)P4,  L-
Ins(1,3,4,5)P4 as substrates (Figure 4.1).  
 
 
Figure 4.1. Substrate specificity of SHIP-1. SHIP-1 protein was immuno-
precipitated from SEB-activated primary human T lymphocytes and added to 
required wells of a 96-well plate. Compound was then added at stated 
concentrations for five minutes at room temperature and Ins(1,3,4,5)P4 (100µM) 
was added for 30 minutes at 37oC. 100µl malachite green solution was then 
added and incubated at room temperature for 15 minutes. Absorbance was then 
measured using a plate reader at 650nm. Data is mean ± SEM of three 
independent experiments. One Way ANOVA followed by Tukey’s post test used 
to determine statistical significance *** p<0.001.  
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Aquinox Pharmaceuticals provided three SHIP-1 activating compounds termed 
AQX-1, AQX-2 and AQX-3, the structures of which have not been disclosed and 
are the subject of a material transfer agreement. The structures of these 
compounds are however related to the published compound AQX-MN100 (255). 
It was first sought to determine which of these compounds was most potent. 
Figure 4.2 shows the effect of AQX-1, AQX-2 and AQX-3 on CXCL11 mediated 
migration of primary human SEB-activated T lymphocytes. AQX-1 was identified 
as the most potent SHIP-1 activating compound provided by Aquinox 
Pharmaceuticals and was subsequently used in the following experiments in this 
thesis. Figure 4.3 is provided by Aquinox Pharmaceuticals and shows the effect 
of AQX-1 on the ability of recombinant SHIP-1 protein to utilise the in vitro 




Figure 4.2 AQX-1 is more potent than analogues AQX-2 and AQX-3.  SEB-
activated T lymphocytes were treated with AQX-1, AQX-2 and AQX-3 for 30 
minutes at the stated concentrations then migration assessed using the 
Neuroprobe chemotaxis assay as described in the Material and Methods. Data 
represents the % of CXCL11 (10nM) control ± SEM of three independent 
experiments. 
 




Figure 4.3 AQX-1 increases SHIP-1 catalytic activity (Data provided by 
Aquinox Pharmaceuticals).  AQX-1 (0-300 µM) was incubated with SHIP1 in 
the malachite green phosphatase assay using 1,3,4,5-inositol tetrakisphosphate 
(IP4) as a substrate. The amount of phosphate released was calculated in pmol 
from a phosphate standard curve and % activation of the enzyme by AQX-1 was 
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4.2.2. Effect of SHIP-1 activation on BCR mediated signalling 
The PI3K signalling pathway is crucial for the activation of B lymphocytes (419). 
SHIP-1 has previously been shown to inhibit BCR mediated signalling (420), 
reducing PI(3,4,5)P3 levels and inhibiting PI(3,4,5)P3 dependent signalling (421). 
Btk is recruited and activated by PI(3,4,5)P3, which in turn phosphorylates and 
activates PLCγ which produces IP3. IP3 binds IP3 receptors in the endoplasmic 
reticulum and causes the release of Ca2+ into the cytosol (Figure 4.4). Upon 
engagement of Fc regions of IgG, FcγRIIB recruits SHIP-1 which binds the 
inhibitory receptor and contributes to FcγRIIB mediated negative regulation of 

































Figure 4.4. B-cell receptor induced PI3K signalling. BCR ligation results in 
formation of the signalosome, composed of LYN, SYK, BLNK, PLCγ, BTK and 
PI3K. Recruitment of PI3K leads to the generation of PI(3,4,5)P3, optimal 
activation of BTK, PLCγ induced release of intracellular calcium and Akt 
activation. The FcγRIIB receptor recruits SHIP-1 which negatively regulates 
accumulation of PI(3,4,5)P3 and hence negatively regulates BCR mediated 
signalling. 
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BCR ligation induces calcium flux in B lymphocytes and is crucial for the 
activation of B cells (422). Stimulation of B cells with anti-IgG (whole molecule) in 
vitro has previously been shown to induce calcium flux (423, 424). Stimulation of 
B cells with anti-IgG Fab fragments stimulates the BCR but does not recruit 
FcγRIIB. In contrast, stimulation with whole molecule anti-IgG cross-links the 
BCR with FcγRIIB and recruits SHIP-1 from the cytosol to the surface 
membrane. Therefore whole molecule IgG was used in this thesis as a positive 
control for the effects of a SHIP-1 activator and to investigate the effect of SHIP-1 
activating compounds on BCR mediated signalling. To investigate the effect of 
pharmacological SHIP-1 activation on BCR mediated calcium flux, the A20 B cell 
lymphoma cell line was used. A20 cells were pre-treated with AQX-1 for 30 
minutes then stimulated with anti-mouse IgG antibody (whole molecule). Figure 
4.5 A, demonstrates that activation of SHIP-1 abrogates BCR mediated calcium 
flux in B lymphocytes in a concentration dependent manner (Figure 4.5 B, 
p<0.001). 
 
To further investigate the effect of AQX-1 on BCR mediated signalling, Western 
blotting was used to identify the effect of SHIP-1 activation on Akt, PLCγ and NF-
κB phosphorylation. A20 B cells were pre-treated for 30 minutes with AQX-1 then 
stimulated with anti-mouse IgG antibody (whole molecule) for 5 minutes to cross-
link the BCR. Figure 4.6 A shows that BCR cross-linking induces the 
phosphorylation of Akt, PLCγ and Nf-κB. Activation of SHIP-1 catalytic activity 
was found to inhibit BCR mediated phosphorylation of Akt and NF-κB, although 
less of an effect was seen on the status of PLCγ phosphorylation (Figure 4.6 B). 



















Figure 4.5. Activation of SHIP-1 abrogates BCR induced calcium flux. 1x106 
A20 B cells per point were stained with Fluo-4 and treated with AQX-1 as stated. 
Calcium flux was measured using a F-4500 fluorescence spectrophotometer as 
stated in the Materials and Methods. Cells were then stimulated with anti-IgG 
(17µg/ml) at 30 seconds post recording. Ionomycin (6µg/ml) was added at 120 
seconds post recording. A) Shows representative calcium recordings from a 
single experiment. Upper panel shows control conditions, lower panel shows 
cells pre-treated with AQX-1 (30µM) before recording. B) Data is % of ionomycin 
control mean ± SEM of three independent experiments. One Way ANOVA 
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Figure 4.6. Activation of SHIP-1 inhibits BCR mediated signalling.  1x106 
A20 B cells were treated with AQX-1 at stated concentrations for 30 minutes. 
Cells were then stimulated with anti-IgG antibody for 5 minutes, lysed and levels 
of phosphorylated Akt, phosphorylated PLCγ, phosphorylated NF-κB and total 
ERK were determined using Western blotting. A) Shows representative blot from 
a single experiment. B) Blots were quantified using ImageJ software. Data is 
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4.2.3.  SHIP-1 activation inhibits chemokine mediated Akt phosphorylation  
CXCR4 is a G protein-coupled receptor (GPCR) that is expressed at high levels 
by naïve CD4 T lymphocytes and is crucial for lymphocyte recirculation (100, 
425). PI3K is known to become activated following ligation of the CXCR4 
receptor by its ligand CXCL12 (177), whilst SHIP-1 has also been implicated in 
the regulation of GPCR signalling (245). Expression of a constitutively active 
membrane localised SHIP-1 mutant in Jurkat cells (which usually lack SHIP-1 
expression) was found to inhibit chemokine mediated Akt phosphorylation and 
chemotaxis (245). It was therefore investigated whether activation of SHIP-1 
using the SHIP-1 activating compound, AQX-1, would disrupt CXCL12/CXCR4 
mediated signalling. Pharmacological activation of SHIP-1 using AQX-1 
abrogated (p<0.05) CXCL12 mediated Akt phosphorylation in freshly isolated 
naïve human CD4 T lymphocytes (Figure 4.7 A).  
 
Previously activated T lymphocytes have been shown to be less sensitive to 
PI3K inhibitors than naïve lymphocytes (426, 427), with activation of PI3K a 
dispensable signal for CCR4 mediated T lymphocyte chemotaxis (428). 
However, T cell dependence on PI3K mediated signalling can differ depending 
on the type of assay used to assess migration (429). It was therefore important in 
this thesis to investigate the effect of SHIP-1 modulators on both naïve and 
previously activated T cells. Following antigen encounter, the chemokine 
receptor CXCR3 is up-regulated by T lymphocytes and is crucial for T cell 
recruitment into inflamed tissues (430). Previously activated T cells were treated 
with AQX-1 for 30 minutes then stimulated with the CXCR3 ligand, CXCL11 
(10nM) for 5 minutes. Levels of phosphorylated Akt were then detected using 
Western blotting. Activation of SHIP-1 was found to potently reduce 
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Figure 4.7. SHIP-1 activation inhibits chemokine mediated Akt 
phosphorylation in primary human T lymphocytes. A) Naïve CD4 cells were 
treated with AQX-1 for 30 minutes then stimulated with CXCL12 (10nM) for 5 
minutes. Cells were then lysed and levels of phospho-Akt (ser473) and total ERK 
determined using western blotting. B) SEB-activated T lymphocytes were treated 
with AQX-1 for 30 minutes then stimulated with CXCL11 (10nM) for 5 minutes. 
Cells were then lysed and levels of phospho-Akt, and total ERK were determined 
using Western blotting. The blots were then quantified using ImageJ software, 
lower panels below A) and B) shows mean ± SEM of three independent 
experiments. One Way ANOVA followed by Tukey’s post test used to determine 
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4.2.4. Effect of AQX-1 on Jurkat signalling and motility 
The human leukemic cell line Jurkat lacks expression of the phosphatases PTEN 
and SHIP-1 (245). If selective, AQX-1 would therefore be predicted to have no 
effect on Jurkat cells. However, previous studies using SHIP-1 activating 
compounds based on the structure of pelorol have identified modest (15% 
inhibition at 15µM) inhibition of cell functions in the absence of SHIP-1 
expression (255, 350), indicating that there are some off-target effects with these 
compounds. In this thesis, Western blotting was used to determine the effect of 
AQX-1 on chemokine mediated Akt phosphorylation, whilst the Neuroprobe 
assay was used to determine the effect of AQX-1 on Jurkat cell migration. Figure 
4.8 A shows that AQX-1 at 30µM caused a reduction in Akt phosphorylation. 
Although no increase in Akt phosphorylation was seen in response to CXCL12 
stimulation this is likely due to the constitutively high basal Akt phosphorylation 
associated with the leukemic Jurkat cell line. Figure 4.8 B shows that AQX-1 at 
30µM reduced CXCL12 mediated migration. However, the effect of AQX-1 on 
Jurkat cells was minimal compared to the effect of AQX-1 on Akt phosphorylation 
and on migratory responses of cells that do express SHIP-1 (Figure 4.7 and 
Figure 4.10).  
 
4.2.5. Effect of SHIP-1 activation on TCR mediated Akt phosphorylation 
Activation of the PI3K/Akt signalling cascade has previously been shown to occur 
in response to ligation of the TCR, and is crucial for T lymphocyte activation, 
proliferation and cytokine secretion (99, 163). SHIP-1 is recruited to the surface 
membrane upon CD3/CD28 ligation (267), implicating a possible role of SHIP-1 
in the regulation of TCR signalling. However in mice, no disruption to TCR 
mediated signalling was seen following the silencing of SHIP-1 expression (300). 
In this thesis the role of SHIP-1 and SHIP-2 in the regulation of TCR-induced 
signalling in primary human T lymphocytes was investigated.  
 
Pharmacological activation of SHIP-1 inhibited anti-TCR antibody stimulated Akt 
phosphorylation in naïve CD4 T cells, as assessed by Western blotting (Figure 
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4.9 A), and in previously activated T cells as assessed by flow cytometry (Figure 
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Figure 4.8. Effect of AQX-1 on Jurkat cell motility. A) Jurkat cells were treated 
with AQX-1 for 30 minutes then stimulated with CXCL12 (10nM) for 5 minutes. 
Cells were then lysed and levels of phospho-Akt (ser473) and total ERK 
determined using Western blotting. B) Jurkat cells were treated with stated 
concentrations of AQX-1 then basal and chemokine mediated migration 
assessed using the Neuroprobe chemotaxis assay as described in the Materials 
and Methods. Data is the number of migrated cells (basal or CXCL12 (10nM)) ± 
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Figure 4.9. SHIP-1 activation in naïve and previously activated primary 
human lymphocytes inhibits TCR mediated Akt phosphorylation. A) Naïve 
CD4 cells were treated with AQX-1 for 30 minutes, stimulated with anti-CD3 
antibody (UCHT1, 10µg/ml) for 5 minutes then lysed. Levels of phosphorylated 
Akt and total ERK were then determined using Western blotting. Lower panel 
represents the mean ± SEM of three independent experiments. B) SEB-activated 
T lymphocytes were incubated with AQX-1 for 30 minutes then stimulated with 
anti-CD3 antibody (UCHT1, 10µg/ml) for 5 minutes. Cells were fixed and levels of 
phosphorylated Akt determined using flow cytometry. Upper panel shows 
representative flow cytometry plots of a single experiment. Lower panel shows 
mean ± SEM of three independent experiments. One Way ANOVA followed by 
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4.2.6.  SHIP-1 activation inhibits chemokine mediated directional migration  
The accumulation of lymphocytes at sites of inflammation via migratory 
responses is driven by chemokine-induced signals, whilst PI3K mediated 
signalling is an important, although sometimes dispensable, signalling pathway 
for lymphocyte migration and homing (100, 177, 428). In addition, silencing of 
SHIP-1 expression in primary human T lymphocytes has previously been shown 
to reduce basal but not directional motility in vitro (295). Because SHIP-1 
activation adversely affected chemokine induced signalling, the effect of SHIP-1 
activation on basal and chemokine induced lymphocyte migration was 
investigated.   
 
Using a Neuroprobe plate-based chemotaxis assay that measured migration 
across a synthetic membrane in response to a chemokine gradient, AQX-1 was 
found to abrogate basal migration by both naïve and previously activated T cells 
(Figures 4.10 A and B). In addition, AQX-1 inhibited directional responses to two 
different chemokines, namely naïve cell responses to CXCL12 (Figure 4.10 A), 
and previously activated T cell responses to CXCL11 (Figure 4.10 B). 
Interestingly, AQX-1 inhibited naïve cell directional migration (IC50 3µM) more 
potently than inhibition of previously activated T cell directional migration (IC50 
23µM). 
 
PI3K dependence of migrating T cells has previously been shown to differ 
depending on the assay used to assess migration (174). It was therefore 
important to determine the effect of AQX-1 on T cell migration using a separate 
migration assay. In contrast to the Neuroprobe assay, the IBIDI µ-slide 
chemotaxis assay allows tracking of individual cells across a horizontal, 
fibronectin coated surface using video microscopy. Using the IBIDI assay, the 
activation of SHIP-1 was found to abrogate CXCL11 mediated migration as 
measured by accumulated distance (Figure 4.10 C and D) and velocity (Figure 
4.10 E), although no reduction in basal migration in the presence of AQX-1 was 
observed. This may be because cells are located on a horizontal fibronectin 
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coated plate, with basal cells showing very little movement. Therefore in contrast 
to the Neuroprobe assay, using the IBIDI assay there is very little basal 
movement to potentially be inhibited by AQX-1. 
 
To ensure that the reduction in chemokine mediated signalling and abrogated 
motility was not due to the down-regulation of chemokine receptor surface 
expression, cells were treated for three hours with AQX-1, then CXCR3 surface 
expression examined by flow cytometry. Figure 4.10 F shows that AQX-1 at 
concentrations of 10µM and below has no effect on CXCR3 expression, however 
at 30µM CXCR3 expression is slightly, but statistically significantly (p<0.05) 
reduced. However, this reduction does not correspond with the levels of AQX-1 
mediated inhibition of Akt phosphorylation or cell motility.  
 
The ability of cells to sense a chemokine gradient and become polarised is 
crucial for cell motility and has been shown to be PI(3,4,5)P3 dependent (100, 
431). Because SHIP-1 activation inhibited the ability of human lymphocytes to 
migrate towards a chemokine gradient, the effect of SHIP-1 activation on cell 
lamellipodia extension was investigated. Figure 4.11 shows that in the presence 
of a chemokine gradient and situated on a Poly-L-Lysine coated surface, T 
lymphocytes display a polarised phenotype with a distinct lamellipodia extension 
and a visible back to the cell. Figure 4.11 shows that when SHIP-1 is activated by 
AQX-1, lymphocytes are unable to become polarised in response to chemokine 
stimulation.    
 








0                              30 
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Figure 4.10. Activation of SHIP-1 reduces naïve and activated primary 
human lymphocyte basal and chemokine mediated motility. A) Naïve CD4 
cells were treated with stated concentrations of AQX-1 then basal and 
chemokine mediated migration was assessed using the Neuroprobe chemotaxis 
assay as described in the Materials and Methods. Data represents the % of 
controls (basal or CXCL12 (10nM)) ± SEM of three independent experiments. B) 
SEB-activated T lymphocytes were treated with AQX-1 for 30 minutes at the 
stated concentrations then migration was assessed using the Neuroprobe 
chemotaxis assay as described in the Material and Methods. Data represents the 
% of controls (basal or CXCL11 (10nM)) ± SEM of three independent 
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experiments. C) Cells were treated with AQX-1 for 30 minutes then migration 
with or without CXCL11 (100nM) gradient was recorded using the IBIDI 
Chemotaxis µ-slides and video-microscopy as described in the Material and 
Methods. Data represents three separate experiments with twenty cells recorded 
under each condition in each experiment. C) Images show twenty cell tracks from 
a single representative experiment. D) Accumulated distance calculated using 
ImageJ. E) Velocity calculated using ImageJ. Data represents the mean ± SEM 
of three independent experiments. F) SEB-activated T lymphocytes were treated 
with AQX-1 at stated concentrations for three hours and surface expression of 
CXCR3 analysed using flow cytometry. Data represents the mean ± SEM of 
three independent experiments. One Way ANOVA followed by Tukey’s post test 
used to determine statistical significance * p<0.05. 
 
 
No Treatment                                     AQX-1 (30µM) 
 
Figure 4.11. Lamellipodia extension is abrogated by activation of SHIP-1. 
SEB-activated T lymphocytes were added to the IBIDI Chemotaxis µ-slides with 
a 100nM CXCL11 gradient applied. 15 minutes prior to addition cells were either 
left untreated or treated with AQX-1. Cells were allowed to rest for 15 minutes 
then single images were taken using confocal microscopy. Images are 
representative of two independent experiments. Red arrow indicates location of 
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4.2.7. Effect of pharmacological SHIP-1 activation on the proliferation of 
CD4 T lymphocytes  
Given the crucial role of PI3K/Akt in cell proliferation (143, 163), the effect of 
SHIP-1 activation on TCR-mediated clonal expansion of human T lymphocytes 
was subsequently investigated. Using the MTT assay which assesses cell 
metabolism, lymphocyte growth was shown to be significantly inhibited (p<0.05) 
by the activation of SHIP-1 (Figure 4.12 A). CFSE staining was then used to give 
a clearer indication of the effect of SHIP-1 activation on proliferation, not just on 
cell growth. As shown in Figure 4.12 B and C, AQX-1 treatment increased the 
percentage of cells retained in generation 1 and 2, whereas fewer cells were 
seen to progress to generations 3 and 4. This indicates that activation of SHIP-1 
inhibited the ability of human CD4 T lymphocytes to proliferate and progress 
through cell divisions following TCR stimulation in vitro. 
 
 












Figure 4.12. Activation of SHIP-1 inhibits TCR mediated growth and 
proliferation. A) Naïve CD4 cells were pre-treated with AQX-1 at stated 
concentrations then incubated with anti-CD3/28 antibody coated beads and IL-2 
(36U/ml) for 48 hours. MTT assay was then used as described in Materials and 
Methods to assess cell metabolism. Data is mean ± SEM of the % of control from 
three independent experiments. One Way ANOVA followed by Tukey’s post test 
used to determine statistical significance * p<0.05. B) and C) Naïve CD4 cells 
were stained with CFSE, treated with AQX-1, then incubated with anti-CD3/28 
antibody coated beads and IL-2 (36U/ml) for four days. Flow cytometry was then 
used to measure CFSE staining levels. B) Shown are flow cytometry plots from a 
single representative experiment. C) Data is mean ± SEM of the % of population 
in each proliferative generation from three independent experiments.   
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4.2.8. Effect of SHIP-1 activation on cytokine secretion by CD4 T 
lymphocytes 
TCR mediated cytokine secretion by human T lymphocytes has previously been 
shown to be PI3Kδ dependent (160). SHIP-1 activators are currently in clinical 
trials for asthma (406), whilst Th2 polarised cells are key in driving allergic 
asthma (95). It was therefore asked whether the activation of SHIP-1 catalytic 
activity would inhibit TCR mediated cytokine secretion by Th2 polarised cells. 
Th2 polarised cells were stimulated with anti-CD3/anti-CD28 antibody coated 
beads for 16 hours in the presence of AQX-1. Activation of SHIP-1 was found to 
significantly inhibit the secretion of IL-5 (Figure 4.13 A), TNFα (Figure  4.13 C), 
IL-13 (Figure 4.13 B) and IL-4 (Figure  4.13 D). The secretion of IL-17A also has 
crucial roles in promoting inflammation and is secreted by Th17 polarised 
lymphocytes (432). The activation of SHIP-1 was found not to significantly reduce 
IL-17A secretion by Th17 polarised cells (Figure 4.13 E). To determine if 
cytokines were still being expressed by these cells but that AQX-1 was inhibiting 
the secretion of cytokines, the intracellular expression of IL-4 was determined 
using flow cytometry after 16 hours of TCR stimulation in the presence of AQX-1. 
Figure 4.14 indicates that intracellular IL-4 levels were reduced by activation of 
SHIP-1, implying that TCR mediated expression of IL-4 protein is inhibited by the 
activation of SHIP-1.  
 
 








Figure 4.13. Cytokine secretion is inhibited by activation of SHIP-1. Naive 
CD4 cells were incubated with anti-CD3/CD28 antibody coated beads and Th2 
polarising cytokine cocktail for 8 days. 1×106 cells were then treated with stated 
concentrations of AQX-1 and stimulated with anti-CD3/28 antibody coated beads 
at a 1:1 ratio for 16 hours at 37oC, 5% CO2. Levels of A) IL-5 B) IL-13 C) TNFα 
and D) IL-4 in the supernatant were determined using the MSD SECTOR 6000 
instrument as described in the Materials and Methods. E) Naive CD4 cells were 
incubated with anti-CD3/28 antibody coated beads and Th17 polarising cytokine 
cocktail for 8 days. 1×106 cells were then treated with stated concentrations of 
AQX-1 and stimulated with anti-CD3/28 antibody coated beads at a 1:1 ratio for 
16 hours at 37oC, 5% CO2. Levels of IL-17A in the supernatant were determined 
using an IL-17A ELISA as described in the Materials and Methods. Data is mean 
% of controls ± SEM from three independent experiments. One Way ANOVA 
followed by Tukey’s post test used to determine statistical significance * p<0.05, 
*** p<0.001. 
 














Figure 4.14. Effect of AQX-1 on intracellular IL-4 production. 1×106 Th1 or 
Th2 polarised lymphocytes were treated with AQX-1 at the stated concentrations 
for 30 minutes then stimulated with anti-CD3/CD28 antibody coated beads at a 
1:1 ratio for 16 hours. Cells were then fixed and levels of IL-4 determined using 
flow cytometry. Flow cytometry plots show % cells positive for IL-4 expression. 
 
 
4.2.9. Effect of SHIP-1 activation on T cell adhesion to fibronectin and 
ICAM1 
T cells are continually recruited from the circulation into peripheral tissues. 
Ligation of the TCR is known to increase adhesion of lymphocytes (433), whilst 
TCR mediated signalling can increase integrin affinity and drive antigen 
dependent transendothelial migration (100, 434, 435). The ability of lymphocytes 
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to adhere to extracellular matrix components is a crucial step in the accumulation 
of lymphocytes at the focus of inflammation (436), whilst transendothelial 
migration and extravasation requires the binding of the integrin LFA-1 to its 
substrate ICAM1 (81, 437). LFA-1 binding to ICAM1 is also crucial for the 
formation and sustainment of an intercellular synapse between lymphocytes and 
antigen presenting cells (438, 439). In addition, a recent study has shown that 
silencing of SHIP-1 expression in neutrophils increased their adhesion (296). In 
this thesis, AQX-1 was found to abrogate TCR induced adhesion of both naïve 
(p<0.001, Figure 4.15 A) and previously activated (p<0.001, Figure 4.15 B) T 
cells to fibronectin, a major glycoprotein of the extracellular matrix. In addition, 
the ability of naïve CD4 lymphocytes (Figure 4.15 C, p<0.05) and previously 
activated T lymphocytes (Figure 4.15 D, p<0.01) to adhere to ICAM1 was found 
to be potently inhibited by the activation of SHIP-1 using AQX-1.  
 
It was next asked whether the cause of adhesion abrogation following SHIP-1 
activation was due to the down-regulation of adhesion receptors. However, 
SHIP-1 activation with AQX-1 was found to have no effect on the expression 
levels of CD11a (component of LFA-1) or CD49d (component of VLA-4) by naïve 
T cells (Figure 4.16 A) or by previously activated T cells (Figure 4.16 B). 
However, LFA-1 exists in different states of affinity which determine the strength 
of ICAM1-LFA-1 binding interactions. It was therefore investigated whether SHIP-
1 activation affects the affinity state of integrin’s expressed by lymphocytes. The 
activated affinity state of LFA-1 can be detected using the monoclonal antibody 
KIM127, as previously reported (81). Pharmacological activation of SHIP-1 was 
found to significantly reduce the expression of LFA-1 in its activated affinity state 
by both naïve (Figure 4.16 C) and previously activated (Figure 4.16 D) human T 
lymphocytes.  
 






Figure 4.15. Lymphocyte adhesion to fibronectin or ICAM1 is abrogated by 
activation of SHIP-1. A) Naïve CD4 cells were treated with AQX-1 at stated 
concentrations and adhesion to a 96-well fibronectin coated plate in response to 
anti-CD3 stimulation (UCHT1, 10µg/ml) was assessed as described in Material 
and Methods. Data is mean ± SEM of three independent experiments. B) SEB-
activated T lymphocytes were treated with AQX-1 for 30 minutes then adhesion 
to a fibronectin-coated surface in response to anti-CD3 stimulation (UCHT1, 
10µg/ml) was assessed. Data represents the mean ± SEM of three independent 
experiments. C) Naïve CD4 cells were treated with AQX-1 for 30 minutes then 
adhesion to an ICAM1 coated surface in response to anti-CD3 stimulation 
(UCHT1, 10µg/ml) was assessed. Data represents the mean ± SEM of three 
independent experiments D) SEB-activated T lymphocytes were treated with 
AQX-1 for 30 minutes then adhesion to an ICAM1 coated surface in response to 
anti-CD3 stimulation (UCHT1, 10µg/ml) was assessed. Data represents the 
mean ± SEM of three independent experiments. One Way ANOVA followed by 
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CD11a CD49d B)  
A) CD11a CD49d 
 
Figure 4.16. SHIP-1 activation reduces expression of LFA-1 in its activated 
affinity state. A) Naïve CD4 cells were incubated with AQX-1 for three hours 
then levels of CD11a (left graph) and CD49d (right graph) surface expression 
were analysed by flow cytometry.  Data is mean fluorescent index ± SEM of three 
independent experiments. B) SEB-activated T lymphocytes were incubated with 
AQX-1 for three hours then levels of CD11a (left graph) and CD49d (right graph) 
surface expression were analysed by flow cytometry.  Data is mean fluorescent 
index ± SEM of three independent experiments. C) Naïve CD4 cells or D) SEB-
activated cells were treated with AQX-1 for 30 minutes then stained with KIM127 
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(10µg/ml) for 30 minutes at 4°C then washed twice in PBS. Cells were then 
incubated for 30 minutes with anti-mouse FITC conjugated antibody at 4°C. Cells 
were then washed twice in PBS and analysed by FACSCanto flow cytometry. 
Data is mean fluorescent index ± SEM of three independent experiments. One 
Way ANOVA followed by Tukey’s post test used to determine statistical 






4.2.10.    Effect of  pharmacological SHIP-1 activation on the viability of T 
cells 
PI3K/Akt signalling is crucial for lymphocyte survival (163, 440), whilst 
pharmacological modulation of SHIP-1 would alter levels of PI(3,4,5)P3 and 
levels of PI(3,4)P2, thereby altering the recruitment and activation of downstream 
PI3K effector proteins. In addition, pharmacological inhibition of SHIP-1 has been 
shown to induce the apoptosis of SHIP-1 expressing leukemic cells (325, 352). 
Because SHIP-1 modulation is being considered for anti-cancer therapy (350, 
352), it is important to know what the effect of SHIP-1 modulation would be on 
non-cancerous T lymphocytes because of the important role of T cells in anti-
cancer immuno-surveillance (441). In addition, induced cell death could, in 
alternative assays have been misread as an inhibition of lymphocyte function.  
 
SEB-activated T cells were treated for 24 hours with AQX-1 then stained with 
7AAD to give an indication of cell membrane permeability and hence cellular 
viability. Figure 4.17 A and B show that 24 hours post SHIP-1 activation, no 
evidence for increased cell death could be detected in T lymphocytes.  















Figure 4.17. No effect on cell viability following SHIP-1 activation. 1x106 day 
9-12 post isolation CD4 cells were treated with AQX-1 for 24 hours, washed once 
in PBS then stained with 7AAD and analysed using flow cytometry. Left hand 
panel shows representative flow cytometry plots from a single experiment. Graph 
shows mean ± SEM of three independent experiments. One Way ANOVA 
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4.2.11.  The effect of pharmacological SHIP-1 activation on the 
association of SHIP-1 with protein binding partners 
 
Previous studies on the role of SHIP-1 in lymphocytes have used genetic 
strategies to silence the expression of SHIP-1 (Table 1.5). Given the crucial 
catalytic and non-catalytic roles of SHIP-1, silencing SHIP-1 expression in 
previous studies was not able to determine whether it was the catalytic or non-
catalytic activity of SHIP-1 that was responsible for the altered cell phenotype. In 
addition, the tyrosine phosphorylation of SHIP-1 in response to stimuli has been 
shown to be crucial for the interaction of SHIP-1 with other proteins, for example 
DOK1 and shc, and to be required for SHIP-1 mediated cellular functions (442, 
443).  
 
The effect of AQX-1 on the association of SHIP-1 with other proteins was first 
investigated using immuno-precipitation of SHIP-1 following TCR stimulation, and 
then  associated proteins visualised using Silver Staining (Figure 4.18 A). Protein 
corresponding to the molecular weight of SHIP-1 is indicated and was increased 
in the post-SHIP-1 immuno-precipitated lanes. However no associated binding 
partners of SHIP-1 could be identified. Subsequently, the tyrosine 
phosphorylation of SHIP-1 after TCR stimulation following AQX-1 treatment was  
investigated using immuno-precipitation of SHIP-1 and immunoblotting. Tyrosine 
phosphorylation of SHIP-1 following TCR stimulation in the presence of AQX-1 is 
shown in Figure 4.18 B.  
 
 
Chapter 4: Results 
134 
IgG        IP: SHIP-1 








Heavy chain Ig 
Light chain Ig 
IP: IgG           SHIP-1 
        -         +        +       UCHT1 (10µg/ml) 




Figure  4.18. Effect of AQX-1 on TCR mediated tyrosine phosphorylation of 
SHIP-1 and binding of SHIP-1 to associated proteins. A) SEB-activated T 
lymphocytes were treated with AQX-1 at stated concentrations for 30 minutes 
and stimulated with anti-CD3 antibody (UCHT1, 10µg/ml) for 5 minutes. Cells 
were then lysed and SHIP-1 immuno-precipitated and proteins visualised using 
Silver staining as described in Materials and Methods. Gel is representative of 
two independent experiments. B) SEB-activated T lymphocytes were treated with 
AQX-1 at stated concentrations for 30 minutes and stimulated with anti-CD3 
antibody (UCHT1, 10µg/ml) for 5 minutes. Cells were then lysed and SHIP-1 
immuno-precipitated. Using Western blotting, levels of phosphorylated tyrosine 
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4.3. Pharmacological SHIP-1 inhibitors 
 
4.3.1 SHIP-1 inhibitor validation 
In this thesis, in collaboration with Dr Andy Watts (Pharmacy and Pharmacology, 
The University of Bath), the 3AC (Figure 4.19 A) compound was used to probe 
the effect of SHIP-1 inhibition on primary human T lymphocyte signalling and 
function. In addition, the effect of chemical modifications to the amide group of 
the 3AC compound (Indicated in Figure 4.19 and listed in Table 4.1 and Table 
4.2) were investigated on its ability to increase potency of SHIP-1 inhibition and 






Figure 4.19. Chemical structures of 3AC derivatives. A) R1 and R2 refer to 
alkyl modifications of the amine group (by Dr Andy Watts, University of Bath) to 
investigate if potency of SHIP-1 inhibition in lymphocytes could be increased 
compared to unmodified 3AC (R1=R2=H). B) Alternative (Beta) stereochemistry 










Name Chemical modification to the amine 
group indicated in figure 4.19 A 
 R1 R2 
3AC/ alpha amino H H 
Ethyl Et H 
Diethyl Et Et 
Methyl Me H 
Dimethyl Me Me 
Methyl Ethyl Et Me 
 
Table 4.1. Description of the chemically modified 3AC derivatives and the 









Name Chemical modification to the alternative 
stereochemistry of the amine group indicated in 
figure 4.19 B 
Beta amino H H 
Beta hydroxyl Hydroxyl group  
 
Table 4.2. Description and names of the chemically modified 3AC 
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3AC has previously been shown to selectively inhibit the catalytic activity of 
SHIP-1, but not PTEN or SHIP-2 (325). To confirm that the 3AC compound 
produced at the University of Bath did inhibit the catalytic activity of SHIP-1, a 
malachite green phosphatase assay was used in conjunction with immuno-
precipitated SHIP-1 protein from primary human T lymphocytes. Figure 4.20 A 
shows that 3AC significantly (p<0.001) inhibited the catalytic activity of SHIP-1, in 
accordance with published results on this compound (325). Subsequently, the 
effect of chemical modifications to 3AC on the ability of these novel derivatives to 
inhibit the catalytic activity of SHIP-1 protein was investigated. Figure 4.20 B and 
C indicate that no chemical modifications to the 3AC compound investigated in 
this thesis were successful in increasing the potency of inhibition of SHIP-1 
catalytic activity compared to unmodified 3AC. 3AC at 0.5 mM in Figure 4.20 A 
had little effect on SHIP-1 activity, whilst 3AC at 0.5 mM in Figure 4.20 B had a 
comparable effect to 3AC at 1mM. These two graphs were generated at different 
times, therefore this difference may be due to variation between donors or may 
be due to differences in the total amount of SHIP-1 protein present per assay.  
 






Figure 4.20. The effect of 3AC and derivatives on the catalytic activity of 
SHIP-1.  SHIP-1 protein was immuno-precipitated from SEB-activated primary 
human T lymphocytes and added to required wells of a 96-well plate. A) 3AC and 
B) 3AC, Ethyl, Methyl or Methyl Ethyl was then added at stated concentrations 
for five minutes at room temperature and Ins(1,3,4,5)P4 (100µM) was added for 
30 minutes at 37oC. 100µl malachite green solution was then added and 
incubated at room temperature for 15 minutes. Absorbance was measured using 
a plate reader at 650nm. Data is mean ± SEM of three independent experiments. 
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One Way ANOVA followed by Tukey’s post test used to determine statistical 
significance *p<0.05, **p<0.01, ***p<0.001. C) Shows the mean % of control ± 
SEM of three independent experiments. 
 
 
4.3.2 Comparison of the effect of 3AC and its novel derivatives on the 
phosphorylation of Akt in response to CXCL11 and TCR stimulation 
 
Because the pharmacological activation of SHIP-1 was found to inhibit GPCR 
mediated Akt phosphorylation, it was therefore investigated whether the inhibition 
of SHIP-1 activity using 3AC would affect GPCR mediated signalling in primary 
human T lymphocytes. Figure 4.21 A and B show that 3AC significantly (p<0.01) 
reduced CXCL11 induced Akt phosphorylation. It was then investigated whether 
chemical modifications to the amino group of 3AC (Table 4.1 and 4.2) would 
increase the potency of 3AC as an inhibitor of CXCL11 mediated Akt 
phosphorylation. Figure 4.21 C shows that the addition of an ethyl group to 3AC 
increased the potency of Akt inhibition. In contrast, addition of diethyl, methyl, 
dimethyl or methylethyl groups decreased the potency of 3AC mediated 
inhibition. In addition, altered stereochemistry of the amino group (beta) 
decreased the ability of 3AC to inhibit CXCL11 mediated Akt phosphorylation 
(Figure 4.21 C). To examine if there were any off-target effects of 3AC or novel 
derivatives, the effect of 3AC or related derivatives was investigated on the 
phosphorylation of Akt in Jurkat cells. Figure 4.22 A, B and C show that 3AC and 
novel derivatives showed no effect on Akt phosphorylation in cells which lack 
expression of SHIP-1. 
 
Subsequently it was investigated what effect the use of 3AC or related novel 
derivatives would have on TCR mediated Akt phosphorylation in primary human 
T lymphocytes. Inhibition of SHIP-1 activity with 3AC reduced TCR mediated Akt 
phosphorylation (Figure 4.23), as assessed by flow cytometry. Figure 4.23 B also 
indicates that addition of an ethyl group to the 3AC structure produced more 
potent inhibition of TCR mediated Akt activation than 3AC alone.  






EtOH       3AC (15µM) 
pAkt 




Figure 4.21. Effect of 3AC and derivatives on CXCL11 mediated Akt 
phosphorylation. A) SEB-activated T cells were treated with 3AC (20µM) for 30 
minutes then stimulated with CXCL11 (10nM) for 5 minutes. Cells were lysed and 
levels of phospho-Akt (ser473) and total ERK were determined using Western 
blotting. The blots were quantified using ImageJ software. B) Shows mean % of 
CXCL11 control ± SEM of three independent experiments. C) SEB-activated T 
cells were treated with 20µM of 3AC, Ethyl, Diethyl, Methyl, Dimethyl, Methyl 
Ethyl or Beta amino for 30 minutes then stimulated with CXCL11 (10nM) for 5 
minutes. Cells were lysed and levels of phospho-Akt (ser473) and total ERK 
were determined using Western blotting. The blots were quantified using ImageJ 
software. Graph shows mean % of CXCL11 stimulated control ± SEM of three 
independent experiments. Student paired t test was performed to determine 
statistical significance ** p<0.01, *** p<0.001. 
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Basal         CXCL12      UCHT1 
-     +      -      -    +    -      -    +      -     alpha amino (20µM)  
-     -      +      -    -    +      -    -      +     alpha dimethyl (20µM)  
Basal         CXCL12      UCHT1 
-     +      -      -    +    -      -    +     -     beta amino (20µM)  
-     -      +      -    -    +      -    -     +     beta hydroxyl (20µM)  
Basal            CXCL12         UCHT1 
-     +    -      -    -    +     -     -    -     +    -      -          alpha methyl (20µM) 
-     -    +      -    -    -     +     -    -     -    +      -          alpha ethyl (20µM) 











Figure 4.22. Effect of 3AC and derivatives on Akt phosphorylation in Jurkat 
cells. Jurkat leukemic cells were treated with A) Beta amino or Beta hydroxyl, B) 
3AC or Dimethyl, C) Methyl, Ethyl or Diethyl at a concentration of 20µM for 30 
minutes then stimulated with CXCL11 (10nM) or UCHT1 (10µg/ml) for 5 minutes. 
Cells were lysed and levels of phospho-Akt (ser473) and total ERK determined 














Methyl ethyl  
Basal                                                    UCHT1 (10µg/ml)  





Figure 4.23. Effect of 3AC and derivatives on TCR mediated Akt 
phosphorylation. SEB-activated T lymphocytes were incubated with 3AC, Ethyl, 
or Methyl Ethyl for 30 minutes then stimulated with anti-CD3 antibody (UCHT1, 
10µg/ml) for 5 minutes. Cells were fixed and levels of phosphorylated Akt 
determined using flow cytometry. B) Flow cytometry plots shown are of a single 
experiment. B) Shows mean ± SEM of three independent experiments.  
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4.3.3. Effect of SHIP-1 inhibition on T lymphocyte motility 
It was subsequently investigated what effect the pharmacological inhibition of 
SHIP-1 activity would have on T lymphocyte migration in vitro, and whether 
chemical modifications to the structure of 3AC would alter its ability to modify 
lymphocyte migration. Inhibition of SHIP-1 with 3AC was found to abrogate both 
basal (IC50 4µM) and CXCL11 (IC50 10µM) mediated directional migration of 
primary human T lymphocytes in a concentration-dependent manner (Figure 4.24 
A). It was then determined what the effect of modifications to the amino group of 
3AC would have on its ability to inhibit lymphocyte migration in the same 
Neuroprobe chemotaxis assay. Interestingly, the addition of an ethyl group to 
3AC slightly increased the potency of inhibition of basal migration (IC50 3µM) and 
CXCL11 mediated migration (IC50 5µM) compared to unmodified 3AC (Figure 
4.24 B). In contrast, other modifications to the structure of 3AC did not increase 
potency for inhibition of basal migration (Figure 4.24 C-F) or CXCL11 mediated 




4.3.4. Effect of SHIP-1 inhibition on T lymphocyte proliferation 
Because SHIP-1 inhibition reduced TCR mediated Akt phosphorylation, the effect 
of pharmacological SHIP-1 inhibition on TCR-mediated proliferation of human T 
lymphocytes was investigated. Forty eight hours post TCR stimulation of naïve 
CD4 cells, co-incubation with 3AC showed significant inhibition (p<0.001) of 
lymphocyte metabolism as measured by the MTT assay (Figure 4.25 A). 
Subsequently, use of the CFSE proliferation assay showed that no effect on the 
proliferation of CD4 lymphocytes in response to TCR ligation was seen with 3AC 
at concentrations of 1 or 10µM (Figure 4.25 B and C). Results from using 20µM 
concentration of 3AC for 4 days cannot be shown because this was found to be 
toxic for T cells in vitro. The effect of SHIP-1 inhibition on T cell viability is 
assessed in section 4.3.6. 
 







Figure 4.24. Effect of 3AC and derivatives on lymphocyte motility. SEB-
activated cells were treated with stated concentrations of A) 3AC (n=5) B) Ethyl 
(n=3) C) Diethyl (n=3) D) Methyl (n=3) E) Dimethyl (n=5) or F) Beta amino (n=2) 
for 30 minutes then basal and chemokine mediated migration was assessed 
using the Neuroprobe chemotaxis assay as described in the Materials and 




















Figure 4.25. Effect of 3AC on cell growth and proliferation. A) Naïve CD4 
cells were pre-treated with 3AC at stated concentrations then incubated with anti-
CD3/CD28 antibody coated beads and IL-2 (36U/ml) for 48 hours. MTT assay 
was then used as described in Materials and Methods to assess cell metabolism. 
Data is mean ± SEM of the % of control from three independent experiments. 
One Way ANOVA followed by Tukey’s post test used to determine statistical 
significance *** p<0.001. B) and C) show naïve CD4 cells were stained with 
CFSE, treated with stated concentrations of 3AC, then incubated with anti-
CD3/CD28 antibody coated beads and IL-2 (36U/ml) for four days. Flow 
cytometry was then used to measure CFSE staining levels. B) Shown are flow 
cytometry plots from a single experiment. C) Data is CFSE MFI mean from a 
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4.3.5.  Effect of SHIP-1 inhibition on TCR mediated cytokine secretion and 
adhesion 
 
In section 4.2.8 it was shown that activation of SHIP-1 reduced cytokine 
secretion by Th2 polarised cells. In this section it was determined what the effect 
of pharmacological SHIP-1 inhibition was on TCR stimulated cytokine secretion 
by Th2 polarised cells. 3AC treatment did not significantly effect secretion of IL-
13 or IL-5 (Figure 4.26 A and B). However levels of IL-4 (50%, Figure 4.26 C) 
and levels of TNFα (25%, p<0.05, Figure 4.26 D) were increased compared to 
untreated cells.  
 
Subsequently the effect of SHIP-1 inhibition on T cell adhesion was investigated. 
In neutrophils the silencing of SHIP-1 expression has been shown to increase 
adhesion (296), however the pharmacological inhibition of SHIP-1 in this thesis 
was found to abrogate the ability of both naïve CD4 cells (Figure 4.27 A) and 
previously activated lymphocytes (Figure 4.27 B, p<0.05) to adhere to fibronectin.  
 
It was next asked whether the cause of adhesion abrogation following SHIP-1 
inhibition was due to the down-regulation of adhesion receptors. Three hours of T 
lymphocyte incubation with 3AC showed no effect on CD11a or CD49d 
(components of the integrin’s LFA-1 and VLA-4) expression by naïve CD4 cells 
(Figure 4.28 A) or previously activated T cells (Figure 4.28 B). Section 4.2.9 of 
this thesis utilised the KIM127 antibody to examine the affinity state of LFA-1 
following SHIP-1 activation. It was therefore investigated whether SHIP-1 
inhibition also had an effect on the affinity state of integrin’s expressed by 
lymphocytes. 3AC treatment consistently reduced the activated affinity state of 
LFA-1 compared to control treated cells in three donors, however this was not 










Figure 4.26. Effect of 3AC on cytokine secretion by Th2 polarised T 
lymphocytes. Naive CD4 cells were incubated with anti-CD3/28 antibody coated 
beads and a Th2 polarising cytokine cocktail for 8 days. 1×106 cells were then 
treated with stated concentrations of 3AC for 30 minutes and stimulated with anti-
CD3/28 antibody coated beads at a 1:1 ratio for 16 hours at 37oC, 5% CO2. 
Levels of A) IL-13 B) IL-5 C) IL-4 and D) TNFα in the supernatant were 
determined using the MSD SECTOR 6000 instrument as described in the 
Materials and Methods. Data is mean % of controls ± SEM from five independent 
experiments. One Way ANOVA followed by Tukey’s post test used to determine 











Figure 4.27. Effect of SHIP-1 inhibition on the adhesion of lymphocytes to 
fibronectin. A) Naïve CD4 cells were treated with 3AC at stated concentrations 
and the adhesion to a 96-well fibronectin coated plate was assessed as 
described in Material and Methods. Data is mean ± SEM of three independent 
experiments. B) SEB-activated T lymphocytes were treated with 3AC for 30 
minutes and adhesion assessed on a fibronectin-coated surface as described in 
Material and Methods. Data represents the mean ± SEM of three independent 
experiments. One Way ANOVA followed by Tukey’s post test used to determine 
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Figure 4.28. Effect of SHIP-1 inhibition on the expression of integrin’s A) 
Naïve CD4 cells were incubated with 3AC for three hours then levels of CD11a 
(left graph) and CD49d (right graph) surface expression were analysed by flow 
cytometry.  Data is mean fluorescent index ± SEM of three independent 
experiments. B) SEB-activated T lymphocytes were incubated with 3AC for three 
hours then levels of CD11a (left graph) and CD49d (right graph) surface 
expression were analysed by flow cytometry.  Data is mean fluorescent index ± 
SEM of three independent experiments. C) SEB-activated cells were treated with 
3AC for 30 minutes then stained with KIM127 (10µg/ml) for 30 minutes at 4°C 
then washed twice in PBS. Cells were then incubated for 30 minutes with anti-
mouse FITC conjugated antibody at 4°C. Cells were then washed twice in PBS 
and analysed by FACSCanto flow cytometry. Data is mean fluorescent index ± 
SEM of three independent experiments. One Way ANOVA followed by Tukey’s 
post test used to determine statistical significance. 




4.3.6.  Effect of SHIP-1 inhibition on T lymphocyte viability 
 
Three hours of incubation with 3AC at 20µM was found to increase cell death in 
SEB-activated primary human T lymphocytes as measured by propidium iodide 
staining (Figure 4.29 A) and the LDH assay (Figure 4.30 A). In addition, there 
was a similar magnitude rise of cell death above basal at 20µM 3AC in the Jurkat 
cell line (which lacks expression of SHIP-1) as measured by propidium iodide 
staining (Figure 4.29 B), although this was not detected using the LDH assay 
(Figure 4.30 B). Novel derivatives of 3AC showed no increase in cell death of 
Jurkat cells (Figure 4.29 B and 4.30 B). In primary cells however, addition of an 
ethyl group to 3AC was found to increase cell death compared to unmodified 
3AC treatment alone (Figure 4.29 A and 4.30 A), whilst addition of a methyl 




















































Alpha amino  Ethyl Methyl 
27.5 27.5 

















Figure 4.29. Effect of 3AC and novel derivatives on cell death as measured 
by propidium iodide staining. A) 1x106 day 9-12 post isolation SEB-activated 
cells were treated with stated concentrations of 3AC, Ethyl or Methyl Ethyl for 3 
hours, washed once in PBS then stained with propidium iodide and analysed 
using flow cytometry. Shown are representative flow cytometry plots from a 
single experiment. B) 1x106 Jurkat cells were treated with 3AC, Ethyl or Methyl 
for stated time, washed once in PBS then stained with propidium iodide and 
analysed using flow cytometry. Shown are representative flow cytometry plots 













Figure 4.30. Effect of 3AC and derivatives on cell death as measured by 
LDH release. A) SEB-activated primary T lymphocytes or B) Jurkat cells were 
suspended in phenol red free-RPMI medium at 1×106/ml and 90µl aliquoted into 
required wells of a 96-well plate, in triplicate. 3AC or modified compound was 
added at stated concentration for three hours at 37oC, 5% CO2. The LDH assay 
was completed as described in the Materials and Methods and the absorbance 
measured at 490nm using a plate reader. A) and B) Data represents the mean ± 
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4.3.7. Effect of 3AC on proteosomal degradation of SHIP-1 
The treatment of multiple myeloma cells with 3AC for forty-eight hours has been 
shown to induce proteosome-dependent degradation of SHIP-1 protein (352). 
This would cause loss of SHIP-1 mediated non-catalytic functions in addition to 
the inhibition of catalytic activity with 3AC. In this thesis it was investigated 
whether the treatment of primary human T lymphocytes with 3AC for forty-eight 
hours would also cause the degradation of SHIP-1 protein. However, no change 
in SHIP-1 protein levels were seen following 48 hours of up to 10µM 3AC 
treatment (Figure 4.31 A and B), 20µM could not be used due to the potent 
increase in cell death at this concentration. This indicates that in primary  human 
T lymphocytes the effects of 3AC treatment may be restricted to inhibition of 








Figure 4.31. Effect of 3AC on SHIP-1 protein expression. SEB-activated T 
lymphocytes were treated with stated concentrations of 3AC for 48 hours. Cells 
were then lysed and levels of SHIP-1 or ERK detected using Western blotting. A) 
Representative membrane from a single experiment. B) Data is mean ± SEM of 
three independent experiments. One Way ANOVA followed by Tukey’s post test 
used to determine statistical significance. 
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4.4. Pharmacological SHIP-2 inhibitors 
 
4.4.1 Biphenyl 2,3’, 4,5’, 6-pentakisphosphate and novel analogues 
SHIP-2 has previously been shown to utilise Ins(1,3,4,5)P4 as an in vitro 
substrate (356). In accordance with this, in this thesis using a malachite green 
phosphatase assay, recombinant SHIP-2 protein was able to hydrolyse the 
substrates D-Ins(1,3,4,5)P4 (both the commercially available product from 
Echelon and the substrate provided by Dr Andy Riley, The University of Bath) 
and Di-C8-Ptdns(3,4,5)P3 (Figure 4.32). SHIP-2 was unable to utilise Di-C16-
Ptdns(3,5)P2 or the enantiomer of D-Ins(1,3,4,5)P4, L-Ins(1,3,4,5)P4 as 
substrates (Figure 4.32).  
 
 
Figure 4.32. Substrate specificity of SHIP-2. Recombinant SHIP-2 protein 
(0.16µM) was incubated with stated substrate at required concentration for 30 
minutes at 37oC. 100µl malachite green solution was then added and incubated 
at room temperature for 15 minutes. Absorbance was then measured using a 
plate reader at 650nm. Data is mean ± SEM of three independent experiments. 
One Way ANOVA followed by Tukey’s post test used to determine statistical 
significance *** p<0.001.  
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Novel benzene polyphosphates have been described to mimic inositol 
polyphosphates which act as substrates for SHIP-2. Biphenyl 2,3’, 4,5’, 6-
pentakisphosphate (BiPh(2,3’,4,5’,6)P5) however is not hydrolysed by SHIP-2 
and therefore acts as an inhibitor of SHIP-2 catalytic activity (356). 
BiPh(2,3’,4,5’,6)P5 is not cell permeable but has proved useful in cell free, 
structural studies of the active site of SHIP-2 (357). In this study two structurally 
related compounds, BiPh(2,2’,4,4’,5,5’)P6 and BiPh(3,3’,4,4’,5,5’)P6 were also 
investigated for their ability to inhibit SHIP-2 catalytic activity. Using a malachite 
green phosphatase assay, all three Biphenyl compounds were shown to inhibit 
the catalytic activity of recombinant SHIP-2 protein (Figure 4.33 A-C).  
 
Because of the structural similarities between SHIP-1 and SHIP-2 (Figure 1.10), 
it was asked whether the reported SHIP-2 inhibitor, BiPh(2,3’,4,5’,6)P5, or the 
two structurally related novel compounds, would also be able to inhibit the activity 
of SHIP-1. Subsequently, immuno-precipitated SHIP-1 protein isolated from 
primary human T cells was used in the malachite green phosphatase assay. All 
three benzene polyphosphate compounds were able to inhibit the activity of 
SHIP-1 protein (Figure 4.33 A-C), whilst no specificity for SHIP-1 or SHIP-2 
inhibition was evident by BiPh(2,3’,4,5’,6)P5 (Figure 4.33 A), 
BiPh(2,2’,4,4’,5,5’)P6 (Figure 4.33 B) or BiPh(3,3,’,4,4’,5,5’)P6 (Figure 4.33 C). 
Values in Table 4.3 do show a slight reduction in the IC50 value for the inhibition 
of SHIP-2 activity compared to the activity of SHIP-1, however this concentration 
range between isoforms would not allow individual isoform targeting. In addition 
this difference may be due to recombinant SHIP-2 protein compared to immuno-
precipitated SHIP-1 protein used in these assays. 
 





Figure 4.33. Biphenyl compounds inhibit SHIP-1 and SHIP-2 catalytic 
activity. Recombinant SHIP-2 protein (0.16µM) or SHIP-1 protein immuno-
precipitated from SEB-activated primary human T lymphocytes was incubated 
with A) BiPh(2,3’,4,5’,6)P5, B) BiPh(2,2’,4,4’,5,5’)P6, or C) BiPh(3,3’,4,4’,5,5’)P6 
at stated concentrations for five minutes at room temperature and Ins(1,3,4,5)P4 
(100µM) added for 30 minutes at 37oC. 100µl malachite green solution was then 
added and incubated at room temperature for 15 minutes. Absorbance was then 
measured using a plate reader at 650nm. Data is mean ± SEM of three 
independent experiments.  
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Table 4.3. % inhibition and IC50 values of Biphenyl compounds on SHIP-1 
and SHIP-2 activity in the malachite green phosphatase assay 
 
 
4.4.2. The effect of cell permeable SHIP-2 inhibitors on chemokine and TCR 
mediated signalling in primary human T lymphocytes 
Because the Biphenyl SHIP-2 inhibitors used previously were not cell permeable, 
they could not be utilised for investigating the role of SHIP-2 in T lymphocyte 
functions. However, Suwa et al described a cell-permeable inhibitor of SHIP-2 
catalytic activity, termed AS1949490, in 2009 (355). AS1949490 inhibited SHIP-2 
catalytic activity with an IC50 value of 0.62µM and was found to increase the 
phosphorylation of Akt and increase glucose uptake by myotube cells. In 
addition, in vivo, AS1949490 lowered plasma glucose levels (355). 
Subsequently, another selective cell permeable inhibitor of SHIP-2 was identified, 
AS1938909, which was found to increase Akt phosphorylation, glucose uptake 
and increase expression of the glucose transporter molecule GLUT1 in myotube 
cells (444). In this thesis, AS1949490 and AS1938909 were provided by Dr 
Steve Mills (University of Bath) and used as pharmacological tools with which to 
probe the role of SHIP-2 in primary human T lymphocyte signalling and function.  
 
SHIP-2 has previously been described to have an important role in the regulation 
of cell polarization and motility in glioma cells (335) and in podocytes (336). 
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Silencing of SHIP-2 expression was also found to increase the migration of 
keratinocytes in vitro (337). However the role of SHIP-2 in lymphocyte function is 
not known. The effect of SHIP-2 inhibition on primary human T lymphocyte 
chemokine mediated Akt phosphorylation was therefore assessed. AS1938909 
treatment of T cells showed a slight increase in Akt phosphorylation, however 
this was variable between human donors and was not a statistically significant 
effect on CXCL11 mediated Akt activation (Figure 4.34). In addition AS1949490 
had no effect on CXCL11 mediated Akt phosphorylation (Figure 4.34).  
 
The previously described role of SHIP-2 in the negative regulation of IgE-induced 
mast cell de-granulation and cytokine production (445) and in the regulation of 
glucose metabolism, provided a rationale to investigate the role of SHIP-2 in 
mediating T lymphocyte signalling and growth in response to TCR stimulation. 
The inhibition of SHIP-2 using AS1949490 (Figure 4.35 A) or AS1938909 (Figure 
4.35 B) showed no effect on TCR mediated phosphorylation of Akt. 
Subsequently, the MTT assay was used to assess the effect of SHIP-2 inhibition 
on the metabolism of CD4 cells 48 hours post TCR stimulation. Co-incubation of 
primary human T lymphocytes with AS1949490 showed increased cell 
metabolism (Figure 4.35 C) however there were large variations between donors 
and this was not statistically significant. No effect was seen with compound 
AS1938909 on lymphocyte metabolism (Figure 4.35 D).  
 
 
4.4.3. Effect of SHIP-2 inhibition on T lymphocyte motility and adhesion 
SHIP-2 has previously been described to have an important role in the regulation 
of cell polarization and motility in glioma cells (335) and in podocytes (336). 
Silencing of SHIP-2 expression was also found to increase the migration of 
keratinocytes in vitro (337). Basal motility of T lymphocytes was found to be 
unaffected by SHIP-2 inhibition (Figure 4.36 A), whereas CXCL11 mediated 
migration showed a 40% inhibition by SHIP-2 inhibition (Figure 4.36 B), however 
this was not statistically significant. In addition, because of the known role of 
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SHIP-2 in regulating actin cytoskeleton rearrangement and cell spreading (335, 
446), it was possible that SHIP-2 regulated adhesion of T lymphocytes. However, 
no effect of pharmacological inhibition of SHIP-2 was observed on the ability of T 
lymphocytes to adhere to fibronectin in vitro (Figure 4.36 C). 
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Figure 4.34. Effect of SHIP-2 inhibition on chemokine mediated Akt 
phosphorylation in primary human T lymphocytes. SEB-activated primary 
human T lymphocytes were incubated with AS1949490 or AS1938909 for 30 
minutes prior to stimulation with CXCL11 (10nM) for 5 minutes. Cells were then 
lysed and levels of phospho-Akt and total ERK were determined using Western 
blotting. A) Is a representative western blot from a single experiment. B) and C) 
Show data analysed using ImageJ software, B) AS1938909 and C) AS1949490. 
Data is mean ± SEM of three independent experiments. One Way ANOVA 
followed by Tukey’s post test used to determine statistical significance. 






Figure 4.35. Effect of SHIP-2 inhibitors on TCR mediated Akt 
phosphorylation and TCR mediated cell growth. SEB-activated T 
lymphocytes were incubated with A) AS1949490 or B) AS1938909 for 30 
minutes then stimulated with anti-CD3 antibody (UCHT1, 10µg/ml) for 5 minutes. 
Cells were fixed and levels of phosphorylated Akt determined using flow 
cytometry. Data is mean ± SEM of three independent experiments. C) and D), 
Naïve CD4 cells were pre-treated with C) AS1949490 or D) AS1938909 at stated 
concentrations and incubated with anti-CD3/CD28 antibody coated beads and IL-
2 (36 Units/ml) for 48 hours. MTT assay was then used as described in Materials 
and Methods to assess cell metabolism. Data is mean ± SEM of three 
independent experiments. One Way ANOVA followed by Tukey’s post test used 
to determine statistical significance. 






Figure 4.36. Effect of SHIP-2 inhibitors on motility and adhesion of primary 
human T lymphocytes. SEB-activated primary human T lymphocytes were 
treated with AS1949490 or AS1938909 at stated concentrations (µM) and motility 
assessed using the Neuroprobe chemotaxis assay as described in the Materials 
and Methods. Data is mean ± SEM of two independent experiments, A) basal 
motility and B) CXCL11 (10nM) mediated motility. C) SEB-activated T 
lymphocytes were treated with AS1949490 or AS1938909 for 30 minutes then 
adhesion in response to UCHT1 (10µg/ml) was assessed on a fibronectin-coated 
surface. Data represents the mean ± SEM of two independent experiments. 
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4.5.1 Results Section 4.2 Summary  
• AQX-1 was the most potent of three SHIP-1 activating compounds tested 
in a T cell chemotaxis assay 
• AQX-1 treatment of B cells inhibited calcium flux and Akt phosphorylation 
in response to BCR ligation 
• Activation of SHIP-1 inhibited GPCR and TCR mediated Akt 
phosphorylation in naïve and previously activated T cells 
• Basal and chemokine mediated motility of naive and previously activated 
T lymphocytes is inhibited by the activation of SHIP-1 
• Extension of the lamellipodia and polarisation of T lymphocytes in 
response to chemokine is abrogated by AQX-1 
• Proliferation of CD4 T lymphocytes was inhibited by the activation of 
SHIP-1 
• Cytokine production by Th2 polarised cells is reduced by the activation of 
SHIP-1 
• Activation of SHIP-1 inhibits the ability of T lymphocytes to adhere to 
fibronectin and ICAM1 
• The activation state of LFA-1 is reduced following activation of SHIP-1  
• AQX-1 had no effect on T cell viability 
 
 
4.5.2 Results Section 4.3 Summary  
• Chemical modifications to the structure of 3AC did not result in increased 
inhibition of the catalytic activity of SHIP-1 
• Inhibition of SHIP-1 reduced chemokine mediated phosphorylation of Akt 
in naïve and previously activated primary human T lymphocytes 
• Ethyl addition to the 3AC structure increased inhibition of CXCL11 
mediated Akt phosphorylation and motility compared to un-modified 3AC 
•  3AC reduced TCR mediated Akt phosphorylation, whilst addition of an 
ethyl group to 3AC increased the potency of inhibition 
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• Basal and chemokine mediated motility of naive and previously activated 
T lymphocytes is abrogated by the inhibition of SHIP-1 
• Inhibition of SHIP-1 decreased cell metabolism (probably due to increased 
cell death) but had no effect on cell proliferation 
• 3AC increased the secretion of IL-4 and TNFα 
• Inhibition of SHIP-1 reduced the ability of T lymphocytes to adhere to 
fibronectin and ICAM1 
• 3AC decreased primary human T lymphocyte viability, whilst addition of an 
ethyl group further decreased cell viability 
 
 
4.5.3 Results Section 4.4 Summary  
• BiPh(2,3’,4,5’,6)P5 and two novel compounds, BiPh(2,2’,4,4’,5,5’)P6 and 
BiPh(3,3’,4,4’,5,5’)P6 were shown to inhibit the catalytic activity of SHIP-2 
and SHIP-1 
• SHIP-1 and SHIP-2 shared identical substrate specificities in a cell free 
assay 
• Inhibition of SHIP-2 had no significant effect on GPCR mediated Akt 
phosphorylation 
• SHIP-2 inhibition had no effect on TCR mediated signalling 
• CD4 T lymphocyte metabolism may be increased by the inhibition of 
SHIP-2 during ex vivo cell culture 
• SHIP-2 inhibition had no effect on T lymphocyte motility 
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4.6. Results Chapter 4 Discussion 
 
4.6.1 SHIP-1 activation inhibits BCR mediated calcium flux and Akt 
phosphorylation 
PI3K mediated signalling is required for the survival and proliferation of B cells in 
response to BCR ligation (447). In addition, SHIP-1 has previously been shown 
to inhibit BCR mediated Akt activation in B cells (423, 448), whilst binding of 
SHIP-1 to the FcγRIIB receptor is crucial for SHIP-1 mediated inhibition of BCR 
induced calcium flux (449). It was therefore hypothesized that the use of a SHIP-
1 activator would inhibit PI3K dependent signalling events following BCR ligation. 
Btk is recruited and activated by binding to PI(3,4,5)P3 (127, 450), Btk in turn 
activates PLCγ which produces IP3. IP3 binds IP3 receptors in the endoplasmic 
reticulum releasing calcium in response to BCR stimulation (451). In this thesis it 
was shown that pharmacological activation of SHIP-1 inhibited BCR mediated 
calcium flux. In addition, activation of SHIP-1 inhibited Akt phosphorylation. NF-
κB signalling was reduced by SHIP-1 activation, however PLCγ phosphorylation 
was reduced by only 20% at 30µM. The phosphorylation status of PLCγ was 
assessed at 783 because this site is important for enzymatic activation (452). 
However there are a number of other phosphorylation sites on PLCγ that are 
activated by Btk (453). In addition phosphorylation at 783 is not sufficient for 
lipase activation (454). Therefore more detailed analysis of the phosphorylation 
status of PLCγ is required before it can be categorically stated that PLCγ 
activation is not inhibited by the pharmacological activation of SHIP-1.  
 
The inhibition of BCR mediated signalling by SHIP-1 activation has important 
implications for the treatment of B cell mediated inflammatory disorders such as 
SLE (455). In addition, inhibition of PI3K mediated signalling using CAL-101 has 
been shown to inhibit B cell interactions with protective microenvironments in B 
cell lymphomas (147, 148). Therefore SHIP-1 activation may offer an alternative 
or complimentary means of modulating PI3K mediated signalling in the treatment 
of B cell lymphomas.  
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4.6.2. Activation or inhibition of SHIP-1 inhibits GPCR mediated signalling, 
motility and polarisation of T lymphocytes  
Naïve CD4 T lymphocytes express high levels of the GPCR CXCR4, with its 
ligand CXCL12 crucial for the trafficking of naïve CD4 T lymphocytes through 
secondary lymphoid organs (456). CXCL12/CXCR4 mediated migration in 
lymphocytes has previously been shown to be dependent upon PI3K signalling 
(427). The results here showed that activation of SHIP-1 in naïve cells inhibited 
CXCL12 mediated Akt phosphorylation and migratory responses and imply that 
SHIP-1 regulates GPCR mediated signalling. These results are in accordance 
with recent findings by Lam et al, who demonstrated that overexpression of SHIP 
in neutrophils impaired migration (457). 
 
Upon activation by antigen, T lymphocytes alter their chemokine receptor 
expression profile to allow them to exit secondary lymphoid organs and home to 
peripheral sites of infection. CXCR3 is up-regulated and highly expressed by 
activated T lymphocytes, whilst the ligand for CXCR3, CXCL11, has been shown 
to induce Akt activation in T lymphocytes (426, 458). Chemokine induced 
migration of activated T lymphocytes however appears less sensitive to PI3K 
inhibitors than naïve lymphocytes (426, 427), although PI3K dependence may 
differ on the type of assay used to assess T lymphocyte migration (429). The 
results in this thesis showed that SHIP-1 activation inhibited chemokine mediated 
migration of both naïve and previously activated T lymphocytes. It is interesting 
to note however, that naïve CD4 lymphocytes were more susceptible to lower 
concentrations of AQX-1 than were activated T lymphocytes, perhaps 
demonstrating this previously reported reduction in dependence on PI3K for 
chemokine mediated migration in activated T lymphocytes (427). In addition, 
SHIP-1 activation caused a dramatic loss in lamellipodia extension in response to 
chemokine’s, consistent with the role of PI(3,4,5)P3 as a mediator of Rac 
activation at the leading edge of a cell (459). ARAP3 is a GAP for RhoA and is 
regulated by PI(3,4,5)P3 (460), whilst deficiency in ARAP3 resulted in cells 
unable to produce lamellipodia in response to stimulation (461). The activation of 
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SHIP-1 may therefore result in decreased ARAP3 recruitment and activation and 
hence decreased lamellipodia formation in response to chemokine stimulation.  
 
Interestingly, the inhibition of SHIP-1 was also shown to inhibit chemokine 
mediated Akt phosphorylation and chemotaxis of T lymphocytes. This may be 
due to the SHIP-1 product PI(3,4)P2 being able to activate Akt in addition to 
PI(3,4,5)P3 (252). These findings are also in accordance with the effects of 
silencing SHIP-1 expression on T lymphocyte migration (295). 
 
4.6.3. Modulation of SHIP-1 activity abrogates TCR mediated signalling and 
alters TCR mediated proliferation and cytokine secretion 
Evidence for a role of SHIP-1 in regulating TCR signalling has proven somewhat 
contradictory. Interactions between CD3 and the TCR ζ chain with the SH2 
domain of SHIP-1 have been observed in vitro (462). In addition the stimulation 
of CD3 and CD28 caused tyrosine phosphorylation and increased catalytic 
activity of SHIP-1, as well as a marked re-distribution of SHIP-1 from the cytosol 
to the surface membrane (463). These observations indicate that SHIP-1 may 
regulate the accumulation of PI(3,4,5)P3 at the surface membrane following TCR 
signalling. However, T cell restricted silencing of SHIP-1 protein expression in 
mice was found to cause no differences from wild-type mice in terms of TCR 
induced signalling or proliferation (464). The results observed in this thesis 
indicate a crucial role for SHIP-1 in the regulation of TCR mediated Akt 
phosphorylation, proliferation and cytokine secretion in vitro, in human T 
lymphocytes. A possible explanation for the contrasting results may be the use of 
human T lymphocytes in this thesis, compared to mouse T lymphocytes used in 
the previous study mentioned. In accordance with this thesis, in the human 
leukemic cell line Jurkat, which lacks expression of SHIP-1, re-introduction of 
SHIP-1 expression was found to inhibit cellular proliferation by affecting the G1 
phase of the cell cycle by influencing Rb and p27kip1 expression (465) and by 
causing up-regulation of KLF2 (Kruppel-like factor 2), a negative regulator of T 
cell proliferation (466). In addition, loss of SHIP-1 function or expression has 
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been identified in acute lymphoblastic leukaemia (467) and acute myeloid 
leukaemia (468, 469), implying that SHIP-1 may act as a tumour suppressor 
gene in certain haematopoietic cancers, restricting lymphocyte proliferation.  
 
SHIP-1 deficient mice show increased numbers of myeloid immune-regulatory 
cells and granulocytes (303, 407, 470, 471). SHIP-1 antagonizes the signalling of 
haematopoietic growth factor receptors (472) and restricts blood cell production 
(409, 470). However, SHIP-1 deficiency in mice had no effect on numbers of T 
cells in the spleen, thymus or lymph nodes (300). In B cells SHIP-1 deficiency led 
to increased B cell proliferation in response to BCR stimulation in vitro (473). 
Pharmacological inhibition of SHIP-1 in mice with 3AC led to expansion of 
myeloid immunoregulatory cells, increased granulocyte numbers as well as 
increased recovery of red blood cells, neutrophils and platelets in 
myelosuppressed mice (325). The use of a pharmacological SHIP-1 inhibitor has 
therefore been proposed to restore blood cell numbers in patients with 
myelodysplastic syndrome or myelosuppressive infection (195, 325). However, in 
this thesis the inhibition of SHIP-1 with 3AC in primary human T lymphocytes in 
vitro was found to have no effect on TCR mediated proliferation up to 10µM 
concentration. This may be due to differences between cell types or differences 
between in vivo and in vitro studies, with in vivo treated cells likely to have pro-
survival and proliferation signals from accessory cells which in vitro cells lack. It 
would therefore be interesting to examine the effect of 3AC on T cell numbers in 
vivo to compare with the results gained from this thesis.  
 
Asthma and chronic obstructive pulmonary disorder are largely driven by 
cytokines produced by Th2 CD4 cells (95, 474), whilst corticosteroids are a 
standard treatment for asthma and have been shown to reduce cytokine 
production (474, 475). Severe asthmatic patients however can develop 
resistance to corticosteroid treatment (474). Therefore alternative therapies to 
either complement or replace existing treatments are required. In this thesis 
activation of SHIP-1 was shown to inhibit cytokine secretion by Th2 polarised 
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cells, providing evidence that modulation of SHIP-1 activity may prove 
therapeutically beneficial in the treatment of airway inflammation. These results 
are in accordance with a number of studies which show that TCR mediated PI3K 
signalling is required for T lymphocyte cytokine secretion (121, 160), in particular 
IC87114, a PI3Kδ selective inhibitor, inhibited IL-5, IL-13 and IL-4 secretion in 
mice in a concentration-dependent manner (211). These results also agree with 
a recent study which showed that SHIP-1 has a crucial role in the secretion of IL-
10 (476). In addition, results in this thesis showed that activation of SHIP-1 
reduced intracellular cytokine levels as well as secreted cytokines. This is an 
important distinction because inhibition of PI3Kδ has previously been shown to 
reduce cytokine secretion, but not to effect intracellular levels of cytokine (167). 
These results therefore indicate that activation of SHIP-1 inhibits the transcription 
of cytokine proteins, perhaps by influencing the activation of NF-κB and NFAT 
transcription factors which have previously been shown to regulate cytokine 
transcription in lymphocytes (477). Intriguingly, the inhibition of SHIP-1 in 
lymphocytes increased secretion of IL-4 and TNFα. These results are in 
accordance with another study which showed that lack of SHIP-1 expression was 
associated with increased pro-inflammatory cytokine secretion following infection 
by Francisella tularensis novicida (478).  
 
4.6.4. SHIP-1 modulation inhibits T lymphocyte adhesion and reduces 
expression of high-affinity LFA-1 
Integrin dependent adhesion of lymphocytes to components of the extracellular 
matrix, as well as to endothelial cells and antigen presenting cells is an essential 
mechanism that is critical for effective cell migration, extravasation and for the 
formation of immunological synapses (479). PI3K signalling has previously been 
shown to be crucial for lymphocyte adhesion (480), whilst SHIP-1 has also been 
implicated in LFA-1 mediated lymphocyte adhesion (481). In addition and more 
recently, loss of SHIP-1 expression in neutrophils enhanced cell adhesion due to 
increased fibronectin mediated PI(3,4,5)P3 signalling (482). In this thesis, 
activation or inhibition of SHIP-1 in human T lymphocytes abrogated the ability of 
Chapter 4: Results 
169 
T lymphocytes to adhere to fibronectin and ICAM1. These results indicate that 
accumulation of both PI(3,4,5)P3 and PI(3,4)P2 is crucial for the ability of immune 
cells to adhere to extra cellular matrix components.  
 
In addition it was shown in this thesis that SHIP-1 activation or inhibition does not 
alter the total expression levels of CD11a or CD49d. However, SHIP-1 activation 
or inhibition did reduce surface expression of the high affinity state of LFA-1 (also 
known as αLβ2 integrin) detected by the monoclonal antibody KIM127, as 
previously reported (483). These results agree with a previous study which 
showed that PI3K inhibition decreased integrin activation, whilst addition of 
PI(3,4,5)P3 increased integrin activation (484), although it seems that PI(3,4,5)P3 
is not solely responsible for LFA-1 activation given that SHIP-1 mediated 
production of PI(3,4)P2 is also required for optimum activation. The small 
GTPase Rap1 is crucial for the recruitment of Talin to the integrin aIIβ3. The 
FERM domain of Talin binds the integrin β-subunit which in turn causes a 
conformational change, whereby the integrin goes from the bent, low-affinity 
form, to the extended form resulting in an intermediate affinity integrin state (80). 
Rap1 is, in platelets at least, activated by a PI3K dependent mechanism (485). 
Therefore a possible mechanism for SHIP-1 activation/inhibition causing a 
decrease in integrin activation is the reduction in Rap1 activation, reduced Talin 
mediated binding to the cytoplasmic tail of LFA-1 and thereby reduced LFA-1 
activation state detected by KIM127 which leads to reduced lymphocyte binding 
to ICAM1. In addition, the PIP3 binding Rap1-activated RhoA GAP, ARAP3, has 
been shown to regulate integrin adhesion in neutrophils (82, 486). 
Pharmacological modulation of SHIP-1 and the resulting altered accumulation of 
PI(3,4,5)P3 and PI(3,4)P2 at the surface membrane may therefore result in 
disrupted ARAP3 recruitment and subsequent altered integrin affinity.  
 
4.6.5. Effect of SHIP-1 modulation on cell viability 
The PI3K/Akt signalling pathway is crucial for the promotion of lymphocyte 
survival through a number of downstream pathways (487). For example, Akt 
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inhibits the pro-apoptotic function of Bax (488) and phosphorylates and 
inactivates the pro-apoptotic function of Bad (489). In addition, PI3K elevates NF-
κB activity (490) which results in increased expression of pro-survival and anti-
apoptotic proteins (491). Pharmacological activation of SHIP-1 in multiple 
myeloma cells has also been shown to increase apoptosis (350). However, in 
this thesis it was found that activation of SHIP-1 had no effect on primary human 
T lymphocyte viability. A possible reason for this contrast to cancer cells is 
oncogenic addiction. Cancer cells can become ‘addicted’ to signalling pathways 
for their survival and are more dependent upon this pathway for their survival 
than non-cancerous cells (492). The results in this thesis therefore indicate that 
in non-cancerous T lymphocytes, mechanisms exist to compensate for increased 
SHIP-1 activity and to prevent cell death.  
 
Treatment of primary human T lymphocytes with 3AC at 20µM however was 
found to induce cell death. This is in contrast to a number of studies which have 
used genetic strategies to show that SHIP-1 is pro-apoptotic in myeloid cells and 
in B lymphocytes (493). SHIP-/- mice display increased numbers of myeloid cells 
due to increased survival and proliferation of their progenitors, as well as 
decreased sensitivity to apoptotic cell death (272, 470). A mutation which 
reduced the catalytic activity of SHIP-1 has also been identified in acute myeloid 
leukaemia cells (316) and overexpression of SHIP-1 inhibited myeloid leukemic 
cell growth (494), further supporting the role of SHIP-1 as a pro-apoptotic protein. 
Intriguingly however, silencing of SHIP-1 protein expression in primary human T 
lymphocytes had no effect on cell viability (295) whilst the pharmacological 
inhibition of SHIP-1, (which may have been theorized to promote cell survival 
based on the previous evidence discussed) has been shown to induce the 
apoptosis of myeloid and lymphocyte leukemic cells in vitro and in vivo (325, 
352). This is in accordance with results obtained in this thesis whereby 
pharmacological inhibition of SHIP-1 increased cell death of non-cancerous T 
lymphocytes. This may be due to the ability of SHIP-1’s product, PI(3,4)P2 to 
activate Akt and promote cell survival (240), whilst inhibition of Akt can sensitize 
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cancer cells to death receptor induced apoptosis (495). It is interesting to note 
that Jurkat cells which lack expression of SHIP-1 were not sensitive to 3AC 
mediated death, indicating that the effects on primary T cells were SHIP-1 
mediated.  
 
Intriguingly however, Tarasenko et al showed that deficiency in SHIP-1 
expression in vivo in mice does not cause a change in T cell numbers (300). One 
possible explanation for this discrepancy may be that in this thesis human T 
lymphocytes were investigated whilst Tarasenko et al looked at T cells in mice. 
Another possible explanation may be that results in this thesis were gained from 
in vitro assays, whilst Tarasenko et al showed no change in T cell numbers in 
vivo. T cells in vivo may receive pro-survival signals from other immune cells as 
well as from non-immune stromal cells, much like leukemic cells do from stromal 
cells which aids leukemic cell resistance to apoptosis from chemotherapy (496). 
In this thesis therefore, isolated T cells were cultured in vitro in isolation and 
received no pro-survival signals from neighbouring cells. If 3AC were to also kill 
non-cancerous T cells in vivo in humans this would have important implications 
for the potential use of SHIP-1 inhibitors as anti-cancer agents because of the 
important role of T cells in anti-cancer immuno-surveillance (441). Killing of 
leukemic cells with a SHIP-1 activator (350) may prove safer than the use of a 
SHIP-1 inhibiter because no toxic effects on non-cancerous T lymphocytes were 
seen with AQX-1 in this thesis.  
 
This thesis showed that primary human T cells which had been activated with 
anti-CD3/anti-CD28 antibody coated beads for 9-12 days showed more viable 
cells in the population than did T cells which had been activated with SEB. 
Activation of PBMCs in vitro has previously been shown to cause activation 
induced cell death (497), whilst in this thesis it appears that SEB is a more potent 
inducer of activation induced T cell death than anti-CD3/anti-CD28 antibody 
coated beads. Both populations were cultured in the presence of IL-2 (36 
units/ml) and in the same culture medium. The anti-CD3/anti-CD28 antibody 
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coated bead activated cells had been isolated from the PBMC population on day 
0 by negative separation using the Naïve CD4+ T cell Isolation Kit II (Miltenyi 
Biotech). In contrast SEB-activated T cells had been generated by addition of 
SEB to the whole PBMC population. Differences in cell viability may therefore be 
due to the co-incubation with antigen presenting cells in the case of SEB-
activated cells and the absence of antigen presenting cells in the anti-CD3/anti-
CD28 antibody coated bead activated cell cultures. Activation induced cell death 
occurs after TCR ligation of recently activated peripheral T cells (498, 499), 
therefore the SEB cells may be more susceptible to activation induced cell death 
because they consist of both naïve and antigen experienced T cells from the 
PBMC population, whilst the anti-CD3/anti-CD28 bead activated T cells were 
generated specifically from naïve CD4 T cells isolated from the PBMC 
population.  
 
4.6.6. Pharmacological inhibition of SHIP-1 activity inhibited lymphocyte 
function: the two PIP hypothesis 
From the above discussed results, it is apparent that pharmacological inhibition 
or activation of SHIP-1 often produced very similar outcomes in terms of effects 
on T cell chemotaxis, TCR signalling, GPCR signalling and adhesion. As an 
explanation for both the substrate, PI(3,4,5)P3, and the product of SHIP-1 
enzymatic function, PI(3,4)P2, being required for Akt activation, William Kerr has 
proposed a “Two PIP hypothesis” (353). This proposes that both the product and 
substrate of SHIP-1 is required for a cancer cell to maintain a malignant state. 
Evidence for a positive role of PI(3,4)P2 in cancer cell survival includes the fact 
that Akt can bind both PI(3,4)P2 and PI(3,4,5)P3 (252). In addition, raised levels 
of PI(3,4)P2 have been identified in leukemic cells (500) and PI(3,4)P2 has been 
shown to increase the transformation of embryonic fibroblasts (501). In 
accordance with this two PIP hypothesis, both SHIP-1 activators and SHIP-1 
inhibitors can inhibit the growth of leukemic cells (325, 350, 352). The results 
from this thesis indicate that the two PIP hypothesis may also be relevant to 
primary human non-cancerous T lymphocytes. Activation or inhibition of SHIP-1 
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activity is sufficient to reduce Akt activation and inhibit Akt dependent lymphocyte 
functions (Figure 4.37). It remains to be seen whether this also applies to other 
cells of the immune system that are regulated by SHIP-1 mediated signalling.  
 
In this thesis the effect of SHIP-1 inhibition on Akt mediated lymphocyte functions 
was investigated because Akt is a major downstream effector protein of PI3K. 
However, it would be interesting to determine whether the two PIP hypothesis 
also occurs with other PI(3,4,5)P3 dependent proteins, such as Itk. In this 
situation use of 3AC may have the opposite effect of a SHIP-1 activator by 
driving inositol signalling away from PI(3,4)P2 dependent events and theoretically 



























Figure 4.37. Primary human T lymphocyte Akt activation and PI3K 
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4.6.7. Effect of pharmacological activation of SHIP-1 on the association of 
SHIP-1 with other proteins 
Silencing the expression of SHIP-1 does not allow the discrimination between 
catalytic and non-catalytic functions of SHIP-1 on the altered cell phenotype. It is 
proposed that pharmacological SHIP-1 activation would leave SHIP-1 non-
catalytic functions intact, fulfilling an important criterion for research. Use of a 
SHIP-1 activator to probe the role of SHIP-1 in lymphocyte function may allow 
the role of the catalytic site of SHIP-1 to be identified. This is important because 
of the various non-catalytic roles SHIP-1 has in protein-protein interactions and in 
the physical inhibition of PI3K recruitment (195, 256, 259, 261, 262, 287, 295). In 
this thesis, cells were treated with AQX-1 then SHIP-1 protein was immuno-
precipitated to try to pull-down proteins that were physically associated with 
SHIP-1. Using silver staining to visualise proteins was effective in demonstrating 
SHIP-1 was successfully immuno-precipitated, however no co-associated 
proteins could be identified, even in the positive control lane. There appeared to 
be protein bands staining throughout the gel, possibly because of staining of the 
antibodies used during immuno-precipitation, or the degradation of proteins 
during immuno-precipitation and lysis of cells. This made it difficult to see any 
proteins that were or were not associated with SHIP-1. To achieve a stronger 
signal from any co-associated proteins with SHIP-1, it may be beneficial to use a 
chemical cross-linking agent to bind associated proteins together before lysis 
(502).  
 
4.6.8. Effect of chemical modifications to the structure of 3AC on the 
potency of SHIP-1 inhibition 
Modification of the structure of 3AC was initiated in order to identify potential 
means with which to increase the potency of 3AC in vitro and in order to increase 
the potency of 3AC mediated SHIP-1 inhibition. Modifications to 3AC were made 
to the amino group by Dr Andrew Watts (Pharmacy and Pharmacology, The 
University of Bath), these included the addition of ethyl or methyl groups, or the 
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inversion of the stereochemistry from alpha for the reported 3AC compound to a 
novel beta configured amino group (Table 4.1 and 4.2).  
 
The addition of an ethyl group to 3AC showed increased potency in cell based 
assays. These included increased inhibition of Akt phosphorylation, cell motility, 
and increased lymphocyte cell death (cell death was not seen in Jurkat cells 
which lack expression of SHIP-1) compared to unmodified 3AC. Surprisingly 
however, the addition of an ethyl group to 3AC reduced the inhibition of SHIP-1 
catalytic activity in a cell free malachite green phosphatase assay, compared to 
unmodified 3AC. Other modifications to the structure of 3AC that were tested in 
this thesis did not increase potency in cell based assays and all modifications 
resulted in a reduced ability to inhibit SHIP-1 catalytic activity compared to 
unmodified 3AC.  
 
Modifications to the structure of 3AC to improve potency have been investigated 
by other research groups, with results presented by Viernes DR and Kerr WG, at 
the Inositol Phospholipid Signalling in Physiology and Disease conference in 
New York, 26th June 2012. Viernes DR and Kerr WG showed evidence that 
removal of the tail section of 3AC increased killing of leukemic cells, although the 
effects on SHIP-1 catalytic activity were not shown.  
 
4.6.9. Benzene polyphosphates inhibit the catalytic activity of both SHIP-2 
and SHIP-1  
The novel Biphenyl 2,3’, 4,5’, 6-pentakisphosphate compound mimics the inositol 
polyphosphate substrate of SHIP-2 (Figure 4.38), but has a more rigid phosphate 
regiochemistry compared to natural inositol phosphatases (356). Biphenyl 2,3’, 
4,5’, 6-pentakisphosphate cannot be utilized as a substrate and has previously 
been shown to potently inhibit the catalytic activity of SHIP-2 (356). Results in 
this thesis showed that Biphenyl 2,3’, 4,5’, 6-pentakisphosphate also inhibits the 
activity of SHIP-1 equally as potently as the inhibition of SHIP-2. These results 
therefore have important implications for the potential use of benzene 
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polyphosphates in a clinical setting. SHIP-2 inhibitors are being investigated for 
the treatment of type 2 diabetes due to the role of SHIP-2 in the negative 
regulation of insulin signalling (355). The co-inhibition of SHIP-1 would disrupt 
the immune system and may make patients more susceptible to infection during 
treatment. Alternatively, were the Biphenyl 2,3’, 4,5’, 6-pentakisphosphate 
compound or novel analogues to be made cell permeable, the dual inhibition of 
SHIP-1 and SHIP-2 activity may have potential applications for anti-cancer 
therapy. Indeed, it has recently been described that a dual SHIP-1/SHIP-2 
inhibitor killed multiple myeloma cells (352). This is particularly important in 
cancer because resistance to SHIP-1 inhibition can occur in multiple myeloma 
cells by the up-regulation of SHIP-2 expression (352).  
 
Biphenyl 2,3’, 4,5’, 6-pentakisphosphate in its current form is not cell permeable 
and as such does not permit further investigation into its therapeutic potential in 
cell based assays. A cell permeabilization protocol based on that used by Ward 
et al, in 1990 (503) was attempted. This was however unsuccessful, with very 
few viable and permeable cells obtained. This unfortunately meant that during 
this thesis the effect of benzene polyphosphates on T lymphocyte function in cell 
based assays could not be assessed.  
 
However, Vandeput et al, 2007 stated that Biphenyl 2,3’, 4,5’, 6-
pentakisphosphate could be used as a lead compound in the synthesis of cell 
permeable 5-phosphatase inhibitors (356), which would allow the effect of dual 
SHIP-1 and SHIP-2 inhibition to be assessed. In addition, Biphenyl 2,3’, 4,5’, 6-
pentakisphosphate has already proved a useful tool in structural studies, 
whereby SHIP-2 in complex with Biphenyl 2,3’, 4,5’, 6-pentakisphosphate was 
used to identify a flexible loop expressed by SHIP-2 which folds over and 
encloses the ligand (357). Targeting of this region may allow more specific SHIP-
2 inhibitors to be developed.  
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Figure 4.38. Overlay of the structure of Biphenyl 2,3’, 4,5’, 6-
pentakisphosphate and the SHIP substrate Ins(1,3,4,5)P4. Biphenyl 2,3’, 4,5’, 




The results in this thesis also indicate that SHIP-1 and SHIP-2 share similar 
substrate specificities. This suggests that targeting the active site of SHIP-1 or 
SHIP-2, by mimicking their substrates, may not allow the selective inhibition of 
either isoform. Indeed, as mentioned previously, Aquinox Pharmaceuticals used 
allosteric modulation of SHIP-1 to specifically activate the catalytic activity of 
SHIP-1 but not SHIP-2 (255).  
 
An interesting observation when comparing the substrate specificities of SHIP 
enzymes, was that both SHIP-1 and SHIP-2 could hydrolyse D-Ins(1,3,4,5)P4 but 
neither could utilize L-Ins(1,3,,45)P4 as a substrate. Aligning the two enantiomers 
shows that only the positioning of the OH groups differ (Figure 4.39). This 
indicates that substrate utilization by SHIP-1 and SHIP-2 is not determined solely 
by the number and pattern of phosphate groups on the inositol ring. These 
results indicate that the positioning of the two OH groups are crucial for SHIP-1 
and SHIP-2 to utilize Ins(1,3,4,5)P4 as a substrate.  













Figure 4.39. Comparison of the positioning of phosphate groups and OH 
groups between the enantiomers D-Ins(1,3,4,5)P4 and L-Ins(1,3,4,5)P4. The 
position of the OH groups differs between enantiomers and may be crucial for the 
utilization of Ins(1,3,4,5)P4 as a substrate by SHIP-1 and SHIP-2. These images 




4.6.10. Effect of SHIP-2 inhibitors on primary human T lymphocyte 
signalling and function 
Cell permeable, selective inhibitors of SHIP-2 activity were first described in 2009 
(355). In this thesis, these novel SHIP-2 inhibitors were obtained from Dr 
Stephen Mills (Pharmacy and Pharmacology, The University of Bath) and used to 
probe the role of SHIP-2 in primary human T lymphocytes, with little currently 
known about the role of SHIP-2 in the immune system. 
 
The results in this thesis showed that SHIP-2 inhibition had no significant effect 
on chemokine mediated Akt phosphorylation or motility, nor indeed on the ability 
of lymphocytes to adhere to fibronectin in response to TCR stimulation. This was 
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perhaps a surprising result because of previously published work showing the 
role of SHIP-2 in cell polarity and migration (335, 336). This discrepancy may be 
explained by the fact that these previously published results were obtained from 
glioma cells and podocytes whereas the cell type investigated in this thesis was 
primary T lymphocytes. Therefore the role of SHIP-2 in cell migration may differ 
between SHIP-1 expressing immune cells and non-immune cells which do not 
express SHIP-1. In support of this are the earlier results from this thesis which 
showed that selective pharmacological modulation of SHIP-1 activity alone is 
sufficient to abrogate lymphocyte migration. Another possible explanation for the 
discrepancy seen is because the previous two studies discussed identified the 
role of SHIP-2 in cell motility using protein knock-down (335, 336), whereas in 
this thesis pharmacological inhibitors were used which left SHIP-2 protein 
expression present. Therefore it could be hypothesised that it is the non-catalytic 
functions of SHIP-2 and the numerous binding partners of SHIP-2 (195) (Table 
1.4) that are crucial in the regulation of cell motility and polarization. In 
accordance with this, Venkatareddy et al, 2011 identified SHIP-2 as being part of 
a protein complex composed of nephrin, filamin and lamellipodi, which was 
crucial for lamellipodia formation (336). It would therefore be interesting to 
compare the effects of pharmacological SHIP-2 inhibition with the effects of 
silencing SHIP-2 protein expression on primary human T lymphocytes. This 
would allow the delineation of the roles of either catalytic or non-catalytic 
functions of SHIP-2.  
 
Because SHIP-2 has previously been shown to play a role in immune cell antigen 
receptor signalling (445), it was investigated in this thesis whether SHIP-2 
inhibition would affect TCR mediated signalling in T lymphocytes. The use of two 
reported SHIP-2 inhibitors did not however show any effect on TCR mediated Akt 
phosphorylation. SHIP-2 inhibition using AS1949490 did intriguingly however, 
appear to increase T lymphocyte metabolism as assessed by the MTT assay, 
this was not statistically significant however on the three donors used. Because 
no effect was seen on TCR mediated Akt phosphorylation, this indicates that 
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SHIP-2 may act on T cell growth through other means. One possibility is that 
SHIP-2 may negatively regulate glucose metabolism in lymphocytes. Following 
activation, T lymphocytes require glucose to support energy requirements for 
growth, proliferation and differentiation (504). In particular, following TCR 
stimulation the expression of Glut1 (Glucose transporter 1) is increased and 
Glut1 is localized to the surface membrane (505) where it facilitates glucose 
transport across the plasma membrane. Pharmacological inhibition of SHIP-2 
has been shown to increase Glut1 expression and promote glucose metabolism 
in myotube cells (444). Results in this thesis therefore identify a possible, highly 
novel role of SHIP-2 in the negative regulation of lymphocyte metabolism, 
although further work is required to investigate this hypothesis.  
 
 
In summary, the utilisation of novel pharmacological SHIP-1 or SHIP-2 
modulating compounds in this thesis has demonstrated that activation or 
inhibition of SHIP-1 has a profound effect on various T cell and B cell functions 
(summarised in Figure 4.40). These results therefore indicate that 
pharmacological modulation of SHIP-1 may offer an exciting new mechanism for 
the targeted inhibition of PI3K mediated signalling in leukocytes and may offer 
therapeutic use in T and B lymphocyte driven pathologies. Indeed, Aquinox 
Pharmaceuticals have recently completed Phase 2 clinical trials with a SHIP-1 
activating compound for the treatment of airway inflammation (195). 
 





















Figure 4. 40. Pharmacological activation or inhibition of SHIP-1 results in 
disrupted T lymphocyte function. SHIP-1 regulates both GPCR and TCR 
mediated signalling. Inhibition of SHIP-1 with 3AC or activation of SHIP-1 with 
AQX-1 resulted in altered cytokine secretion, decreased migration, decreased 
integrin affinity and adhesion, whilst activation of SHIP-1 also decreased 
proliferation. 3AC increased cell death. In contrast, the pharmacological inhibition 
of SHIP-2 had no significant effects on T lymphocyte function. 
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5.1. Background and objectives of research 
Oncogenic mutations of PI3K have been shown to occur in various cancers (506-
509), whilst the mutation or loss of expression of lipid phosphatase regulators of 
PI3K mediated signalling is also known to occur (195, 492, 510). For example, 
PTEN is a well known tumour suppressor gene that is frequently mutated in 
various cancers (193, 237). Overactive PI3K and Akt mediated signalling 
promotes a wide range of cellular responses that support the development of 
cancer, such as increased cell growth, decreased apoptosis and increased 
proliferation (511). Improved knowledge of the role of tumour suppressor genes 
in cancer is expected to aid the development of novel anti-cancer therapies.  
 
INPP4b is a lipid phosphatase regulator of PI3K mediated signalling which de-
phosphorylates PI(3,4)P2, removing the phosphate on the D-4 position of the 
inositol ring to form PI(3)P (339). INPP4b therefore negatively regulates PI(3,4)P2 
dependent signalling events (Figure 1.9). INPP4b has recently been described as 
a tumour suppressor gene in prostate and breast cancer (339, 342, 344). 
Knockdown of INPP4b expression was shown to increase Akt phosphorylation 
and cell proliferation, whilst restoration of INPP4b expression in INPP4b-null 
breast cancer cells reduced Akt activation and inhibited anchorage independent 
growth (343). However, it was not known whether human T lymphocytes 
expressed INPP4b, or whether INPP4b is still active and functional in leukemic 
cells. This thesis therefore aimed to characterise the expression and activity of 
INPP4b in primary human T lymphocytes and in leukemic cell lines.  
 
5.2. Analysis of INPP4b expression and function in leukemic 
cells and primary non-cancerous T lymphocytes 
 
5.2.1 Expression of INPP4b by leukemic cell lines and primary human T 
lymphocytes 
The loss of expression of lipid phosphatase regulators of PI3K mediated 
signalling has previously been reported in leukemic T cell lines (512). However, 
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the protein expression of INPP4b in leukemic cell lines or primary human T 
lymphocytes has not previously been investigated. In this thesis, the expression 
of INPP4b, in addition to the expression of other lipid phosphatases was 
assessed in HUT-78, CEM, MOLT-4 and Jurkat leukemic cell lines. Expression of 
INPP4b was also assessed in primary human naïve CD4 T lymphocytes and in 
previously activated T lymphocytes.  
 
Surprisingly, INPP4b protein could be detected in all leukemic cell lines 
investigated as well as in both primary cell types isolated; naïve CD4 and SEB-
activated lymphocytes (Figure 5.1). This was in contrast to the expression of 
PTEN, which was lost in Jurkat, MOLT-4 and CEM cells. Loss of PTEN 
expression also corresponded with high levels of phosphorylated Akt (Figure 
5.1). SHIP-1 expression was lost only in the Jurkat cell line as previously 
reported (512), whilst SHIP-2 expression was also lost in the Jurkat cell line. 
Intriguingly, phosphorylated GSKα/β (a phosphorylation target of Akt) was high in 
HUT-78 cells, even though expression of PTEN and SHIP-1 was evident and low 
phosphorylated Akt levels were detected.  
 
5.2.2. Catalytic activity of INPP4b isolated from leukemic cells 
Although INPP4b protein could be detected in all the leukemic cell lines 
investigated, it was not known whether inactivating mutations had occurred in the 
gene of INPP4b in leukemic cells. To determine whether INPP4b isolated from 
the leukemic cell lines Jurkat, CEM, HUT-78 and MOLT-4 was catalytically 
active, INPP4b protein was immuno-precipitated and tested in the malachite 
green phosphatase assay for its ability to utilise its reported in vitro substrate 
Ins(1,3,4)P3 (348). INPP4b isolated from the leukemic cell lines HUT-78 (Figure 
5.2 A), Jurkat (Figure 5.2 B), MOLT-4 (Figure 5.2 C) and CEM (Figure 5.2 D) was 
able to utilise Ins(1,3,4)P3 as a substrate, indicating that INPP4b detected in 
Figure 5.1 was catalytically active.  
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Figure 5.1. Analysis of the expression of lipid phosphatases and the 
phosphorylated state of downstream PI3K effector proteins by primary and 
leukemic human lymphocytes. 1x106 of Jurkat, MOLT-4, CEM, HUT-78, SEB-
activated primary human T lymphocytes and naïve CD4 cells were lysed and 
levels of phospho-Akt, phospho-GSK, ERK, INPP4b, SHIP-1, SHIP-2, PTEN and 
β-actin determined using Western blotting. A) Shows representative blots from a 
single experiment. B) Blots were quantified using ImageJ software. Data is mean 
± SEM of four independent experiments. 
 
 






Figure 5.2. Analysis of the catalytic activity of INPP4b extracted from 
leukemic cells. INPP4b protein was immuno-precipitated from A) HUT-78, B) 
Jurkat, C) MOLT-4 or D) CEM and added to required wells of a 96-well plate. 
Ins(1,3,4,)P3 (100µM) was added for 30 minutes at 37oC. 100µl malachite green 
solution was then added and absorbance measured using a plate reader at 














Chapter 5: Results 
187 
5.2.3. Distribution of INPP4b in leukemic cells and in non-cancerous 
primary human T lymphocytes following TCR ligation 
Because INPP4b was found to be both expressed and catalytically active in 
leukemic cell lines, it was next sought to determine whether the intracellular 
location of INPP4b differed between leukemic cells and primary cells, which may 
have affected the ability of INPP4b to interact with its substrate within an intact 
cell.  
 
Confocal microscopy was used to determine the intracellular distribution of 
INPP4b in Jurkat cells and in previously activated T lymphocytes following TCR 
ligation with an anti-CD3 (UCHT1) antibody. Figure 5.3 A indicates that under 
basal conditions in primary cells, INPP4b is evenly distributed throughout the cell. 
Five minutes post TCR stimulation, INPP4b protein is lost from the cytosol and is 
primarily located at the cell membrane. In Jurkat cells INPP4b appears to be 
located at the surface membrane and in the cytosol, however the distribution of 
INPP4b does not appear to change following TCR stimulation (Figure 5.3 B).  
 
To further investigate the intracellular distribution of INPP4b, sub-cellular 
fractionation and Western blotting was used to separate cytosolic proteins from 
membrane bound proteins. Figure 5.4 A shows that in primary cells INPP4b is 
increasingly accumulated at the cell membrane following TCR ligation. In 
contrast, Figure 5.4 B shows that the distribution of INPP4b is not altered 
following TCR ligation in Jurkat cells. The membrane bound protein CD3 was 
used as a positive marker for isolated membrane bound proteins. CD3 protein 
was detected in the membrane bound protein lanes of Jurkat and primary cell 
samples as expected but was not present in the cytosolic fraction of cell lysates 
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Figure 5.3. Distribution of INPP4b following TCR ligation in primary T cells 
and in leukemic Jurkat cells. A) SEB-activated primary human T lymphocytes 
were stimulated with anti-CD3 (UCHT1, 10µg/ml) for the indicated time points. 
Cells were then fixed and stained for INPP4b as described in the Materials and 
Methods. INPP4b was visualised using confocal microscopy. Images are 
representative of two independent experiments. B) Jurkat cells were stimulated 
with anti-CD3 (UCHT1, 10µg/ml) for the indicated time points. Cells were then 
fixed and stained for INPP4b as described in the Materials and Methods. INPP4b 
was visualised using confocal microscopy. Images are representative of two 
independent experiments. 
 















Figure 5.4. Location of INPP4b following TCR stimulation in primary T cells 
and in leukemic Jurkat cells. A) 5x106 SEB-activated primary human T 
lymphocytes or B) 5x106 Jurkat cells were stimulated with anti-CD3 antibody 
(UCHT1, 10µg/ml) for indicated time points. Cells were then lysed in hypotonic 
lysis buffer and sonicated. Cytosolic proteins were separated from membrane 
bound proteins by subcellular fractionation as described in the Materials and 
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5.2.4. Tyrosine phosphorylation of INPP4b in lymphocytes 
 
SHIP-1 has previously been shown to become tyrosine phosphorylated following 
TCR ligation (512), whilst the tyrosine phosphorylation of SHIP-1 in response to 
CD28 ligation was associated with cellular redistribution of SHIP-1 from the 
cytosol to the surface membrane as well as increased SHIP-1 catalytic activity 
(267). Tyrosine phosphorylation of SHIP-1 has also been reported to promote the 
proteosomal degradation of SHIP-1 (513).  
 
The effect of receptor ligation on INPP4b tyrosine phosphorylation in T cells has 
not previously been examined. In this thesis, no tyrosine phosphorylation of 
immuno-precipitated INPP4b was identified in response to GPCR or TCR ligation 
in primary cells (Figure 5.5 A) or in Jurkat cells (Figure 5.5 B). Jurkat cells were 
stimulated with CXCL12 because the CXCR4 receptor is expressed by Jurkat 
cells at high levels whilst CXCR3 expression is low. Both Figure 5.5 A and B 
show that in the total cell lysates, phosphorylated ERK could be detected in 
response to GPCR and TCR stimulation. This indicates that the cells did respond 
to stimulation, however INPP4b did not appear to become tyrosine 
phosphorylated in response to this stimulation. 
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Figure 5.5. No detection of tyrosine phosphorylation of INPP4b in response 
to chemokine or TCR stimulation. A) 5x106 SEB-activated primary human T 
lymphocytes or B) 5x106 Jurkat cells were stimulated with CXCL11 or CXCL12 
(10nM) or with anti-CD3 antibody (UCHT1, 10µg/ml) for 5 minutes. Cells were 
then lysed and INPP4b immuno-precipitated as described in the Materials and 
Methods. Levels of phospho-Tyrosine residues, INPP4b and phospho-ERK were 
then determined using Western blotting. Red arrows indicate phosphorylated 
bands induced by chemokine or TCR stimulation. Results are representative of 
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5.3. Expression of INPP4b by Th17 polarised cells 
 
PI3K mediated signalling has a crucial role in regulating the differentiation of 
lymphocytes and myeloid cells into distinct polarised phenotypes (297, 301, 302). 
In addition, SHIP-1 is required for the development of Th17 polarised cells, with 
SHIP-1 deficient mice showing increased regulatory T cell development and 
decreased Th17 differentiation (298). The role of INPP4b in Th17 development 
has not however previously been investigated. Because INPP4b negatively 
regulates the accumulation of SHIP-1’s enzymatic product PI(3,4)P2, it could be 
hypothesised that INPP4b negatively regulates Th17 development. Eight days 
post CD4 T cell activation and in vitro culture, it was found that INPP4b protein 
levels were significantly (p<0.05) reduced in cells cultured under Th17 polarised 
conditions  compared to cells cultured under un-polarised ‘Th0’ conditions 
(Figure 5.6 A and B).  This contrasts with SHIP-1 expression which was 
comparable between Th17 polarised cells and Th0 un-polarised cells. As 
expected, re-stimulation of Th17 polarised cells with anti-CD3/anti-CD28 
antibody coated beads for 16 hours on day 8 post isolation and activation 

































Figure 5.6. Expression of INPP4b by Th17 polarised primary human T cells. 
Naïve CD4 cells were stimulated with anti-CD3/CD28 antibody coated beads in 
Th0 or Th17 polarised conditions as described in the Materials and Methods for 8 
days. A) 1×106 day 9 post isolation Th0 and Th17 cells were lysed and levels of 
phospho-Akt, ERK and SHIP-1 determined using Western blotting. Results are 
representative of six independent experiments. B) Blots were quantified using 
ImageJ software. Data is mean ± SEM of six independent experiments. Student 
paired t test was performed to determine statistical significance * p<0.05. C) 
1×106 day 9 post isolation Th0 and Th17 cells were stimulated with anti-
CD3/CD28 antibody coated beads for 16 hours. Levels of IL-17A in the 
supernatant were then detected using an IL-17A ELISA as described in the 
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5.4. Results Chapter 5 Summary 
 
• INPP4b protein expression was detected in naive and previously activated 
primary human T lymphocytes  
• Protein expression of INPP4b was detectable in the leukemic cell lines 
Jurkat, HUT-78, CEM and MOLT-4  
• INPP4b extracted from leukemic cells was catalytically active in a cell free 
malachite green phosphatase assay 
• In primary T cells INPP4b was recruited to the surface membrane 
following TCR stimulation 
• In Jurkat cells INPP4b distribution did not change following TCR ligation 
• Tyrosine phosphorylation of INPP4b was not detected following GPCR or 
TCR stimulation in Jurkat or in primary T cells 
• INPP4b expression was reduced in Th17 polarised human T lymphocytes 
compared to un-polarised T lymphocytes 
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5.5. Results Chapter 5 Discussion 
 
INPP4b negatively regulates levels of PI(3,4)P2 and has recently been described 
as a tumour suppressor gene in breast cancer (342, 343), laryngeal cancer (514) 
and in prostate cancer (344). No research had previously been published on the 
role of INPP4b in lymphocytes, in addition it had not been investigated whether 
INPP4b expression or activity was lost in leukemic cells. However, whilst this 
thesis was being undertaken an article was published that used a single 
nucleotide polymorphism array to identify mutations in INPP4b that were 
associated with acute lymphoblastic leukemia in children with Downs syndrome 
(347). This study did not use cell-based assays to investigate INPP4b function 
and did not investigate INPP4b protein expression in lymphocytes isolated from 
patients without Downs syndrome.  
 
In this thesis, INPP4b protein expression was detected in primary human T 
lymphocytes as well as in a range of leukemic cell lines. This is in contrast to the 
expression of SHIP-1 and PTEN which were lost in a number of leukemic cell 
lines investigated. This perhaps indicates that INPP4b does not act as a tumour 
suppressor gene in leukaemia. However, this was an isolated analysis of four 
leukemic cell lines and therefore an analysis of primary leukemic samples from a 
large scale patient study would be required to determine if INPP4b loss of 
expression does occur in leukaemia’s. However, results from this thesis do 
indicate that the loss of INPP4b expression is not required for leukemic cell 
development. These results also showed that as expected, leukemic cells which 
have lost PTEN expression also have high basal phosphorylation of Akt.  
 
Although INPP4b protein expression was detected in leukemic T cell lines, it was 
not known whether this was catalytically active. Indeed, in a variety of cancers 
PTEN is often mutated and inactivated (515). However, INPP4b protein extracted 
from all leukemic cells investigated in this thesis was found to be catalytically 
active. Again, this could indicate that INPP4b loss of function is not required for 
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transformation of leukemic cells. Although INPP4b is expressed and is 
catalytically active, it was not known whether INPP4b was recruited to the 
surface membrane where it acts on its substrate in primary cells, or whether this 
recruitment of INPP4b was disrupted in cancer cells. Intriguingly, it was found 
that the distribution of INPP4b in Jurkat cells at the surface membrane did not 
alter after TCR ligation, in contrast to primary cells whereby INPP4b was 
recruited to the surface membrane following TCR stimulation. This was surprising 
given that INPP4b is involved in the negative regulation of PI3K mediated 
signalling, which is overactive in Jurkat cells. However, because Jurkat cells lack 
SHIP-1 expression, perhaps levels of PI(3,4)P2 are insufficient for INPP4b to 
have an effect on cell signalling and therefore over-accumulation of INPP4b at 
the surface membrane does not negatively regulate Jurkat cell Akt activation. It 
would be interesting to follow this experiment with an investigation into the 
distribution of INPP4b in leukemic cells which do express SHIP-1, for example in 
CEM or MOLT-4 leukemic cells.  
 
Because INPP4b negatively regulates accumulation of the enzymatic product of 
SHIP-1, PI(3,4)P2, and SHIP-1 has been shown to be required for the 
development of Th17 polarised cells (298), the expression of INPP4b by human 
Th17 polarized cells was analysed. Interestingly, although SHIP-1 expression 
was comparable between Th17 polarised cells and Th0 un-polarised cells, 
INPP4b protein levels were significantly reduced. This is a highly interesting 
finding that for the first time implicates INPP4b in the development of Th17 cells. 
It would be extremely interesting to determine if INPP4b protein is reduced at an 
early stage of Th17 differentiation in response to Th17 polarising cytokines and 
thereby promotes Th17 differentiation, or if in fact after Th17 differentiation has 
occurred INPP4b expression then becomes reduced, perhaps acting in a positive 
feedback mechanism to further increase Th17 development (Figure 5.7). For 
example, Th17 cells are known to up-regulate the IL-23 receptor after 
differentiation, with IL-23 signalling playing a crucial role in the maintenance of 
the Th17 phenotype (516). There are currently no pharmacological inhibitors of 
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INPP4b, however a lentiviral delivery system could be used to silence INPP4b 










Figure 5.7. Th17 polarised cells express reduced levels of INPP4b protein. 
PI(3,4)P2 promotes Th17 development whilst INPP4b negatively regulates 
accumulation of PI(3,4)P2. It is not clear however whether INPP4b becomes 
down-regulated in Th17 cells as a positive feedback mechanism to further 
increase Th17 development (as is the case for increased IL-23R expression), or 
whether Th17 polarizing cytokines induce INPP4b down-regulation which then 
acts to allow Th17 differentiation.  
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6.1. Current Overview 
This thesis aimed to investigate the role of lipid phosphatase regulators of PI3K 
mediated signalling in primary human T lymphocytes through the utilisation of 
novel small molecule modulators of SHIP-1 and SHIP-2 activity. In addition, the 
role of INPP4b in leukemic cells and the effect of PI3K inhibition on Th17 cell 
development was investigated.   
 
The acute inhibition of PI3Kδ activity was shown to inhibit TCR mediated Akt 
phosphorylation and reduce the secretion of IL-17A by human T lymphocytes. In 
contrast the prolonged inhibition of PI3Kδ activity or the down-regulation of PI3Kδ 
expression in primary human T lymphocytes resulted in increased secretion of IL-
17A.  
 
An allosteric activator of SHIP-1 was shown to inhibit the ability of primary human 
T lymphocytes to adhere to fibronectin and ICAM1 and caused a decrease in the 
affinity state of the integrin LFA-1. In addition, SHIP-1 activation inhibited 
chemokine mediated signalling and in vitro cell motility. Activation of SHIP-1 also 
reduced TCR mediated Akt phosphorylation, proliferation and cytokine secretion. 
In B cells, pharmacological activation of SHIP-1 abrogated BCR mediated 
calcium flux and Akt phosphorylation. Intriguingly, the pharmacological inhibition 
of SHIP-1 showed similar effects on primary human T lymphocyte function as the 
use of a SHIP-1 activator. Inhibition of SHIP-1 was shown to inhibit T lymphocyte 
migration, adhesion, and TCR mediated signalling. This may be due to the so 
called ‘Two PIP hypothesis’ proposed by William Kerr (353), whereby a cancer 
cell requires certain levels of both PI(3,4,5)P3 and PI(3,4)P2 for optimal Akt 
activation. This thesis has shown for the first time that T lymphocytes extracted 
from healthy human donors also appear to require a balance of PI(3,4,5)P3 and 
PI(3,4)P2 for maximal Akt activation and PI3K dependent lymphocyte functions. 
 
The reported SHIP-2 inhibitor BiPh(2,3’,4,5’,6)P5 was shown to inhibit the activity 
of SHIP-1 with equal potency as the inhibition of SHIP-2 activity. 
Chapter 6: General Discussion 
200 
Pharmacological inhibition of SHIP-2 but not SHIP-1 showed little effect on 
primary human T lymphocyte function, indicating that SHIP-1 is the primary SHIP 
protein involved in T lymphocyte function. Although potential evidence for a role 
of SHIP-2 in the negative regulation of lymphocyte metabolism was seen. 
 
No evidence for loss of expression or activity of INPP4b was evident in leukemic 
cells compared to primary human T lymphocytes, indicating that, in contrast to 
PTEN and in certain cases SHIP-1, INPP4b does not act as a tumour suppressor 
gene in leukaemia. Intriguingly, INPP4b expression was down-regulated in Th17 
polarised cells, indicating a possible role for INPP4b in Th17 differentiation.  
 
The results gained from this thesis have provided novel insights into the role of 
inositol lipid phosphatases in leukocytes and will be of relevance in the 
development of drugs that target PI3K and SHIP. In the following section the 
implications of these results on treating inflammatory disorders and leukaemia is 
discussed. In addition, the results acquired during this thesis have raised a 
number of questions and have provided a basis for further research to be 
undertaken. Potential experiments to be carried out based on the results 
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6.2. Therapeutic potential of targeting SHIP  
 
The lack of progress in the development of selective PI3Kγ inhibitors with which 
to treat inflammatory disorders has led to the search for alternative or 
complementary means with which to modulate PI3K mediated signalling in 
leukocytes. SHIP-1 was identified as an ideal drug target due to its restricted 
expression in leukocytes and because of the role of SHIP-1 as a modulator of 
PI(3,4,5)P3 mediated signalling. Activation of SHIP-1 would therefore in theory 
mimic the actions of a PI3K inhibitor.  
 
In this thesis, it was demonstrated that the pharmacological activation of SHIP-1 
inhibited various functions that are crucial for T lymphocytes to drive 
inflammation and hence to promote inflammatory disorders. These results are in 
accordance with data published at a conference in 2011 by Aquinox 
Pharmaceuticals, whereby it was shown that activation of SHIP-1 in Brown 
Norway rats significantly reduced OVA-induced lung infiltration (reviewed in 
(108)). In addition, whilst this thesis was being written two articles were published 
by researchers from Aquinox Pharmaceuticals showing that the SHIP-1 activator 
AQX-1125 reduced splenocyte cytokine production, inhibited leukocyte 
chemotaxis and inhibited mast cell activation in vitro. AQX-1125 also showed 
>80% oral bioavailability and had a >5 hour terminal half-life (517). In vivo, AQX-
1125 inhibited LPS mediated pulmonary neutrophil infiltration and reduced 
smoke induced airway inflammation (518). Together these results indicate that 
pharmacological activation of SHIP-1 may be therapeutically useful for the 
treatment of inflammatory disorders. Indeed, Aquinox Pharmaceuticals lead 
SHIP-1 activating compound, AQX-1125 has recently completed phase 2 clinical 
trials for the treatment of mild to moderate asthma, with LPS challenge in healthy 
human volunteers resulting in a 66% decrease in neutrophil numbers in sputum 
by AQX-1125 treatment (351).  
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Pharmacological SHIP-1 inhibitors have previously been identified to kill leukemic 
cells both in vitro and in vivo (325, 352) and to increase red blood cell, neutrophil 
and platelet numbers in vivo in mice (325). SHIP-1 inhibition in this thesis 
however decreased the viability of primary human T lymphocytes. This indicates 
that increased blood cell numbers following SHIP-1 inhibition may be cell-type 
specific, or that in vivo, cells are protected from SHIP-1 inhibition mediated 
apoptosis, perhaps through interactions with stromal cells or other cell types as 
has been described for the protection of leukemic cells from chemotherapy (519, 
520). This is an important point to take into account because decreased numbers 
of non-cancerous T cells during anti-cancer therapy would reduce T cell 
mediated anti-tumour responses. Another concern in the use of a SHIP-1 
inhibitor therapeutically is that genetic deficiency in SHIP-1 in mice has been 
shown to cause a number of pathologies, including osteoporosis (521), intestinal 
inflammation (522), fibrotic lung disease (302) and a shortened lifespan due to 
infiltration of the lungs with myeloid cells (470). However, pharmacological 
inhibition of SHIP-1 in mice for 7 days was found not to cause myeloid lung 
infiltration and did not cause lung pathology (325). It remains to be seen 
however, what the effects of more long term pharmacological SHIP-1 inhibition 
are, or indeed what the effects of SHIP-1 inhibition are in humans.  
 
Because SHIP-1 has both catalytic and non-catalytic functions (195, 259, 275, 
289), the pharmacological inhibition or activation of the catalytic site of SHIP-1 
may not be sufficient to block all of SHIP-1 mediated functions. Small molecule 
targeting of SHIP-1 activity may be insufficient to prevent pathology if the 
pathology is driven by the non-enzymatic functions of SHIP-1. In contrast, if 
pathology is driven primarily by the catalytic function of SHIP-1, the selective 
inhibition of catalytic activity may be beneficial because this would limit unwanted 
side-effects that result from deficiency in SHIP-1 protein (302, 470, 521, 522). 
However, 48 hour treatment with 3AC was shown to induce proteosomal 
degradation of SHIP-1 in leukemic cells (325), and hence pharmacological 
inhibition of SHIP-1 may lead to the loss of both catalytic and non-catalytic 
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functions, although loss of SHIP-1 expression in primary T cells was not seen in 
this thesis.  
 
There is currently a huge requirement for improved therapies that target B cell 
lymphomas, with chronic lymphocytic leukaemia (CLL) currently incurable by 
chemotherapy due largely to the development of drug resistance (523). CLL cells 
proliferate in pseudo-follicles within bone marrow and lymphoid tissue (519, 524), 
where they are protected from chemotherapy induced apoptosis by interactions 
with stromal cells. CLL access to these tissues is dependent upon chemokine 
signalling, whilst cell adhesion aids the retention of cells within the 
microenvironment (519, 525). Disruption of these chemokine mediated leukemic-
stromal cell interactions by inhibiting PI3Kδ activity with CAL-101 was found to 
release leukemic cells into the blood where they are more susceptible to 
chemotherapy induced apoptosis (147, 148). In this thesis, the pharmacological 
activation or inhibition of SHIP-1 was shown to inhibit chemokine mediated 
signalling and migration, and to abrogate the ability of lymphocytes to adhere to 
fibronectin and ICAM1. Pharmacological modulation of SHIP-1 activity may 
therefore offer an alternative or complementary approach to targeting PI3K 
mediated signalling in leukaemia. 
 
SHIP-2 inhibitors are currently being developed for the treatment of diabetes and 
obesity (354, 355). Results gained from this thesis provide evidence that 
pharmacological inhibition of SHIP-2 has little effect on T lymphocyte TCR 
signalling, adhesion or chemokine mediated signalling and motility. Given the 
described role of SHIP-2 in actin reorganisation, cell motility and cell polarisation 
(335-337, 526), this was perhaps a surprising set of results. However, these 
results do indicate that the pharmacological inhibition of SHIP-2 for therapeutic 
use may have little unwanted immunosuppressive effects. The results of this 
thesis therefore support the identification of SHIP-2 as a viable drug target for the 
treatment of diabetes.  
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6.3. Future direction 
 
Results gained during this thesis have opened up new avenues of research 
which could be explored to further increase the understanding of the role of lipid 
phosphatases in lymphocyte function. 
 
Both the inhibition and activation of SHIP-1 activity was found to inhibit the ability 
of T lymphocytes to migrate in response to chemokine’s and to adhere to 
fibronectin and ICAM1. Pharmacological inhibition of PI3K inhibits leukocyte 
transendothelial migration (527) and the down-regulation of SHIP-1 expression 
also reduced T lymphocyte transendothelial migration (295). It would therefore be 
interesting to determine the effect of AQX-1 or 3AC on the transendothelial 
migration of T lymphocytes.  This would also give further insight into the potential 
effect of SHIP-1 modulation on leukocyte homing during an inflammatory 
response (208). For example, primary human T lymphocyte transmigration 
across a human umbilical vein endothelial cell monolayer grown on a Transwell 
membrane could be assessed as previously described (295) in the presence of 
AQX-1 or 3AC.  
 
The inhibition of BCR mediated calcium flux and Akt phosphorylation in the A20 
mouse B lymphoma cell line following SHIP-1 activation indicates that SHIP-1 
activation may be beneficial for the treatment of inflammatory disorders that 
involve B cell antibody production, for example SLE (528). It would be extremely 
interesting to repeat these experiments in primary human B cells isolated from 
healthy human donors to give more clinically relevant results. In addition the 
effect of SHIP-1 activation on B cell maturation, antibody class switching and 
secretion of antibodies could be investigated.  
 
Calcium flux is induced in T cells in response to TCR stimulation and is a crucial 
PI3K dependent mechanism for T cell activation (529, 530). In this thesis BCR 
mediated calcium flux in B cells was shown to be abrogated by AQX-1, this 
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therefore raises the possibility that pharmacological modulation of SHIP-1 activity 
in T lymphocytes may also influence TCR mediated calcium flux. Supporting this 
is the fact that PI(3,4,5)P3 activates Itk, which in turn activates PLCγ resulting in 
calcium release from the endoplasmic reticulum. In addition, SHIP-1 has 
previously been implicated in the negative regulation of TCR mediated calcium 
flux in T cells (530). AQX-1 and 3AC could be used to probe the role of SHIP-1 in 
TCR mediated calcium flux in primary human T lymphocytes.  
 
Pharmacological inhibition of SHIP-1 has been shown to induce the apoptosis of 
myeloid and lymphocyte leukemic cells in vitro and in vivo (325, 352). In this 
thesis, pharmacological inhibition of SHIP-1 increased cell death of non-
cancerous T lymphocytes. This may be due to the ability of SHIP-1’s product, 
PI(3,4)P2 to activate Akt and promote cell survival (240), whilst inhibition of Akt 
has been shown to sensitize cancer cells to death receptor induced apoptosis 
(495). SHIP-1 has also been shown to be recruited to the cytoplasmic tails of 
death receptors (531), and to influence Fas-mediated and ROS-mediated cell 
death pathways (493, 532, 533). It would therefore be extremely interesting to 
investigate the effect of SHIP-1 inhibition on death receptor induced cell death in 
primary human T lymphocytes.  
 
The recent progress in the development of PI3Kδ inhibitors to treat leukaemia’s 
has shown an intriguing mechanism whereby chemokine-mediated interactions 
between leukemic cells and non-cancerous stromal cells are disrupted. This 
causes the release of leukemic cells away from protective microenvironments 
and into the blood stream where they are more susceptible to cell death by 
chemotherapy (147, 148). In this thesis it was shown that SHIP-1 activation or 
inhibition reduced lymphocyte adhesion to ICAM1 and fibronectin, and inhibited 
TCR and chemokine mediated Akt phosphorylation. It is therefore plausible that 
pharmacological SHIP-1 modulation would mimic a PI3Kδ inhibitor in a cancer 
model and decrease association between leukemic cells and the 
microenvironment. This could be assessed by measuring the effect of AQX-1 on 
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CXCR4-dependent CLL cell migration beneath marrow stromal cells in vitro 
which mimics in vivo homing of CLL cells to tissues, as previously described 
(148, 534, 535). The effect of SHIP-1 activation on nurse cell like-mediated CLL 
survival using a co-culture method as previously described (148) could also be 
investigated. These experiments would support the already published data which 
indicate that pharmacological activation of SHIP-1 may be an effective anti-
cancer agent (350). 
 
Benzene polyphosphates were identified in this thesis to be dual inhibitors of 
SHIP-1 and SHIP-2.  Cell based assays using these compounds were however 
not carried out because these compounds in their current state are not cell 
permeable (356). However, benzene polyphosphates could be made cell-
permeable by masking the lipophilic phosphate derivatives (356) and may 
therefore offer potential as anti-cancer agents. Indeed, novel SHIP-1/SHIP-2 cell-
permeable inhibitors have recently been identified to kill breast cancer cells that 
express SHIP-2 but not SHIP-1, and have been shown to induce the apoptosis of 
multiple myeloma cells (352). During anti-cancer therapy, the dual inhibition of 
SHIP-1 and SHIP-2 may be advantageous over SHIP-1 selective inhibition 
because SHIP-2 has been shown to become up-regulated in SHIP-1 inhibitor 
resistant leukemic cells (352).  
 
In this thesis no loss of expression or function of INPP4b was evident in leukemic 
cells. This was perhaps surprising given that INPP4b has previously been 
identified as a tumour suppressor gene in prostate and breast cancer (339, 342-
344) and mutations of INPP4b have also been identified in acute lymphoblastic 
leukaemia in children with Downs syndrome (347). In this thesis four leukemic 
cell lines were investigated for INPP4b expression and activity. It would however, 
be extremely interesting to screen for potential loss of function or loss of 
expression of INPP4b in a larger range of samples isolated from patients with 
leukaemia. 
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